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Hematopoiesis fs an orderly process in which stem cells differentiate into 
mature cells through sequential divisions. Differentiation commitment of stem cells 
and progenitor cells in these processes require the switch on/off and precise 
expression of regulatory genes. To investigate the molecular regulation of 
hematopoiesis, it is easier to start with the studies of a particular leukemia cell line. 
The murine myeloid leukemia cell lines WEHI-3B JCS and its subclone 
JCS-14 can be induced to undergo terminal differentiation by 
differentiation-inducing agents. Prostaglandin E2 (PGE2) is one of the chemical 
inducers for the JCS-14 and JCS cells. According to our preliminary result. They 
showed distinct differentiation responses to PGE2. When 4 \iM of PGE2 was added to 
JCS-14 cell culture, a maximum of over 30% of cells were driven to differentiate 
along the granulocytic lineage. The cells differentiated to metamyelocyte and PMN. 
In contrast, more than 70% of PGE2-treated (25 |iM) JCS cells differentiated into 
macrophage along the monocytic lineage. The inducer dependent lineage 
commitment of JCS-14 and JCS cells may be used as a model for studying the 
regulatory genes expressed by cells in the granulocyte-monocyte lineages. 
Gene expression profiles of PGE^-induced JCS-14 cells were examined by 
using microarray hybridization. A total of 588 identified genes were analyzed. 22 
genes were up-regulated or induced by PGE2, and 214 genes were down-regulated or 
repressed by PGE2. These genes may be essential for hematopoietic cell 
differentiation, proliferation, apoptosis as well as function activation. Among them, 
B-myb, c-erbA and TTF-1 were chosen for following studies. Quantitative mRNA 
expression was investigated by real-time RT-PCR. For B-myb, a gradual 
down-regulation was observed in PGE2-induced JCS-14 cells. In JCS cells, the 
expression of B-myb at 1 hour after induction was more or less the same as 0 hours. 
Then the expression level was then gradually down-regulated. 
The novel functions of these three genes in the differentiation of JCS and 
JCS-14 were further examined using antisense blocking. In our study, the 
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PGE2-induced JCS-14 and JCS cell differentiation were affected under both of the 
sense and antisense treatment of c-erbA and TTF-L Without further investigation, the 
role ofc-erbA and TTF-1 in the JCS-14 and JCS cell differentiation is still unknown. 
On the other hand, the PGE2-induced granulocytic differentiation of JCS-14 cells 
was significantly promoted (P < 0.001) during the antisense B-myb oligonucleotides 
treatment, but not the sense control. Interestingly, the induced JCS-14 cells were 
arrested in the metamyelocytic stage. Similarly, the monocytic lineage differentiation 
of JCS cells was significantly inhibited (P < 0.05) under the same antisense treatment. 
Furthermore, the PGE2-mediated monocytic development of JCS cells was affected, 
judged from the smaller size of the differentiating JCS cells. This may imply that 
repression of B-myb may associate to the inhibition of JCS-14 and JCS cell 
differentiation and maturation. If this correlation is proved, it may suggest that an 
immediately early down-regulation of B-myb is specific to PGE2-induced JCS-14 cell 
differentiation. On the contrary, maintenance of B-myb expression at early may be 
required to monocytic differentiation of PGE2-induced JCS cells. Further speculation 
on function of B-myb should be done in order to confirm its function in myeloid 
differentiation and development. 
Our investigation suggests that a precise regulation of the expression of 
B-myb is required in the PGE2-induced JCS-14 and JCS cell differentiation. Further 
studies of B-myb and other differentially expressed genes may help to dissect the 
control mechanism of myeloid cell differentiation and lineage commitment. 
Hopefully, such studies, would help us gain more understanding of the regulation of 
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Chapter One General Introduction 
1.1 Hematopoiesis -
Hematopoiesis is commonly known as blood cell formation. It is a highly 
active and complex series of cellular process; in humans about one trillion blood 
cells are produced daily. All these cells carry out vital and unique functions in the 
body. They are responsible for oxygen delivery, protection against potential harmful 
agents, tissue repair and for homeostasis after injury. However, the lifespan of most 
hematopoietic cells is short from several hours to weeks, all types of these cells must 
be constantly renewed throughout our life. 
1.1.1 Ontogeny of hematopoiesis 
The location of hematopoiesis has developmental sequence during the 
process of development from embryo to adult in human. The first hematopoietic cell 
is produced in the yolk sac of two week-old embryo. Most of the early hematopoietic 
cells are nucleated and all synthesize hemoglobin in erythropoiesis, and lend a 
reddish colored clumps of cells. Hence, this earliest recognizable embryonic 
hematopoietic site in yolk sac is termed as blood island. By the end of sixth week of 
embryonic development, all the hematopoietic activity of the blood islands subsides 
to the liver. The liver soon becomes the dominant site of hematopoiesis and remains 
active until birth. In contrast with the hematopoietic activity of liver, spleen is a 
secondary important site of embryonic hematopoiesis. It produces blood cells since 
about fourth fetal month. In addition, the formation of lymphocytes appears to occur 
as a process completely separate from the origin of erythropoiesis in spleen. Soon 
after birth, hematopoietic populations decline in the liver, and the relative importance 
of splenic hematopoiesis also progressively declines. 
Embryonic bone marrow begins to play role in hematopoiesis from sixth 
month of fetal life and continue to be the principal site for the remainder of life. The 
embryonic marrow has a markedly different to the earlier centers of hematopoiesis 
by its vigorous and dominant myelopoiesis. After birth, primitive pluripotent stem 
cell development and myelopoiesis occur in the bone marrow, whereas 
lymphopoieisis occurs in the thymus, spleen and lymph nodes. In the adult, most 
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(>95%) hematopoietic tissues is located in the bone marrow cavities of the axial and 
appendicular skeleton. Under certain conditions where the bone marrow is unable to 
meet the demands of hematopoietic cells of body, liver and spleen can resume their 
hematopoietic functions as well as in fetal stage. This phenomenon is known as 
extramedullary hematopoiesis (Hoffbrand, Pettit and Moss, 2001 ； Metcalf and Nicola, 
1995). . 
1.1.2 Hiercharay of hematopoiesis 
Our current understanding of hematopoiesis is embodied in a theory called 
stem cell model of hematopoiesis (Till et ai, 1961). This theory forms the foundation 
for all the studies about normal hematopoiesis, patholgoic hematologic diseases and 
hematologic therapies. 
Stem cell theory 
All hematopoietic cells arise from a common stem cell that is able to 
differentiate to nine distinct blood cell lineages (Figure 1.1): erythrocyte, 
platelet/megakaryocyte, monocyte/macrophage, neutrophil, eosinophil, basophil, T 
cell, B cell and nature killer cell lineages. Hematopoietic cells in each lineage can be 
stratified into three major sequential cell populations, which are stem cells, 
progenitor cells and mature cells. The cells in each succeeding compartment are the 
progeny of, and more numerous than, the cells in the proceeding compartments 
(Metcalf and Nicola, 1995; Schiffman, 1998). 
Stem cells are extremely rare populations in bone marrow cell. The 
frequency of stem cell in marrow is about 1 per 1 m a r r o w cells. Characteristically, 
stem cells have capability for self-renewal and for the production of a large number 
of committed progenitor cells in cell division (Metcalf and Nicola, 1995). Thus, 
constant stem cell pool is tightly maintained, although vast number of mature cells is 
produced continuously daily. 
The most ancestral stem cell, totipotential stem cell, can differentiate to 
pluripotent stem cell and then to either a pluripotent lymphoid stem cell (CFU-L) or 
pluripotent myeloid stem cell (CFU-GEMM). These cells have the capacity to 
differentiate along several distinct cell lineages, but their choices are relatively 
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limited (Pallister, 1994). Moreover, the differentiation commitment is irreversible, 
that means differentiated cell cannot switch to another lineage or revert to primitive 
stem cells. 一 
In contrast to stem cell, progenitor cells have relatively lower or even no 
capacity for self-renewal. Progenitor cells are transit compartments formed by stem 
cells and eventually expending themselves in the production of maturing progeny. 
Generally, progenitor cells have a more and more restricted in their commitment to 
the production of specific blood cell lineage. They are committed usually to a single 
cell lineage. Bi- or trilineage of differentiation do exist, but is less common than 
single lineage. With subsequent division of progenitor cells along the cell lineage, 
mature cells are generated. Mature cell populations represent the vast majority of 
hematopoietic cells. With progressive maturation, these cells gradually have 
restricted capacity for further proliferation or even no further cell division occurs 
(Metcalf and Nicola, 1995). 
3 
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Figure 1.1 Hematopoietic stem cell hierarchy 
CFU-GEMM, colony-forming units-granulocytes, erythrocytes, macrophages and 
megakaryocytes; CFU-L, colony-forming units-lymphoids; BFU-E, erythroid 
burst-forming cell; CFU-GM, granulocyte-macrophage colony-forming unit; CFU-M, 
macrophage colony-forming unit; CFU-Meg, megakaryocyte colony-foming unit; 
CFU-Eo, eosinophil colony-forming unit; CFU-Ba, basophil colony-forming unit 
(adapted from Pro van and Gribben, 2000). 
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1.2 Regulation of hematopoiesis 
Hematopoiesis is not only a controlled expansion of very large numbers of 
mature cells from stem and progenitor cells sequentially, but also a complex series of 
cellular events including differentiation commitment, maturation induction, 
controlled release of mature cells as well as functional activation of cells. Hence, 
hematopoietic regulation is necessary to maintain the required cell production and 
function in the system so as to meet the demands of body at normal or pathological 
conditions. 
In general, both positive signals that stimulate hematopoiesis and negative 
control system, which checks excessive productions, affect regulation of 
hematopoiesis. Bone marrow stromal cells, hematopoietic growth factors (HGF), 
receptor activation, signal transduction and transcription factors have exhibited an 
important role in the stepwise regulatory mechanism. 
1.2.1 Bone marrow stromal cell 
Bone marrow provides a suitable environment for the growth and 
development of hematopoietic cells. It is composed of stromal cells, which are in 
cellular contact with proliferating and differentiating stem and progenitor cells. 
Stromal cells include fibroblasts, endothelial cells, osteoblasts, adipocytes and 
resident bone marrow macrophages. In addition, stromal cells secrete extracellular 
molecules such as collagen, glycoproteins (fibronectin and thrombospondin) and 
glycosaminoglycans (hyaluronic acid and chondroitin derivatives) to form an 
extracellular matrix (Yoder et al, 1995). 
Stromal cells synthesize a number of HGF such as 
monocyte-colony-stimulating factor (M-CSF), stem cell factor (SCF), 
granulocyte-monocyte colony-stimulating factor (GM-CSF)， 
granulocyte-colony-stimulating factor (G-CSF), interleukin 1 (IL-1), interleukin 6 
(IL-6), interleukin 7 (IL-7) and transforming growth factor P (TGF-(3) (Gualtieri et 
al, 1984; Guba et al, 1992). Produced HGF exist in soluble and membrane-bond 
forms, which are presented with stromal cells or components of extracellular matrix. 
Membrane-bond forms of HGF can promote the adhesion of cell to stromal cell 
layers. Besides, hematopoietic cells can bind directly to the heparin sulfate molecules 
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on the surface of marrow stromal cells. Taken together, specific HGF and 
hematopoietic cell interaction can be promoted for the growth of hematopoietic cells 
(Siczkowski et al, 1992). > 
1.2.2 Hematopoietic growth factor 
The hematopoietic growth factors (HGF) or colony stimulating factors 
(CSF) are a class of glycoprotein hormones that obligately regulate the proliferation, 
differentiation, maturation, function of all hematopoietic cells and also suppress 
apoptosis. G-CSF is an example to exhibit all above multiple functions. CSFs are 
mostly produced by stromal cells, monocytes (and macrophages) and T-lymphocytes. 
The biological effect of CSF may act locally at the site of production or circulate in 
plasma (Schiffman, 1998). 
CSFs have a quantitative importance in hematopoiesis. Under basal 
conditions, relatively low concentration of CSFs is produced constitutively for basal 
hematopoiesis. Conversely, CSFs secretion is greatly increased above the basal level 
in response of infection. Antigens or endotoxins activate T-lymphocytes or 
macrophages to secrete tumor necrosis factor (TNF) and IL-1, which then stimulate 
other cells including endothelial cells, fibroblasts, other T cells and macrophages to 
produce GM-CSF, G-CSF, M-CSF, IL-6 and other growth factors. This additional 
CSF production directly increases the production and maturation of neutrophils, 
monocytes, and plasma cells in circulation for protection against harmful agents in 
body (Hoffbrand, Pettit and Moss, 2001; Metcalf and Mihich, 1995). 
CSFs often show synergistic or additive interactions with other growth 
factors in stimulating cell proliferation and differentiation. In other words, 
combination of two or more factors greatly amplifies hematopoietic cell proliferation 
and differentiation. For example, SCF alone cannot direct the proliferation of stem 
cell, but is essential to trigger stem cells to become responsive to other regulators 
such as IL-6, IL-7 and IL-11 for proliferation (Metcalf et al, 1993). 
Another important feature of CSFs is their hierarchical actions. They act 
at different stages and lineages of hematopoiesis (Figure 1.2). Despite IL-3 and 
GM-CSF are multipotential growth factors with overlapping and redundant activities, 
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IL-3 is more effective on the earliest progenitors. According to action on 
hematopoietic cell, CSFs may be divided into three categories: 1) early-acting factors, 
2) intermediate-acting factors and 3) late-acting factors (Ogawa, 1993) (Table 1.1). 
In brief, early-acting factors stimulate the cycling and differentiation of dormant 
stem cell. Intermediate-acting factors are usually non-lineage specific factors having 
overlapping functions to support the proliferation of multipotential progenitors. 
Later-acting factors are lineage-specific, it supports the proliferation and maturation 
of committed progenitors. 
In contrast to the stimulatory functions of CSFs, some hematopoietic factor 
are inhibitory factors. These include interferon, TGF-p and macrophage 
inflammatory protein l a (MIP la). Generally, interferons inhibit the growth of a wide 
range of progenitors in vitro. In contrast, TGF-p and MIP l a are more specific in 
inhibiting the early stages of progenitors and stem cell proliferation respectively 
(Pallister, 1994; Ogawa, 1993). 
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Figure 1.2 A simplified diagram showing the hierarchical role of growth factors 
in hematopoiesis. Multiple growth factors act on the earliest marrow stem and 
progenitor cells. EPO, erythropoietin; PSC, pluripotential stem cell; SCF, stem cell 
factor; TPO, thrombopoietin; GM-CSF, granulocyte and 
monocytes-colony-stimulating factor; M-CSF, monocyte-colony-stimulating factor; 
G-CSF, granulocyte-colony-stimulating factor (adapted from Hoffbrand, Pettit and 
Moss, 2001). 
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Table 1.1 Examples of colony stimulating factors categorized according to their 
hierarchical actions in hematopoiesis 
Colony stimulating factors Target population 
Early-acting factors Stem cells 
IL-1, IL-3，IL-6, IL-7, IL-11, IL-12, LIF, SCF, 
flk-ligand 
Intermediate-acting factors Multipotential progenitor cells 
IL-3, IL-4, GM-CSF 
Late-acting factors Committed progenitor cells 
Epo, M-CSF，G-CSF, IL-5 
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1.2.3 Hematopoietic growth factor receptors and signal transduction 
Hematopoietic growth factors bind to specific transmembrane receptors 
on target cells to trigger intracellular signal transduction pathways. The network-like 
signaling pathways eventually regulate the early responded transcription factors in 
cells. 
Hematopoietic growth factor receptors 
Majority of growth factor receptors is multimeric, composed of an unique 
ligand-specific subunit and one or more common signal-transducing subunits. The 
existence of common signaling subunits provides explanation of the functional 
redundancy and cross-competition of groups of growth factors (Sakamaki et al, 
1992). For instance, the high affinity IL-3 and GM-CSF receptors are high-affinity, 
composed of two subunits, a and (3 . The a subunits are ligand specific and bind their 
ligands with low affinity. Thus, functional difference among IL-3 and GM-CSF may 
be mediated by these unique signaling functions of a subunits. On the other hand, the 
P(Pc) subunit is a common cytoplasmic domain to these two receptors (Miyajima et 
al, 1993). The requirement and sharing of pc for high-affinity binding explain the 
cross-competition and activities overlapping in hematopoiesis among IL-3 and 
GM-CSF respectively. 
Signal transduction 
Ligand-induced homo- or hetero-dimerization of receptor components is 
the initial step of receptor activation. When activated, cytoplasmic signaling 
pathways involving associated or intrinsic tyrosine phosphorylation are triggered. 
Most of the growth factor receptors do not contain intrinsic kinase. They 
associate with members of a family of tyrosine kinases, the Janus associated kinase 
(Jak). Jak is the central mediator in growth factor signaling because they appear to be 
ubiquitously expressed. To date, four members of the Jak family have been identified 
(Jakl, Jak2, Jak3 and Tyk2) (Ihle et al, 1994). These kinases associate directly with 
many receptors in the absence of ligand and are activated and phosphorylate upon 
ligand-receptor binding. Activated Jaks can phosphorylate members of the signal 
transducer and activator of transcription (STAT) family, which are substrates for Jaks. 
This results the dimerization of STATs, either homo-or hetero-dimerization with 
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different STAT proteins. STAT dimers then translocate to the nucleus, where they 
bind specific enhancer sequences in the promoters of target genes (Darnell et al, 
1994; Shuai et al, 1994): The complex association of different receptors with 
particular Jaks and STATs exhibit divergent signal transduction pathways. For 
instance, IL-2 activates Jakl and Jak3, but not Jak2, whereas IL-3 and GM-CSF 
primarily activate Jak2 (Ihle et al, 1994). In contrast, although IL-2 and IL-4 activate 
the same Jaks, they appear to activate different STAT protein. 
Except STATs pathways, Jaks may also activate other pathways. For 
example, ras/raf/MAP kinase. Phosphorylated mitogen activated protein (MAP) 
kinase induce a set of transcription factors, including MYC and FOS, which have 
critical roles in proliferating signal (Kinoshita et al, 1995). 
A small group of growth factor receptors, including SCF receptor or 
M-CSF receptor, switch on signal transduction pathway by their intrinsic tyrosine 
kinase activity. These tyrosine kinase receptors have an extracellular domain linked 
via a single transmembrane bridge to a cytoplasmic tyrosine kinase domain. Ligand 
binding triggers the dimerization of these receptors and consequent activation of the 
tyrosine kinase domain. Phosphorylation of tyrosine residues in the receptor itself . 
generates binding sites for a set of signaling proteins, which initiate complex 
cascades of signal transduction (Hunter et al, 1985; Whetton and Gordon, 1996). 
1.2.4 Transcriptional regulation of myeloid cell development 
The execution of hematopoietic cell development involves induction of 
gene expression cascades. Both lineage and stage specific gene expression pattern 
within the cell are often driven by a few upstream transcription factor genes. This 
stepwise gene expression finally triggers the cascades of proliferation and 
differentiation processes. Hence, an understanding of transcription factor is essential 
to the study of hematopoietic cell regulation. More specifically, myeloid cell 
development would be emphasized to study the determinative role of transcription 
factors in commitment of myeloid progenitors to macrophage and/or granulocyte 
lineages 
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Regulation of myeloid cell specific gene expression 
A vast number of granulocyte- and monocyte-specific genes have shown to 
be differentially expressed during myeloid cell differentiation. Their expression is 
controlled by the activity of particular transcription factors (Friedman, 2002) (Table 
1.2). Collectively, C/EBPs and PU.l act as the most consistent transcription factors 
in granulopoiesis at early monopoiesis. In the following sections, C/EBPs, PU.l and 
some other pivotal transcription factors will be discussed. 
12 
Table 1.2 Transcription factors regulating granulocytic or monocytic specific 
genes (adopted from Friedman, 2002) 
Gene ^ Transcription factors 
Immature granulocytes 
mim-1 C/EBPs, c-Myb 
Myeloperoxidase (MPO) C/EBPs, PU.l，CBF, c-Myb, CDP/HoxAlO 
Neutrophi elastase (NE) C/EBPs, PU. 1/GABP, CBF, c-Myb, Spl 
Myeloblastin (MBN) C/EBPs, PU. 1, c-Myb 
G-CSF receptor C/EBPs, PU. 1 
GM-CSF receptor C/EBPs, PU. 1 
CD 13 c-Myb, Ets-1 or Ets, c-Maf 
Lysozyme C/EBPs, PU.l 
c-fes PU.l , Spl 
Mature granulocytes 
gp91phox PU.l , ICSBP, CDP, HoxAlO 
Lactoferrin (LF) C/EBPs, Sp 1, CDP 
Immature monocytes 
M-CSF receptor C/EBPs，CBF, PU.l , c-Jun 
Lysozyme C/EBPs, PU.l 
Mature monocytes 
Macrosialin PU.l , c-Jun 
Scavenger receptor PU.l , c-Jun 
CD 14 C/EBPs, Spl 
gp91phox PU.l , ICSBP, CDP, HoxAlO 
C D l l b PU.l , Spl 
CD 18 PU.l , GABP, Spl 
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Transcription factor 
CCAAT/enhancer binding proteins (C/EBP) 
The C/EBP family (C/EBPa, C/EBPp, C/EBP6, C/EBPe, C/EBPy and 
CHOP), encoding leucine zipper protein, is one of the important transcription factors 
in regulating myeloid development. The C/EBP proteins bind as a homodimer or 
heterodimer among themselves or with other transcription factors via their 
C-terminal leucine zipper domains. They directly bind to DNA via the basic amino 
terminal regions (Landschulz et al, 1989). During hematopoiesis, full length of 
C/EBPa, C/EBPp and C/EBP5 are predominantly expressed in granulocytes, 
monocytes and eosinophils (Radomska et al, 1998; Muller et al, 1995). C/EBP 
physically interact with another transcription factor, PU.l (Nagulapalli et al, 1995). 
Among them, C/EBPa and C/EBP(3 are under intensive studies related to myeloid 
proliferation and differentiation. 
Expression of C/EBPa is up-regulated during early granulocytic 
differentiation, but is down-regulated upon further granulopoiesis and during 
monocytic differentiation (Cheng et al, 1996; Radomska et al, 1998; Tsutsumi-Ishii 
et al, 2000). It also regulates myeloid-related genes such as the gene encoding IL-6 
receptor, lactoferrin, M-CSF receptor, GM-CSF receptor, G-CSF receptor and PU.l 
(Zhang et al, 1998; Hohaus et al, 1995; Wang et al, 1999; Khanna-Gupta et al, 
2000). Expression of C/EBPa in the myeloid progenitor cell line 32Dcl3 was 
sufficient to induce granulocytic differentiation (Wang et al, 1999). Disruption of the 
C/EBPa gene in mice led to a lack of granulocytes, but retained normal 
monocyte/macrophage development (Zhang et al, 1997). Recent studies pointed out 
that 7% acute myeloid leukemia (AML) patients have mutated C/EBPa gene (Pabst 
et al, 2001). In addition, C/EBPa inhibited cell proliferation in fibrosarcoma lines 
through the cyclin-dependent kinase inhibitor p21 and also act as tumor suppressor 
of hepatoma lines (Watkins et al, 1996; Timchenko et al, 1996). Thus, C/EBPa is 
essential to induce granulocyte differentiation. 
Expression of C/EBPp (also denoted NF-IL6) is increased during myeloid 
differentiation. In contrast to C/EBPa, it directs monocyte/macrophage gene 
expression and development. It includes the monocyte-specific genes encoding 
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G-CSF, CDllc , IL-6 and IL-8 (Stein et al, 1993; Dunn et al, 1994; Zhang et ai, 
1994). Mice harboring a knockout of C/EBPp gene had defects in macrophage 
activation and function, probably resulted in the reduction of G-CSF production 
(Tanaka et al, 1995). 
Other members of C/EBP family such as C/EBP5 and C/EBPs are 
up-regulated during granulocyte differentiation (Morosetti et al, 1997; Yamanaka et 
al, 1997). However, hematopoietic defects in mice lacking C/EBP6 gene were not 
severe (Tanaka et al, 1997). C/EBPe-deficient mice still retained neutrophils, 
although they lacked secondary granules (Yamanaka et al, 1997; Gombart et al, 
2001). These findings suggest that C/EBP5 and C/EBPs are critical in granulocyte 
maturation but insufficient to initiate myeloid differentiation. 
PU.l 
PU.l is a member of the Ets transcription family. PU.l gene is highly 
expressed in myeloid and B cell (Chen et al, 1995). Notably, its mRNA is expressed 
at low level in murine embryonic stem cells and human CD34+ stem cell, but is 
specifically up-regulated with myeloid differentiation. Moreover, inhibition of PU.l 
gene blocked the myeloid progenitor formation (Voso et al, 1994). In addition, high 
level of PU.l expression in murine fetal liver hematopoietic progenitor cells 
preferentially directed macrophage development (DeKoter et al, 2000). Previous 
studies showed that the ability of PU.l to activate its own promoter may play a role 
in maintaining high level of PU.l expression in myeloid development (Chen et al, 
1995). Functional PU.l binding sites have been found in nearly all myeloid restricted 
gene promoters. This includes gene encoding M-CSF receptor, GM-CSF receptor 
and G-CSF receptor (Smith et al, 1996). All these finding suggest that PU.l may 
play a significant role in the commitment of early multipotential progenitors to the 
myeloid lineages, as well as in the further differentiation and maturation of these 
cells. 
The activity of PU.l gene in monocytic differentiation require 
co-activation of c-jun. Overexpression of c-jun in progenitor cell facilitated 
macrophage development (Rangatia et al, 2000). On the other hand, C/EBPa can 
inhibit the PU.l activity by decreasing expression of c-jun and also binding PU.l 
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directly. PU.l also interacts with GATA-1, which is a master regulator of erythroid 
development, through protein interaction (Nerlov et ai, 2000; Zhang et al, 2000). 
Increased expression of either PU.l or GATA-1 would lead to the repression of the 
other factors, then induction of the corresponding downstream cascade of gene 
expression and finally the irreversible commitment of either myeloid or erythroid 
differentiation. • 
AMLl 
AMLl is a member of the core binding factors (CBF). CBF heterodimers 
are comprised of a common CBF(3 subunit and one of three CBFa subunits, CBFal, 
CBFa2 (commonly referred as AMLl) and CBFa3. CBFp does not contact DNA, 
but interacts with CBFa subunits for exhibiting the DNA-binding activity. AML 
interacts with DNA indirectly via the interaction with some Ets family proteins 
including Ets-1 and PU.l and also via interaction with C/EBPa protein (Mao et al, 
1999). AMLl may facilitate the action of other adjacent transcription factors. For 
instance, the AMLl site in M-CSF receptor promoter is located between C/EBPa and 
PU.l sites. Although C/EBP site is critical for the M-CSF receptor activity, C/EBP 
alone cannot activate M-CSF receptor promoter activity. On the other hand, AMLl 
along with CBFp could by itself activate the M-CSF receptor promoter for six foid. 
The synergistic activation by C/EBP plus AMLl and CBPp was much greater, about 
greater than sixty fold (Zhang et al, 1996). 
AMLl expression specially increasesed during early myeloid 
differentiation but then decreased upon differentiation beyond the promyelocyte 
stage (Nuchprayoon et al, 1994). In addition, AMLl activated the expression of 
early myeloid lineage-specific markers such as M-CSF receptor, IL-3, MPO (Skalnik 
et al, 2002). These findings suggested that AMLl is required for the early myeloid 
differentiation. In addition, disruption of the AMLl gene led to severe impairment of 
definitive hematopoiesis in mice and also defect in vitro myeloid lineage 
differentiation in embryonic stem cells (Okuda et al, 1996). 
AMLl gene is involved in the t(8;21) chromosomal translocation 
commonly found in acute myeloid leukemia, which results in the production of the 
AMLl/ETO fusion protein. Expression of the AMLl/ETO fusion protein in the 
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32Dcl3 cell line prevented G-CSF induced granulocytic differentiation (Westemdorf 
et al, 1998). This finding suggested that AMLl/ETO fusion protein may act as a 
dominant negative inhibitor of AMLl activity in myeloid cell development. 
The MYB family - c-myb 
c-myb is one of MYB family numbers encoding transcription factors which 
bind to consensus DNA sequence 5-(C/T)AAC(G/T)-3. The abundant level of c-myb 
is expressed in proliferating progenitors, but its expression is down-regulated upon 
myeloid cell differentiation. Significant down-regulation of c-myb was exhibited 
during promyelocytic cell differentiation of Ml and HL-60 cell lines (Liebermann et 
al, 1989). Furthermore, severe impairment of myelopoiesis was found in c-myb 
deficient mice (Mucenski et al, 1991). 
Some findings revealed that down-regulated of c-myb is important for 
differentiation of myeloid cell lines. Constitutive expression of c-myb induced early 
differentiation of WEHI-3B(D+) cell but blocked the terminal differentiation of the 
cell (Yanagisawa et al, 1991). Similarly, overexpression of c-myb in granulocytic 
differentiation of 32Dcl3 cell induced early myeloid marker, MPO, but prevented the 
induction of late myeloid marker such as LF under the induction of G-CSF (Bies et 
al, 1995). 
Consistent with the down-regulation of c-myb during myeloid cell 
differentiation, it activates early myeloid—specific genes that encode neutrophil 
elastase, myeloperoxidase and myeloblastin (Oelgeschlager et al, 1996; 
Nuchprayoon et al, 1997; Lutz et al, 2001). The activation of the target genes by 
c-myb encoded protein requires the interaction with other transcription factors. For 
instance, it synergizes with C/EBP and PU.l to activate a myeloid promoter of 
neutrophil elastase (Oelgeschlager et al, 1996). 
Myeloid zinc finger 1 (MZF-1) 
MZF-1 is a zinc finger protein preferentially expressed in myeloid 
leukemia cell lines including HL-60, KG-1 and K562. Its mRNA level regulated 
during induced granulocytic differentiation of HL-60 (Hromas et al, 1991). In 
addition, mzf-1 was specially expressed in immature myeloid stage, from myeloblasts 
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to metamyelocytes. Moreover, reduction of mzf-1 expression inhibited the formation 
of granulocyte colony-forming unit (CFU-G) in vitro (Bavisotto et al, 1991). 
Another report revealed that enforced overexpression of mzf-1 prevented apoptosis 
induced by IL-3 withdrawal in IL-3-dependent FDCPl myeloid cell line (Hromas et 
al, 1996). Also, the deficient mice developed a progressive increase in monocytic 
cells followed by the late formation of monocytic leukemia. Taken together, mzf-1 
expression is essential to the granulopoiesis. However, aberrant expression of the 
gene may cause leukemia phenotypes. 
The consensus DNA binding sites of MZF-1 are 5，-AGTGGGGA-3’ and 
5 ‘-CGGGnGAGGGGGAA-3 ‘. Several promoters of the myeloid genes encoding 
CD34, MPO, c-myb and LF contain these consensus MZF-1 binding sites. The mzf-1 
was showed to activate the transcription from CD34 promoter in K562 cell 
differentiation (Morris et al, 1995). Contrarily, overexpression of mzf-1 repressed 
CD34 and c-myb promoter activities in KG-1 myeloid cell (Perrotti et al, 1995). To 
� sum up, the presence of MZF-1 binding sites in several myeloid promoters and its 
regulation imply that mzf-1 may have a general role in the regulation of 
hematopoietic gene expression. 
HoxAlO 
HoxAlO is a homeobox protein which is preferentially expressed in 
myeloid cells. The mRNA level of HoxAlO was highly expressed in human CD34+ 
stem cells and down-regulated during myeloid differentiation. Its expression could 
not be detected in mature neutrophils and monocytes (Sauvageau et ai, 1994; 
Lawrence et al, 1995). 
Further studies showed that overexpression of HoxAlO caused increased 
numbers of blast colonies in vitro and myeloid progenitors in vivo. In addition to 
overexpression studies, knockout mice showed an increase of neutrophils and 
monocyte to two fold than wild-type or heterozygote mice (Zhang et al, 1996). In 
summary, up-regulation of HoxAlO is critical in controlling of myeloid proliferation 
at myeloblastic or promyelocytic stage. Furthermore, down-regulation of the gene 
may be important for myeloid maturation. 
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The JUN family ~ c-jun 
The c-jun encodes leucine zipper nuclear protein which acts as early 
response gene in differentially myeloid cells. It specially up-regulated during 
monocytic differentiation (Lord et al, 1993). Overexpression of c-jun induced 
WEHI-3B(D+) cell to monocytic differentiation even without induction. Also, the 
gene increased the responsiveness of U937 myeloid cell to phorbol esters, which is 
differentiation inducer, during monocytic differentiation (Szabo et al, 1994). Further 
evidence revealed that high expression of c-jun is essential for the monocyte 
differentiation. The encoded protein activated the M-CSF receptor gene indirectly via 
its interaction with PU.l during early monocytic differentiation (Behre et al, 1999). 
Moreover, c-jun and PU.l cooperatively activated the macrosialin and macrophage 
savenger receptor promoter during macrophage maturation (Li et al, 1998). 
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1.3 Deregulated hematopoiesis - Leukemia 
Leukemia is defined as malignant disorder of hematopoietic cells which 
are generally characterized by an uncontrolled clonal proliferation. Such defect is 
caused by deregulated balance between self-renew and differentiation of 
hematopoietic cells, which usually arise from stem cell population. Thus, there is an 
increase of cells and even a blockage of normal differentiation and maturation along 
hematopoietic processes. 
1.3.1 Classification of leukemia 
Leukemia are divided into the four major categories: acute myeloid 
leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) 
and chronic lymphoid leukemia (CLL). This classification is according to the 
developmental form of disease (acute or chronic) and the lineage origin of malignant 
cells (myeloid or lymphoid) (Schiffman, 1998). 
The acute leukemia is characterized by an untrammeied proliferation of 
poorly differentiated hematopoietic cells. These give rise to accumulation of 
malignant blasts (stem and progenitor cells) in the bone marrow and blood. In case of 
AML, more than 30% of hematopoietic cells are blast in bone marrow (Hoffbrand et 
al, 2001). Acute leukemia are aggressive in development, if left untreated, these 
diseases are rapidly fatal because of either uncontrolled infection or bleeding. In 
contrast, chronic leukemia show increased proliferation of blast, but still maintain 
relatively well differentiation of mature cells. This results a sudden increase of both 
progenitor and mature cells, but with normal cell differentiation in body. Despite 
chronic leukemia is less speedy in development, in case of CML, leukemia 
progenitors may lose their ability to differentiate and these diseases become replaced 
with phenotype of acute leukemia. Such blast transformation is extremely difficult to 
cure and is generally fatal in several months (Goldman et al, 1997). 
1.3.2 Molecular basis of leukemia 
Chromosomal aberrations are commonly found in leukemia. In general, 
cooperation or accumulation of multiple genetics changes within a single cell may 
cause transformation of hematopoietic cells. These genetic defects may involve 
chromosomal translocation, inversion, deletion and point mutation of 
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proto-oncogenes whose products are involved in the regulation of cell proliferation, 
differentiation and apoptosis (Pallister, 1994). These molecular events may lead to 
the defect in either signal transduction pathways or gene regulatory programme in 
leukemia. For example, 15% of AML is associated with the translocation t(8;21). 
This translocation results in the juxtaposition of the CBFa gene to the ETO gene, 
which located on chromosome 21 and 8 respectively. The chimeric AML 1/ETO 
protein blocks transactivation by normal CBF. This chimera may lead to the blockage 
of cell maturation in AML (Provan and Gribben, 2000). On the other hand, almost all 
cases (>90%) of CML are characterized by the association of the Philadelphia 
translocation t(9;22), which cause the formation of bcr-abl oncogenic combination 
(Skorski et al, 1997). This oncoprotein probably over-activates the signaling 
pathway of proliferation and survival in hematopoiesis, eventually contribute to the 
formation of CML. 
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1.4 Prostaglandin E2 induced WEHI-3B JCS and JCS-14 cell differentiation 
1.4.1 Induced leukemia cell differentiation 
Leukemia cells are a population of hematopoietic cells that retain the 
proliferation ability, but loss the terminal differentiation ability for completing their 
differentiation and maturation program. Such defect from the normal development 
may occur at various stages between the stem and the mature cell states. 
Paradoxically, vast findings evidence that leukemia cells can be induced to 
differentiate with maturation as well as hematopoiesis in vivo (Hozumi, 1983). 
Myeloid leukemia cells, including the murine (Ml , R453, WEHI-3B) and human 
(HL-60, K562, KG-1) cells are the examples. These leukemia cells do retain some 
normal functions and responsive to certain growth factors as normal cells (Hozumi, 
1985). Some of them are multipotential and can be triggered to differentiate to 
various hematopoietic lineages. For example, murine myeloid leukemia cell lines, 
HL-60 and ML-1, can be induced to differentiate into macrophages and granulocytes 
by various inducers. Despite leukemia cells cannot entirely represent the normal cells, 
they can be easily maintained in culture. Thus, leukemia cell lines are useful models 
for dissecting biology and molecular mechanisms of normal and leukemia cell 
differentiation. 
1.4.2 Inducer of cell differentiation - Prostaglandin E2 
Prostaglandins (PG) are one of the major classes of prostanoid whose 
synthesis is initiated by cyclooxygenase-mediated metabolism of the unsaturated C20 
fatty acid, arachidonic acid, to intermediates, PGG2 and PGH2. These intermediates 
can generate five primary bioactive prostanoids, PGE2, PGFia, PGD2, PGI2 and 
TXA2 in the biosynthesis (Smith, 1992). Among them, PGE2 is the major product in 
the metabolism. Furthermore, PGE2 was firstly identified and was so named because 
they partitioned into ether in its cyclopentane ring (Hamberg et al, 1975). 
PGE2 is widely distributed in mammalian tissues and body fluid. It 
mediates a lot of physiological and pharmacological actions. It has contractile and 
relaxant effects on smooth muscle. The vasodilator effects of PGE2 have long been 
recognized in both arterial and venous muscles (Lydford et al, 1996). The contractile 
effect of PGE2 in other smooth muscle, including trachea, gastric fundus and ileum 
are also revealed (Coleman et al, 1990). Besides, PGE2 acts as modulating effector 
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of platelet aggregation. This action of PGE2 is concentration dependent. It directs 
aggregatory and antiaggregatory activities on platelet when its concentration is 
relatively low and high respectively (Coleman et al, 1990). In addition, PGE2 has 
well-documented contributions in immune response of inflammation. PGE2 regulates 
the functions of macrophages and neutrophils (Taffet et al, 1981; Niiro et al, 1997). 
Macrophages are known to produce a large amount of PGE2 in response to 
proinflammatory stimuli such as IL-1, bacterial lipopolysaccharide (LPS). Released 
PGE2 acts on the macrophages themselves and exert inhibitory effects on 
macrophage activation by negative feedback mechanism (Reddy et al, 1994). 
Moreover, PGE2 inhibits the production of various cytokines such as TNF-a, IL-ip, 
IL-2 and IL-12 by macrophages. Such inhibitory effects of PGE2 are mediated by 
elevation of intracellular second messenger, cyclic adenosine monophosphate 
(cAMP). (Mauel et al, 1995;Zhong et al, 1995). 
The diverse biological effects and functions of PGE2 is correlated to the 
expression of multiple PGE2 receptors (EP receptors). These receptors are designated 
EPl , EP2, EP3 and EP4 which exhibit differential expression in different tissues and 
mediate distinct signal transduction pathways (Coleman et al” 1994; Boie et al, 
1997). For example, EPl and EPS are identified as smooth muscle contricior in 
kidney with high level expression of mRNA (Breyer et al, 2001). In LPS-treated 
C3H/HeJ macrophage, EP2 and EP4 showed differential gene expression during 
macrophage activation (Reiko et al, 2001). 
As described above, PGE2 carries out a regulatory role in inflammation and 
other physiological actions. PGE2 does show notable effect on different 
hematopoietic cells as well as leukemia cell lines. For instance, PGE2 inhibited T cell 
proliferation through down-regulation of JAK3 protein in IL-2 dependent signal 
transduction (Vladimir et al, 1999). Besides, PGE2 showed synergistic actions with 
EPO in the differentiation of erythroid progenitors in vitro through stimulation of 
cAMP/PKA/CREB pathway (Boer et al, 2002). During in vivo myelopoiesis of mice, 
PGE2 suppressed CFU-GM proliferation and induced differentiation toward 
monocytic lineage (Pelus et al, 1988). Interestingly, PGE2 also possesses capability 
to induce leukemia cell differentiation. PGE2 induced monocytic differentiation of 
NB4 and WEHI-3B JCS cells (Chen et al, 1997; Mak et al, 1993). Hence, PGE2 can 
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be employed as a potent differentiation inducer in the study of induced differentiation 
of myeloid leukemia cells. 
1.4.3 WEHI-3B JCS and subline JCS-14 cells 
WEHI-3B JCS leukemia cell line is a isolated and characterized subclone 
of the WEHI-3B D" cell line. WEHI-3B cell is murine myelomonocytic leukemia cell 
line. It was derived from mineral oil injected BALB/c mice. WEHI-3B is 
characterized to be similar to human acute myelomonocytic leukemia (AMML) 
(Murphy et al, 1978). The cells appear as typical blast cells with large and round 
nuclei. WEHI-3B cell line was subdivided into D+ and D" sublines based on the 
responsiveness towards G-CSF induction. WEHI-3B D+ but not WEHI-3B D" was 
able to give granulocyte-macrophage colonies in G-CSF induction. Among the 
G-CSF unresponsive WEHI-3B D" cells, WEHI-3B JCS subclone was isolated upon 
TNF-a stimulation. The distinct WEHI-3B JCS subline can differentiate towards the 
monocytic lineage when incubated with non-cytotoxic concentration of TNF-a 
(600-1200 IJ/ml) (Mak et al, 1993). 
WEHI-3B JCS also showed monocytic differentiation triggered by diverse 
inducers like LPS (Chan et al, 1995), growth factors IL-la or 1L-1(3, or midazolam 
(Mak et al, 1997). Differentiation antigens Mac-1 and F4/80 were up-regulated 
associated with the JCS differentiation upon midazolam induction. Synergistic action 
of IL-4 and IFN-y with TNF-a to induce monocytic differentiation of JCS were also 
observed (Leung et al, 1994). 
Besides bacterial product and cytokine, bioactive components from plant 
extracts also possess inducing ability on JCS cell differentiation. Nobiletin and 
tangeretin from the extracts of the pericarpium of Citrus reticulate not only inhibited 
the proliferation of JCS cells, but also induced the differentiation of macrophages 
and granulocytes (Mak et al, 1996). Biochanin A, belonging to plant flavonoid, 
induced the monocytic lineage of JCS cells (Fung et ai, 1997). The phagocytic 
activity demonstrated by the ability to engulf yeast particles was increased as JCS 
cell differentiated in both cases. The clonogenicity and tumorgenicity of the induced 
JCS cells were significantly reduced under nobiletin and tangeretin stimulation. 
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Differentiation inducing effect of prostaglandins on JCS cell has recently 
been investigated in our laboratory. PGE2 was found to induce monocytic 
differentiation of JCS cells. The subclone JCS-14 showed different response to PGE2. 
The JCS-14 cells tend to differentiate towards granulocytic lineage in PGE2 
treatment. The difference in lineage commitment preference of JCS and JCS-14 cell 
thus provide an ideal model for us to study the genes involved in lineage 
commitment of myeloid leukemia cell lines. Likewise, molecular mechanism during 
these differentiation processes is worthwhile to study. 
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1.5 The aims of study 
Cell differentiation and maturation are essential processes in hematopoiesis. 
Differentiation occurs from the stem cell down to specific lineages via the committed 
progenitor cells. Likewise, differentiation commitment exhibits at different points 
during hematopoiesis for restricting the developmental capacity of cells. In 
multi-potential granulocyte-macrophage progenitor cells, the commitment limits the 
cells to enter either granulocytic or monocytic lineages. These highly complex 
processes in hematopoiesis are precisely controlled. Although the molecular 
mechanism of differentiation program is not fully understand, we may employ 
extend our understanding in this field by studying the leukemia cell lines. 
WEHI-3B JCS and JCS-14 myeloid leukemia cells retain certain inducible 
normal pathways for differentiation. They are bipotential granulocyte-macrophage 
progenitor cells which can be triggered to bypass the differentiation and maturation 
blockage under various inductions. The responses of these two cell lines probably 
resemble the differentiation potential and network-like gene regulation of norma} 
cells. Hence, it is valuable to investigate the genes that direct the myeloid 
differentiation and/or bias the lineage-specific differentiation of both JCS and JCS-14 
cells. 
• Prostaglandin E2 (PGE2) induced WEHI-3B JCS and JCS-14 myeloid 
leukemia cell differentiation was used as a model to delineate the molecular 
mechanism of myeloid cell differentiation. Differential hybridization on microarray 
was applied to identify the transcriptional profiling of 588 characterized genes in 
between PGE2 induced and uninduced JCS-14 cells. Genes that change in mRNA 
levels during differentiation stimulated by PGE2 were proved. Furthermore, 
quantitative expression of mRNA in both PGE2 induced JCS-14 and JCS cells were 
examined by using real-time PGR. With antisense hybridization techniques, the 
functions of particular genes in granulocytic and monocytic differentiation were 
characterized. The study may give us more insights into the understanding of both 
leukemia cell differentiation and normal hematopoiesis. 
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Chapter Two Identification of differentially expressed 
genes during PGEz-induced WEHI-3B 
JCS-14 cell differentiation 
2.1 Introduction • 
Differentiation and lineage commitment are precisely regulated by the 
stepwise genetic mechanism. The genetic program may be triggered by external 
stimuli such as growth factor and other inducing agents. The upstream master genes 
are the target of the signal transduction event resulting in the modulation of primary 
gene transcription. The increase or decrease in these early responded transcriptional 
factors further enhance or suppress the downstream gene transcription. The 
modulating level of gene products eventually mediates the processes of cell 
differentiation and lineage commitment (Clemens, 1991). 
WEHI-3B JCS-14 cells is an ideal model for studying the underlying 
molecular mechanism of differentiation. The change in gene transcript (mRNA) 
abundance was monitored in our study. Although mRNA is not the ultimate gene 
product, transcription is the first step in gene regulation. Most of the genome in cells is 
silent, the gene expression regulation is mostly controlled at the level of transcription 
(reviewed in Mohr et al, 2002). Furthermore, the measurement of mRNA levels is 
considerably cheaper and can be done in a more high-throughout way than direct 
measurements of the protein levels (Brazma and Vilo, 2000). 
As discussed earlier, Prostaglandin E2 (PGE2) plays a key role in 
re-differentiation of leukemia cell lines. It induced monocytic differentiation of 
WEHI-3B JCS cell (Chiu, 2001). On the other hand, PGE2 was suggested to exert 
inducing effect on WEHI-3B JCS-14 cells, which is a subline of JCS cells. In order to 
verify the unique differentiation characteristics of JCS-14 cells, examination of cells 
under PGE2 treatment was performed. In the present study, JCS-14 cell differentiation 
was determined by using cell morphological study. Besides this approach, there are 
numerous methods for determining the differentiation of cells. Brief introduction of 
them will list out in section 2.1.1. 
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After the examination of the commitment preference of JCS-14, the 
differentiation of JCS-14 cells was our next goal. Because PGE2-induced gene 
expression profiles of JCS-14 cells might provide us an insight of molecular 
mechanism in the differentiation commitment and the subsequent maturation of 
differentiated cells. We decided to specially identify the novel function of some 
well-characterized genes such as oncogenes, cell cycle regulators and transcription 
factors, in these cellular processes. Atlas^*^ cDNA Expression Array (Clontech) was 
employed for broad-scale analyzing the profile of gene expression to meet our focus in 
study. Detailed information of this microarray method will be discussed in section 
2.1.2. 
2.1.1 Strategy for studying PGEz-induced JCS-14 cell differentiation 
Cell morphological study 
Mature blood cells in each specific lineage are characterized by the 
significant morphological changes in cell size and nuclear shape. For example, blast 
cell has a relatively large cells with a large nucleus and scanty cytoplasm (high N/C 
ratio). For polymorphonuclear granulocyte, the N/C ratio is low. Moreover, the 
nucleus of the cell consists of two to four lobes connected by fine bands of chromatin 
material. This differentiation assay requires the techniques of histochemical staining 
and microscopic examination of cells (Mak et al, 1993). 
Flow cytometric analysis 
Flow cytometric analysis was used for the immunophenotyping of the 
differentiated cells. Since each cell carry specific surface antigens representing their 
lineage and differentiation state, the expression of these markers can provide 
information of cell types. M a d and F4/80 are monocytic specific markers while Gr-1 
is specific for granulocytic pathway. In assay, cells were incubated with monoclonal 
antibody against lineage specific antigen followed by fluorescein 
isothiocyanate-conjugated secondary antibody. Fluorescent-antibody stained cells 
were analyzed using the flow cytometer, fluorescence-activated cell sorter (FACS). 
Based on the expressed fluorescence intensity of cells, various cell types can be 
identified (Leung et al, 1994). 
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Gene expression analysis 
Cell differentiation and maturation are associated with expression of lineage 
specific genes. For instance, granulocytic development is evident by the expression of 
certain genes, myeloperoxidase and lactoferrin. In monocytic differentiation, gene 
coding for lysozyme and scavenger receptor can be used as the indicators. By using 
polymerase chain reaction (PGR) with appropriate primers and followed by gel 
electrophoresis, stage-specific genes expression can be detected in differentiated cells 
(Liu et al, 2000). 
Assessment of differentiation associated characteristics 
Cell undergoing differentiation and mature cells usually exhibit highly 
specialized functions. For example, granulocytes possess the role of phagocytosis in 
bacterial killing and in mediating the inflammatory response. The phagocytic activity 
of mature cells is determined by the uptake of yeast cell (Mak et al, 1993). The 
engulfing activity can be used to indicate the maturity of cells. Other than this 
approach, nitroblue tetrazolium (NBT) reduction assay can also be applied. The 
production of reactive oxygen species in cells is another differentiation associated 
characteristic. This can be assayed by the nitroblue tetrazolium dye reducing activity 
(Leung et al, 1994). 
2.1.2 Method for studying differential gene expression: Microarray Technology 
To identify large-scale transcriptional expression patterns in cells under 
different conditions, several powerful and high-throughput methods have been 
developed. Among these approaches, microarray (Schena et al, 1995) is a newly 
developed technology which allow quantifying tens of thousands of genes in a single 
assay. Microarray is a hybridization-based method that labeled nucleic acid can be 
used to monitor the expression of nucleic acid molecules attached to a solid support. 
To date, Affymetrix GeneChips™ and spotted cDNA arrays are commonly utilized in 
the array technology. 
One of the earliest applications of microarray technology was in the study of 
transcriptional profile of tumors. Malignant transformation results from accumulation 
of genetic and epigenetic events. Microarray technique was successfully applied to 
study large-scale gene expression in the cancer development. For instance, microarray 
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analysis could provide candidate molecular markers for ovarian cancer (Welsh et ai, 
2001) and prostate cancer (Dhanasekaran et al, 2001). In addition, microarray was 
used in elucidation of complex biochemical pathways also (Shoemaker and Linsley, 
2002). 
Methodology of microarry 
Spotted arrays are manufactured using high-speed robots that use hollow 
pins to deposit cDNA or short oligonucleotides onto a solid substrate, usually a 
specially coated glass microscope slide. Spot sizes range between 80 and 150 |im in 
diameter, and arrays that contain up to 80,000 spots can be created. Nucleotide arrays 
can also be produced on a nylon membrane with spots of slightly larger size in a 
lower-density pattern. The gene sequences to be arrayed are selected from several 
public database, which contain resources to access well-characterized genes and 
expressed sequence tags (ESTs) representative of genes of unknown function 
(Macgregor et al, 2002). 
The most popular application of microarray is the parallel examination of 
two different samples representing a test condition and a control condition. Probes are 
synthesized by reverse transcription of total RNA or mRNA. Labeled nucleotides are 
incorporated during this reaction. In the radiolabeling assay, probes prepared from two 
different samples are labeled with phosphorus-32 or phosphorus-33, and separately 
hybridized on an individual array. Another strategy uses nucleotides labeled with 
fluorescent dyes, commonly green Cy3 and red Cy5, as reporter molecules. Two 
probes are then mixed together and applied on a single microarray. Finally, the signal 
intensities of hybridized probes are measured by appropriate scanning or imaging 
reader. The relative expression levels of gene in two samples can be estimated from 
signal intensities or colors for each spot on the array (Mohr et al, 2002; Ye et al, 
2002). 
Atlas™ cDNA Expression Array (Clontech) allowed a broad-scale 
analyzing the profile of gene expression. The spotted array consisted of 588 known 
genes on a nylon membrane. All these genes were categorized to distinct functional 
classes. They were reported to play key roles in may different biological processes 
such as cell proliferation and differentiation. The additional information of these 
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knoivn goies was available at Clontech's web site. This would facilitated the further 
analysis of these genes in our study. 
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2.2.1 Cell line 
The murine myeloid leukemia cell line WEHI-3B JCS-14 (Mak et ai, 2000) 
was generously contributed by Dr. N. K. Mak in the Department of Biology, the Hong 
Kong Baptist University. JCS-14 cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS, GibcoBRL), 2 mM glutamine, 50 
U/ml penicillin, 50 |il/ml streptomycin and 10 |ig/ml neomycin. Cultures were 
incubated under a humidified atmosphere of 95% air/5% CO2 at 37°C. 
2.2.2 AtlasTM Mouse cDNA Expression Array Clontech 7741-1 
1. Buffer NE 
2. Buffer NT2 
3. Buffer NT3 
4. lOX CDS Primer Mix 
5. Control Poly A+ RNA (0.5 
6. Cot-1 DNA(1 mg/ml) 
7. 1 OX dNTP Mix 5 mM each dCTP, dGTP, dTTP 
8. Deionized H2O 
9. Dithiothretol (DTT) (1 OOmM) 
10. MMLV Reverse Transcriptase 
11. 5X Reaction Buffer 250 mM Tris-HCl (pH 8.3)， 
375 mM KCl, 15 mM MgCb 
12. 1 OX Termination Mix 0.1 M EDTA (pH 8.0)，1 mg/ml 
glycogen 
2.2.3 Chemicals 
1. Agarose Sigma A6013 
2. Canada balsam Sigma CI795 
3. Cesium chloride (CsCl) GibcoBRL 15507-015 
4. Dulbecco's phosphate buffered saline (DPBS) GibcoBRL 21600-051 
5. Diethyl pyrocarbonate (DEPC) Sigma D5758 
6. Ethanol Riedel-deHaen 32221 
7. Ethylenediamine tetraacetic acid (EDTA) Sigma ED2SS 
8. Fetal bovine serum (FBS) GibcoBRL 16000-044 
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9. Guanidinium thiocyanate Sigma G9277 
10. Hemacolor solution 1 Merck 1.11955 
11. Hemacolor solution \ Merck 1.11956 
12. Hemacolor solution 3 Merck 1.11957 
13. Penicillin-streptomycin-neomycin (PSN) GibcoBRL 15640-055 
14. Prostaglandin E2 (PGE2) Sigma P5640 
15. Lauryl sulphate (SDS) Sigma L5750 
16. p-mercaptoethanl Sigma M7154 
17. RPMI-1640 medium GibcoBRL 23400-021 
18. Sodium acetate (NaOAc) Sigma S2889 
19. Sodium bicarbonate Sigma S5761 
20. Sodium chloride (NaCl) Sigma S9625 
21 • Sodium citrate, trisodium salt (NasCitrate- 2H2O) Sigma S4641 
22. Sodium hydroxide (NaOH) Sigma S8045 
23. Sodium phosphate, monobasic (NaHiPCV H2O) Sigma S0751 
24. Tris Pharmacia 17-1321-01 
2.2.4 Solutions and buffers 
1. 1% agarose gel 1 % agarose in 1X TAE buffer 
2. Cesium chloride solution 5.7 M CsCl, O.OIM EDTA (pH 7.5) 
3. 1 OX denaturing solution 1 M NaOH, 10 mM EDTA 
4. DPBS 1 package of RPMI powder dissolved in 
IL milli-Q H2O and autoclaved 
5. Guanidinium thiocyanate solution 4M guanidinium thiocyanate, 0.1 M 
TrisHCl (pH 7.5), 1% P-mercaptoethanI 
6. Hybridization solution 0.1 mg/ml salmon sperm DNA in 
ExpressTM Hyb hybridization solution 
7. 20% Lauryl sulphate (SDS) 200 g SDS per liter H2O 
8. NaOH 1 M NaOH in distilled water 
9. 2X neutralizing solution 1M NaHsPO^HzO (pH 7.0) 
10. 10 mM Prostaglandin E2 1 mg PGE2 dissolved in 284 |il 
absolute ethanol 
11. IX RPMI-1640 medium 1 package of RPMI powder dissolved in 
IL milli-Q H2O, 2 g sodium 
33 
bicarbonate per liter medium, pH 7.2-
7.4 adjusted by NaOH and filter-
一 sterilized by 0.22 |im membrane 
12. RPMI complete medium IX RPMI 1640 medium supplemented 
with 10% FBS and 1% PSN 
13. 20X Standard saline citrate (SSC) 3 M sodium chloride, 0.3 M sodium • 
citrate (pH 7.0) 
14. Wash Solution 1 2X SSC, 1% SDS 
15. Wash Solution 2 O.IXSSC, 0.5% SDS 
2.2.5 Reagents 
1. [a-32p]dATP (10 3,000 Ci/mmol) Amersham PB10204 
2. Express™ Hyb hybridization solution Clontech 8015-1 
3. Salmon sperm DNA GiboBRL 15632-011 
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2.3 Methods 
2.3.1 Morphological study of PGE2-induced JCS-14 cell differentiation 
Untreated cell, cells treated with 0.125, 0.25, 0.5, 1 ,2 ,4 , 8 and 16 ^iM PGE2 
and its ethanol solvent control group at various time after incubation were prepared. 
Approximately 5x10"* cells were cytospined (500 rpm, 5 minutes) onto glass slides in 
the Shandon Cytospin 3 Centrifuge (Shandon Scientific). Cells were fixed with 
Hemacolor 1 for 5 seconds, stained in Hemacolor 2 for 15 seconds and counterstained 
in Hemacolor 3 for 10 seconds. Slides were rinsed with running water for destaining. 
After air-drying, slides were mounted in Canada Balsam and examined at 400X 
magnification. Cells at different stages of differentiation were were categorized as 
immature stage (myeloblasts), intermediate stage (myelocytes) and mature stage 
towards monocytic lineage (macrophage) or mature stage towards granulocytic 
lineage (metamylocyte and polymorphonuclear leukocytes, PMN). The classification 
of cells was according to their morphology, shape of nucleus and nucleus to cytoplasm 
ratio (N/C ratio). At least 500 cells were counted in each cell population. The results 
expressed as mean 士 standard deviation of a? = 3 individual experiments. 
2.3.2 Preparation of total RNA from PGE2-induced JCS-14 cells 
2.3.2.1 Preparation of cell lysates 
WEHI-3B JCS-14 cells were treated with 4 ^iM PGE2 for 5 hours. 
Approximately 1 x 10^ control or induced cells were harvested by centrifugation at 
2,000 rpm for 5 minutes at room temperature. The supernatant was decanted and the 
cells were washed once in cold DPBS. The cells were resuspended in 200 |il cold 
DPBS and the cell suspension was added drop by drop to 5 ml 4 M GT solution under 
vortex. The resulting cell lysates were stored at - 7 0 °C until use. 
2.3.2.2 Isolation of total RNA 
Cellular total RNA was prepared by guanidinium thiocyanate and cesium 
chloride ultracentrifugation method (Chirgwin et al, 1979). 
Frozon cell lysates were recovered in a 65 °C water bath with constant 
vortexing until it was completely thawed. The thawed lysates were kept at 65 °C for 5 
minutes and then chilled on ice quickly. The cell lysates were then squeezed through a 
19 gauge needle 10 times by a sterilized syringe. 2.5 ml cell lysates was laid carefully 
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on top of 1.5 ml 5.7 M CsCl cushion in the polyallomer ultracentrifuge tubes 
(Beckman Cat. No. 270-233833). The preparations were centrifuged in a Beckman 
rotor SW60Ti at 32,000 rpm for 18 hours at 18 T . At the end of the ultracentrifugation, 
all the supernatant at the top ( � 1 cm from the pellets) was removed by aspiration. The 
tube was then quickly inverted and remained in its inverted position to drain out the 
remaining supernatant. Last trace of remained droplets was aspirated without 
disturbing the pellets at the bottom of the tube. The inverted tube was left air-dried for 
5 minutes, then the top portion of the tube was cut off with sterile scalpel. Each RNA 
pellet was then resuspended in 40 at a time (in a total 400 |il) of DEPC-treated water. 
The RNA solution was then transferred to a sterile 1.7 ml eppendorf tube. The RNA 
was precipitated by 45 |il 3 M NaOAc (pH5.2) and 1 ml 100% ethanol. The mixture 
was centrifuged at 14,000 rpm at 4 °C for 30 minutes. The precipitate was then washed 
once by 70% ethanol. Finally, the washed precipitate was vacuum dried in a speed 
vacuum concentrator (Savant) for 10 minutes and redissolved in 50 |il DEPC-treated 
water. The quality and quantity of RNA was estimated by spectrophotometric 
measurement (OD260nm and ODigonm)-
2.3.3 Preparation of cDNA probes 
The synthesis of cDNA probes from total RNA and purification of cDNA 
probes from unincorporated ^^P-labeled nucleotides were done by using the A t l a s [m 
cDNA Expression Arrays (Clontech) following the user manual. 
2.3.3.1 Probe synthesis from total RNA 
Total RNA from each sample (section 2.3.2.2) were reverse transcribed to 
cDNA probe and labeled with [a-^^P]dATP. The labeling master mix (for 4 reactions) 
containing 8 i^l 5X reaction buffer, 4 |il lOX dNTP mix (5 mM each dCTP, dGTP, 
dTTP), 14 [a-32p]dATP (10 ^iCi/^il; 3,000 Ci/mmol), 2 |il DTT (lOOmM) and 4 \i\ 
MMLV (200U/|il) was prepared in an sterile Eppendorf tube and kept on ice until use. 
1 - 2 |li1 RNA solution containing 2 - 5 |ig RNA was mixed with 1 1 OX CDS Primer 
Mix in a new Eppendorf tube. A parallel control reaction was performed with 1 |il 
control Poly A+ RNA instead in another Eppendorf tube. Deionized H2O was added to 
each reaction tube to a final volume of 3 jil if necessary. After mixing by pipetting and 
quick spinning, reaction tubes containing RNA sample were incubated at 70 °C water 
bath for 2 minutes and 48 water bath for 4 minutes sequentially. After completion of 
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the first 2 minutes incubation at 48 °C, 8 of labeling master mix was added to each 
reaction tube. The labeling reaction was done for further 25 minutes at 48 °C and 
placed on ice immediately. 1 |il of 1 OX Termination Mix was added to stop the reaction. 
The labeled probes were stored on ice or at 4 for few hours until use. 
2.3.3.2 Purification of the labeled cDNA probes 
The labeled cDNA probes were diluted with Buffer NT2 to 200 |il total 
volume and mixed well by pipetting up and down. The diluted probes were transferred 
to a NucleoSpin Extraction Spin Column/Collection Tube assembly and centrifuged at 
14,000 rpm for 1 minute. Collection tube with flowthrough after centrifugation was 
discarded. The NucleoSpin Column was then transferred to a new Eppendorf tube. 400 
of Buffer NT3 was added to the Column and the assembly was centrifuged at 14,000 
rpm for 1 minute. Collection tube containing flowthrough was discarded after 
centrifugation. The washing step with Buffer NT3 was repeated twice. Then the 
NucleoSpin Column was transferred to a new Eppendorf tube. Finally, 100 i^l Buffer 
NE was added to the NucleoSpin Column and soaked for 2 minutes. Purified probe 
was eluted by centrifugation at 14,000 rpm for 1 minute. 
2.3.4 Hybridization cDNA probes to the Atlas Array and stringency wash 
The Atlas Array was put in a hybridization bottle and pre-wetted with 
deionized water. Two sets of identical Array were pre-hybridized with 5 ml 
ExpressHyb buffer containing 0.5 mg denatured sheared salmon testes DNA at 68�C. 
The hybridization bottles were rotated constantly for 30 minutes in a hybridization 
chamber. 
Labeled cDNA probes of uninduced or PGE2-induced cell sample (section 
2.3.3.2) was mixed with lOX denaturing solution and incubated at 68°C for 20 minutes. 
The denatured probe was further mixed with 5 }il Cot-1 DNA and 2X neutralizing 
solution and incubated at 68°C for additional 10 minutes. Each concentrated probe 
solution was carefully mixed with prehybridization solution instead of pouring probes 
directly on the surface of the membrane. Two sets of membranes were hybridized with 
different probes at 68°C overnight with continuous agitation. 
After overnight hybridization, hybridization solution was replaced with 200 
37 
ml prewarmed Wash Solution 1. The Atlas Array was washed for 30 minutes with 
continuous agitation at 68°C. Each stringency washing step was repeated three times. 
Then the Array was washed once with Wash Solution 2 at 68°C for 30 minutes and 
further washed with 200 ml of 2X SSC at room temperature for final 5 minutes with 
agitation. After that, two sets of Array were immediately wrapped in plastic wrap. The 
sealed membranes were exposed to Kodak BioMax MR film at - 7 0 � C in X-Omatic 
Cassette (Kodak) for 24 hours. The X-ray films were developed by KODAK M35 
X-OMAT Processor. The hybridization signals were captured by Lumi-Imager (Roche) 
and analyzed by computer program Lumi Analyst 3.1 (Roche). 
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2.4 Results 
2.4.1 Morphological changes of PGEi-treated JCS-14 cells 
WEHI-3B JCS-14 cells were treated with different concentrations of PGE2 
for 2 and 3 days. Cytospin preparation and Hemacolor staining of each sample were 
made. Cells at different stages of differentiation were categorized and scored as blast 
cell, intermediate, metamyelocyte, macrophage and polymorphonuclear cell (PMN) 
under light microscope (Table 2.1). At least 500 cells were counted for each cell 
population and the results are expressed as mean 土 standard deviation of n = 3 
individual experiments. 
Table 2.1 shows the morphological change of PGE2-treated JCS-14 cells. 
With the treatment of PGE2, JCS-14 cells proceeded along the differentiation pathway 
with marked increase in the proportion of cells in the intermediate stage. Most of the 
cells undergoing granulocytic differentiation were in the stages of metamyelocyte and 
PMN. With the treatment of 4 |xM PGE2, over 30% of JCS-14 cells were driven along 
the granulocytic lineage. For the untreated and solvent control groups, majority of 
cells (>96%) remained at the blast stage. 
Figure 2.1 shows the morphology of the PGE^-treated JCS-14 cells. The 
metamyelocytes are characterized by the doughnut shaped nucleus (Fig 2.1 C). The 
PMN are noted by their bi- or tri-lobed nucleus. Blast cells show in figure 2.1 A have a 
higher nucleus to cytoplasm (N/C) ratio. The cells at the intermediate stage have 
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Figure 2.1 Morphological study of PGE2-treated JCS-14 cells. JCS-14 cells (1 x 
104 cells/ml) were incubated with different concentrations (0-16 jiM) of PGE2 at 
37�C for 2 and 3 days. The cells were cytocentrifliged onto the microscopic slides 
and were stained with Hemacolor. JCS-14 cells were cultured in (A) culture medium; 
(B) solvent control medium and (C) 4 |xM PGE2. (Magnification X 400). a: blast cell, 
b: intermediate stage, c: metamyelocyte and d: PMN. 
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2.4.2 Analysis of total RNA from PGEz-induced JCS-14 cells 
WEHI-3B JCS-14 cells were treated with PGE2 for 5 hours. Total RNA of 
induced JCS-14 cells as well as uninduced control cells was extracted by 
guanidinium thiocyanate/cesium chloride ultracentrifugation (Chirgwin et al, 1979). 
The quality and quantity of RNA were determined by spectrophotometric 
measurment (OD260nm and ODzsonm) (Biophotometer, Eppendorf). The purity of each 
sample was estimated by ratio of OD260nm to OD280nm (Table 2.2). 
The integrity of RNA samples was analyzed by gel electrophoresis. 1 jig of 
total RNA of each sample was resolved in 1% agarose gel (Figure 2.2). Clear 28S 
and 18S ribosomal RNA (rRNA) bands were observed. The intensities of 28S bands 
were roughly double of the intensities of 18S bands, which implies the intactness of 
RNA samples without major degradation. No significant genomic DNA 
contamination was found in the samples. 
Table 2.2 Total RNA prepared from PGE2-induced JCS-14 cells 
Sample OD260nm/OD280nm Concentration 
Uninduced JCS-14 cells 2.63 \igl\i\ 
JCS-14 cells of 5 hours PGE2-induction 2.09 2.98 
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Figure 2.2 Total RNA of PGE2-induced JCS-14 cells. Total RNA extracted from 
JCS-14 cells at 0 and 5 hour of PGE2 induction was resolved in 1% agarose gel. 
Distinct 28S and 18S rRNA bands were observed. Lane M was the 1 kb plus DNA 
ladder marker. 
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2.4.3 Hybridization of cDNA probes to Atlas^^ cDNA Expression Array 
To analyze broad-scale expression profile of PGE2-induced JCS-14 cells, 
the A t l a s � M Mouse cDNA Expression Array was used. The cDNA array is a 
positively charged nylon membrane on which 588 mouse cDNAs are immobilized. 
Each PCR-amplified cDNA fragment is 200-500 bp long and is spotted in duplicate 
(10 ng of cDNA) on the membrane. As shown in figure 2.3, the cDNAs are arrayed 
into functional classes that represent many areas of current research such as 
oncogenes, the cell cycle and apoptosis. In addition, negative control dots and 
housekeeping genes are also arrayed. 
Since two membranes were included in the kit, only two different mRNA 
preparation were compared namely. P labeled-cDNAs generated from the total 
RNA samples of untreated and 5 hours PGE2-treated JCS-14 cells (section 2.3.3). 
The labeled cDNA probes were then separately hybridized to the membranes. The 
hybridization patterns were captured by Lumi-Imager (Roche) (Figure 2.4). The 
signals were quantified by computer program Lumi-Analyst 3.1 (Roche) (Table 2.3 
and 2.4). To minimize the false-positive signal in analysis, spots showing less than 
2.5 fold of the background signal were ruled out. Only gene spots with more than this 
value in expression were further investigated and normalized with housekeeping 
gene (Table 2.5). 
Relative expression level were assessed by comparing the signal of two 
samples (Table 2.6). Only those genes with signal differences of more than 2 fold 
were considered as modulated. Differentially expressed genes during PGE2-induced 
JCS-14 cells were listed (Table 2.7). Among the 588 known genes, 236 were found 
to be modulated with more than 2-fold difference in the expression levels between 5 
hours PGE2-induced JCS-14 cells and uninduced cells. Among the differentially 
expressed genes, six types of expression patterns were observed. Nine genes were 
up-regulated after PGE2 induction, in which 3 genes were expressed in more than 4-
fold. Besides, there were 13 induced genes showing expression but were 
undetectable in the untreated cells. On the other hand, 30 genes were down-regulated 
including 3 genes with more than 4-fold decrease and 27 genes with more than 2-fold 
decrease in expression. Finally, 184 genes were repressed in expression after P G E 2 
induction. 
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Figure 2.3 Genes on the Atlas^"^ Mouse cDNA Expression Array. The cDNAs are 
arrayed into distinct functional classes. Block A contains oncogenes, tumor 
suppressor genes as well as cell cycle regulators. Block B contains genes of stress 
response proteins, ion channel & transport proteins and also intracellular signal 
transduction modulators & effectors. Block C includes apoptosis-related proteins and 
DNA synthesis, repair & recombination protein. Block D includes transcription 
factors and general DNA binding proteins. Block E contains the receptors of growth 
factor, chemokine, interleukin, interferon, hormone and neurotransmitter. 
Cell-surface antigen and cell adhesion proteins are also included in block. Block F 
contains genes which are related to cell to cell membrane. They are growth factors, 
cytokines, chemokines, interleukins and interferons. Besides, genes of cytoskeleton , 
motility proteins and protein turnover are included in this block. Several plasmid and 
bacteriophage DNAs are included as negative control, along with 9 housekeeping 
genes in Block G. Genomic DNA spots (dark gray dots) serve as orientation marks to 
for determination of gene coordinates. Detail information of the genes is available on 
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Figure 2.4 Gene expression profiling with the Atlas™ cDNA Expression Array. 
Two identical array membranes were hybridized with the P labeled cDNA probes 
of JCS-14 cells at (A) 0 hour and (B) 5 hours after PGE2 induction at 68�C for 18 
hours. The membranes were then exposed to X-ray film for 24 hours at -70°C. 
Hybridization signals of the film were detected by autoradiography. 
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Table 2.3 Numerical representation of hybridization signals of untreated JCS-14 
cells by Lumi-imager analysis system 
Block A 
1 2 3 4 5 6 7 
a 1.9542 20.29617 10.049805 72.587 丨 5 5.39381 43.03567 16.44465 
b 2.7993 1.07958 33.9547 6.040615 6.986335 9.901187 1.6246805 
c 29.63485 4.109953 1.73222 8.615035 64.932 62.8123 7.879925 
d 1.60534 1.997807 15.53415 4.405005 7.83487 9.455587 2.782165 
e 27.433 4.138433 4.49398 1.1010915 14.58835 1.321512 2.17555 
f 11.72455 30.18117 1.4800205 1.92686 14.64205 2.277297 3.361915 
g 3.1751 8.952383 7.62094 20.33605 2.81795 52.82397 1.3760905 
h 3.449265 14.06483 0.3222015 9.3216 0.794225 5.585403 15.80355 
i 47.14085 95.17123 19.0859 0.5391645 2.17125 23.54927 1.783606 
j 61.34755 丨 0.00873 14.635005 24.74245 47.4277 35.11043 10.03044 
k 17.17171 42.21027 24.96025 21.7612 0.518411 26.7266 12.870545 
I 11.5337 108.7368 48.29745 5.830675 34.8474 14.75123 20.9692 
m 5.23826 9.460147 14.7543 1.4867045 2.06618 10.39279 149.443 
n 22.19345 6.008813 30.00665 3.779125 9.769535 5.790193 21.9418 
Block B 
1 2 3 4 5 6 7 
a 6.9288 43.70376667 13.60305 6.751045 0.738263 18.03683333 4.23439 
b 53.6302 2.54862 3.45457 0.9826965 0.71283 11.96175 48.7651 
c 96.41125 3.95734 4.5839 11.221 3.93032 6.8291 1.9739 
d 109.034 5.857285 3.11913 10.40155 7.7737 1.68785 0.8298415 
e 13.92 丨 98 1.49675 2.97877 35.80825 5.56969 2.50492 3.66315 
f 38.69445 2.62356 8.660195 4.36336 0.948232 3.982025 16.8975 
g 2.431045 4.104415 4.563065 15.7891 1.197708 19.4247 60.2093 
h 19.4576 44.83495 22.8216 12.5437 1.882715 1.233996 3.800565 
I 24.9004 0.4961985 1.40192 10.8572 45.6077 2.35877 7.441885 
j 2.633895 2.071825 2.88761 15.6336 3.521055 5.997075 13.1178 
k 74.03085 7.808325 5.440375 3.398605 6.39813 32.06095 7.237205 
I 16.71055 1.55933 7.731225 2.48089 6.27525 0.4153445 2.29973 
m 40.8588 1.07637 3.19716 5.458435 127.6525 1.0654925 16.23665 
n 4.608675 1.957265 4.38389 5.92657 11.45332 2.590475 4.165265 
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Continue table 2.3 
Block C 
1 2 3 4 5 6 7 
a 1.913279 61.4729 6.262775 8.18856 2.67538 42.09755 6.65899 
b 8.512965 128.7085 3.197925 28.1366 5.98072 28.178 10.07443 
c 18.9959 16.2655 7.490605 126.061 11.841 1.56069 2.95519 
d 2.511215 7.566255 3.7491 28.5072 29.0913 2.5388 6.529335 
e 44.26755 0.6611105 35.8158 61.3423 5.102825 3.55467 2.297765 
f 22.06885 0.3645915 49.55905 4.299195 35.36085 2.99003 4.93824 
g 32.8824 5.65881 5.344345 1.565795 6.53282 3.468235 10.72859 
h 50.89015 2.56947 33.18875 9.551475 15.2513 24.30165 1.2187405 
i 3.54147 3.8995 1.431195 10.23182 2.050835 22.93245 13.67705 
j 2.36425 3.7275 8.22231 14.93925 5.736145 125.477 34.4379 
k 36.8928 85.6674 31.15205 0.6928565 10.14645 3.23997 7.528225 
I 2.589835 4.841745 3.64715 0.8600765 5.111415 44.1411 3.44734 
m 128.253 1.4666345 0.5069 5.01569 3.659285 2.51206 3.82341 
n 11.66565 0.8508575 1.8471 3.66596 24.37975 8.24235 4.37742 
Block D 
1 2 3 4 5 6 7 
a 3.389945 23.582 1.86098 6.353935 0.57069 6.0854 1.148415 
b 5.3133 8.68714 13.29725 92.05805 1.415725 1.6729715 19.1539 
c 0.952989 2.49629 12.66211 3.099495 3.41459 0.8778645 1.79137 
d 9.42241 41.85945 14.99535 6.349105 8.882715 4.627605 6.161615 
e 1.433845 1.81708 0.325827 22.96765 7.61157 0.8063295 16.02915 
f 5.9959 5.81416 4.260385 0.770354 3.487285 2.551495 1.148068 
g 11.28651 73.4188 2.1329 1.266335 1.66785 17.96545 4.10182 
h 丨4.99335 5.637735 59.91685 10.478465 24.90335 21.56775 7.460095 
i 15.9861 0.776421 1.64416 17.23445 1.214319 3.31646 4.98344 
j 8.85086 3.63728 45.58195 82.2498 3.21492 6.086015 126.301 
k 3.272905 2.758605 1.63048 10.41417 3.14011 19.2239 18.1519 
I 28.41695 4.4347 25.803 6.922155 16.17455 23.71695 3.39103 
m 69.2494 4.2567 丨 丨 3.5268 5.08283 112.0755 1.191972 4.48509 
n 22.4893 1.5465025 3.10789 1.4879195 4.036715 3.15376 10.4691 
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Continue table 2.3 
Block E 
1 2 3 4 5 6 7 
a 3.782525 4.30432 1.751875 3.49414 4.09745 4.69137 0.7724355 
b 6.330045 1.380475 1.054942 1.77875 1.23636 2.629525 7.22655 
c 2.92127 1.589712 9.59586 2.20364 1.156269 4.63731 5.18139 
d 7.35714 23.053 8.495 18.0651 4.095475 7.64746 3.11764 
e 3.90671 114.218 4.725255 丨.2681155 1.090267 12.09135 11.59505 
f 1.94042 5.19277 2.377545 5.326465 1.073502 1.226992 3.207025 
g 1.103826 2.91769 0.723724 1.125974 0.864053 45.2607 22.98445 
h 3.72967 27.2606 5.518885 6.32506 3.708235 2.30937 4.07504 
i 1.421199 0.748637 0.323784 1.967505 2.74182 3.16033 1.5699315 
j 丨.61613 2.15771 1.27847 0.5923825 24.72625 24.4764 10.644105 
k 16.5805 2.145145 2.37266 1.319605 0.702106 2.590915 7.219585 
I 11.39555 0.268476 12.94695 3.62836 13.61025 39.158 1.8685315 
m 1.734655 1.398865 4.660645 0.659224 1.35426 8.59543 0.9880425 
n 23.93225 3.995835 2.32757 3.125765 8.16773 1.605738 2.46186 
Block F 
1 2 3 4 5 6 7 
a 2.5411 6.095935 124.4745 6.908735 1.856968 49.69275 1.79354 
b 8.28424 0.260261 8.72738 0.8010445 1.788365 64.36145 1.428669 
c 13.2027 1.43892 2.68815 1.147444 2.49054 2.07895 1.46752 
d 4.396625 2.161355 8.706065 2.91263 2.3844 77.1251 4.05495 
e 2.782025 2.53188 16.2729 9.725015 1.432029 3.33673 1.538055 
f 3.12989 1.38766 2.28171 80.丨 2125 12.98855 1.043411 13.8349 
g 1.154485 7.018105 1.563095 丨.3669 丨 2.997695 9.781985 5.97933 
h 2.57238 56.21045 7.66489 24.1464 11.92055 71.01545 57.04595 
i 0.706443 3.421785 1.85655 0.803007 3.76105 3.85867 2.830075 
j 1.074017 1.102013 3.328745 2.855275 2.475075 6.747945 2.765425 
k 5.39659 3.538035 2.436565 2.12475 1.633795 3.074245 5.00263 
I 53.49035 38.08525 21.1421 7.8693 丨 0.7616 14.0343 41.3556 
m 4.619875 6.076955 147.634 75.8852 0.876671 6.237835 3.213295 
n 7.298325 3.879865 22.21825 2.0905555 1.45977 0.948466 4.21721 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
1.9024 56.57775 6.81835 82.59645 46.29365 丨 72.037 56.1724 
8 9 10 n 12 13 14 
10.06039 44.45765 5.535345 42.88855 丨 30.764 16.9759 94.0995 
15 16 17 18 19 ^ 21 
6.645175 49.62335 4.00498 61.79895 179.866 45.4251 121.691 
Hybridization signals were analyzed by Lumi Analyst 3.1 system. Expression 
intensities were calculated by taking mean value of 2 duplicated dots. Gene spots, 
which showed greater than 2.5-fold of the background signal (3.974), were 
highlighted in bold. They were chosen for further analysis. 
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Table 2.4 Numerical representation of hybridization signals of 5 hours 
PGE2-treated JCS-14 cells by Lumi-imager analysis system 
Block A 
1 2 3 4 5 6 7 
a 1.48134 8.282565 3.09761 10.54163 2.10302 9.48956 8.426095 
b 1.915875 0.503703 11.88275 2.591925 3.731345 1.65665 0.474919 
c 8.27954 丨.701859 0.980397 2.514265 28.3684 25.22715 1.85516 
d 1.68039 4.09079 7.246415 3.17953 2.042 2.988275 2.19626 
e 15.0825 5.606185 1.2143 0.524706 7.216795 0.09386 1.88363 
f 11.25995 9.18738 1.55809 1.56444 7.02986 1.39746 2.104135 
g 1.82512 4.156375 4.77805 5.93826 1.53901 14.8901 2.081525 
h 2.238505 6.55682 0.785786 3.085705 1.51786 0.914492 11.2039 
i 18.82255 71.3556 10.09933 1.051842 2.68931 5.13974 0.498874 
j 25.13593 13.60655 9.97724 8.33288 39.82105 16.3623 2.865835 
k 8.006665 41.3912 11.74289 5.93881 0.469471 13.9574 4.886205 
I 2.32885 76.66485 15.9187 5.70285 22.4636 7.190855 12.74605 
m 2.882655 3.8626 4.328815 0.678627 1.31468 5.569845 102.752 
n 11.41003 1.89368 10.50885 3.543155 2.78655 3.21433 15.48955 
Block B 
1 2 3 4 5 6 7 
a 2.288745 20.68285 3.733825 1.330017 1.535545 8.532345 2.909415 
b 12.4768 1.58132 1.92372 1.073118 1.661705 5.96639 26.28085 
c 46.87845 1.434115 1.5913 2.24064 0.544627 3.2968 2.06632 
d 71.53345 2.014385 1.007008 5.646645 4.061355 1.245389 1.23441 
e 2.89478 丨.385955 0.757136 12.24525 1.200863 1.521065 丨.371656 
f 12.1759 1.869615 1.62661 2.297125 0.93078 1.38308 6.748775 
g 0.994191 2.916955 0.638102 5.35142 0.516532 12.644 31.8449 
h 6.142775 26.00355 2.343035 9.812685 3.700255 0.754287 丨.811995 
i 4.02563 1.095266 4.64401 2.408 34.4867 1.457183 1.625245 
j 1.236325 1.23327 1.339188 9.561535 丨.91 3.8467 丨 1.452365 
k 37.65065 3.31085 1.60389 2.006085 1.363249 24.99465 2.534735 
I 6.8645 0.198827 4.569745 1.19681 4.02009 0.874189 1.008769 
m 33.89105 0.635241 2.1348 2.57445 75.1577 1.644907 6.114935 
n 2.011805 1.472279 2.75751 3.47394 5.02909 0.701446 2.80541 
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Continue table 2.3 
Block E 
1 2 3 4 5 6 7 
a 1.257195 30.30095 2.135765 1.3755425 2.64415 19.80125 1.89458 
b 3.64589 102.413 2.27768 9.36197 4.899045 8.700905 1.63022 
c 4.932205 11.56035 3.534545 99.90995 0.952987 1.0036095 1.291555 
d 丨.013651 5.08619 1.670955 7.49366 9.78303 1.14875 1.493335 
e 11.8026 0.49177 8.96012 8.586425 1.41639 2.08455 0.691219 
f 7.199745 0.9629485 20.19925 22.7761 10.28608 2.12154 1.54974 
g 13.6836 1.3773635 1.53529 0.7634025 1.43203 0.9389355 4.51582 
h 18.96075 丨.461635 10.83167 2.493515 2.645915 3.118585 0.473541 
i 1.624275 1.626965 1.510397 1.76852 1.04166 5.555185 2.83604 
j 1.141061 1.57795 3.39434 5.790095 1.395005 52.2794 11.48547 
k 12.54655 19.802 6.80687 0.7843795 2.0547 0.343984 10.48961 
I 1.337518 1.303978 1.229858 1.12262 1.657145 20.45985 1.213752 
m 85.82605 1.054313 1.016921 1.54627 1.93137 1.94988 0.629448 
n 2.561165 0.7317965 0.824375 _—2.142785 9.717125 2.1951 1.0398 
Block D 
1 2 3 4 5 6 7 
a 2.18322 8.118005 1.741737 15.0593 1.288009 2.651165 1.154217 
b 1.89796 4.168105 7.88891 67.5526 1.715255 1.55065 7.971005 
c 0.731011 1.87109 15.08895 0.811456 2.25131 0.682121 0.960269 
d 3.02947 11.88685 4.79031 2.52708 4.11887 2.963955 3.01191 
e 1.554193 1.866041 0.989653 4.620795 2.82969 1.039301 9.15942 
f 1.133376 1.716485 3.815435 0.595325 2.219365 丨.3251275 0.65814 
g 3.495715 19.965 丨 1.400495 1.800085 3.926565 23.21835 2.611715 
h 2.24295 2.85426 13.09475 3.61043 32.35345 4.838805 2.618229 
i 2.738375 1.809256 0.094416 3.23055 1.560457 0.820386 11.42015 
j 3.78806 2.153395 15.2828 48.38195 1.073844 3.406615 111.2285 
k 0.914457 1.774045 1.400915 0.849831 1.303494 9.64781 8.33834 
I 5.314535 2.253815 8.899505 6.322005 11.1237 8.01577 1.317606 
m 19.8287 1.420225 17.4209 1.83138 104.9337 1.0744 1.731081 
n 4.120395 0.8321595 0.38843 2.304155 3.065415 1.461747 4.33974 
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Continue table 2.3 
Block E 
1 2 3 4 5 6 7 
a 3.022215 1.90658 1.33477 0.712743 0.469991 2.087095 0.290548 
b 3.251865 0.596011 8.993665 2.041655 2.60769 1.3991565 4.58928 
c 2.426895 8.40008 5.635555 7.985105 3.45887 1.697925 3.30025 
d 1.83627 62.7062 2.137995 1.78076 1.627745 1.671135 0.859526 
e 0.502825 2.0458 0.885068 1.316847 1.75339 2.73895 1.46643 
f 1.308109 2.281955 0.579185 丨.004294 1.579655 4.034355 2.486835 
g 1.013689 13.32785 5.95083 7.626335 2.72593 6.508035 14.9284 
h 1.367966 1.219556 1.058375 2.000635 1.254181 97.3479 2.11691 
i 0.834137 2.282135 0.908917 1.559 10.71365 3.3063 1.855295 
j 7.2097 2.33935 1.130124 0.605063 0.018731 1.48402 4.309585 
k 3.557825 1.616655 5.9878 丨 4.87146 6.35029 9.886045 3.127765 
I 1.14663 1.33803 3.981355 1.195117 0.830097 1.1733555 1.45548 
m 5.70822 1.35884 1.128028 1.79156 2.270145 16.4952 0.886151 
n 0.283616 0.998979 1.066609 1.497525 24.9554 3.26956 1.426158 
Block F 
1 2 3 4 5 6 7 
a 0.524386 1.99615 76.1253 3.685205 0.61271 18.92825 2.72501 
b 2.53003 0.51438 6.09407 1.023187 0.308844 29.07085 1.447747 
c 2.63229 1.44584 0.894139 0.902944 1.002787 1.3683575 1.485995 
d 2.151015 0.983167 1.54704 1.9351 1.217285 28.03635 3.347065 
e 1.292585 1.2018225 7.815055 4.158575 1.202521 0.8661455 0.346925 
f 0.258018 1.529892 1.182063 34.42685 2.830005 0.516564 4.381975 
g 1.478499 3.27184 1.306235 0.708148 1.547565 1.850495 1.021555 
h 0.985154 23.4138 2.134675 4.6048 3.10553 19.44135 29.25745 
i 0.619162 2.075565 1.502015 1.56194 2.728005 0.754385 2.204185 
j 1.043429 1.82358 0.784099 2.325555 1.106974 2.408885 0.015566 
k 1.901615 0.489995 1.12896 1.814485 1.309586 2.09348 3.315975 
I 25.52455 10.9314 4.104565 2.922465 2.38565 3.031135 15.31845 
m 0.920749 1.2683345 95.7479 51.36085 0.660698 1.8574525 0.45101 
n 2.10094 0.968791 7.518935 1.288686 0.374316 2.01816 5.33222 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
1.52362 25.3241 36.55909 114.6456 40.23815 丨 06.8247 37.16275 
8 9 10 I j 12 n 14 
2.071415 21.32185 4.241335 21.218 丨 61.216 6.138005 94.1495 
\5 \6 17 18 \9 W 21 
1.72822 15.7565 1.285302 20.7353 177.167 23.7007 74.4478 
Hybridization signals were analyzed by Lumi Analyst 3.1 system. Expression 
intensities were calculated by taking mean value of 2 duplicated dots. Gene spots, 
which showed greater than 2.5-fold of the background signal (5.204), were 
highlighted in bold. They were chosen for further analysis. 
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Table 2.5 Hybridization signals of PGEz-treated JCS-14 cells in normalized 
values 
Block A 
1 2 3 4 5 6 7 
a - 12.519298 - 丨 5.933922 - 丨 4.343701 丨 2.736247 
b - - 17.961065 -
c 12.5147259 - - - 42.879526 38.13145 -
d - - 10.953132 -
e 22.7975653 8.4738849 - - 10.908361 - -
f 17.019688 13.886948 - - 10.6258042 - -
g - - - 8.9758243 - 22.506748 
h - 9.9107928 - 16.934967 
i 28.4507417 丨07.85572 15.265375 - . - - -
j 37.9935614 20.566631 丨 5.080841 12.59535 丨 60.1904847 24.732014 -
k 12.1022687 62.563805 17.749656 8.9766556 - 21.096949 -
I - 115.88078 24.061502 8.6199964 33.9542773 10.869152 丨 9.265964 
m - - - - - 8.4189561 155.31214 
n 17.2465376 - 15.884382 - - - 23.412831 
Block B 
1 2 3 4 5 6 7 
a - 31.26263 - - - 12.896847 -
b 丨 8.858986 - 9.0183435 39.7241434 
c 70.857916 - - - - - -
d 108.12455 - - 8.535041131 - - -
e - - - 18.50899293 - - -
f 18.404169 - - - - - 10.2009374 
g - - - 8.08880137 - 19.111713 48.1343402 
h 9.2849537 39.304998 - 14.83211183 - - -
i - - - - 52.127485 - -
j - - - 丨 4.4524925 - - -
k 56.909872 - 37.780021 -
I 丨 0.375859 - - - - - -
m 51.227146 - - - 113.60269 - 9.24287285 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
a - 45.80061315 - - - 29.9300646 丨 -
b - 丨 54.7997074 - 丨 4.150842 - 丨 3.15162673 -
c - 17.47374647 - 151.01629 - - -
d - - - 丨 1.326847 丨 4.78728464 - -
e 17.83991316 - 丨 3.5434364 12.978587 - - -
f 10.88258736 - 30.5316512 34.426622 丨 5.54764923 - -
g 20.68308981 -
h 28.65962868 - 16.3723216 -
i - - - - 8.396795452 -
j - - - 8.7518676 - 79.02156781 丨 7.3605636 
k 18.9644丨144 29.93119825 丨0.2887474 - - - 丨 5.8552973 
I - - - 、- 30.92555431 -
m 129.7281344 ‘ - - - - -
n - ： - - 14.68766765 -
Block D 
1 2 3 4 5 6 7 
a - 丨 2.2705594 - 22.7624934 - - -
b - - 丨丨.9242768 102.107376 - - 丨 2.0483654 
c - - 22.8073101 - - - -
(i - 丨 7.9672591 - - - . _ 
e - - - - - - 丨 3.8446832 
f - - - - • 
g - 30.1777278 - - - 35.0950933 -
h - - 19.7930289 - 48.9030162 - -
i - - - - - - 17.2618308 
j - - 23.100319 73.1304786 - - 168.124547 
k - - - - - 丨 4.5828964 丨 2.603601 
I 8.0330472 - 13.4518154 9.55586229 16.8137395 12.1160287 -
m 29.9715559 - 26.3321085 - 丨 58.60973 - -
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
b - - 13.59414 -
c - 丨 2.6969225 8.5182766 丨 2.0696779 - - -
d - 94.7819262 - - - - -
g - 20.丨 45365 丨 8.9948224 11.5273884 - 9.83705 丨丨 22.564635 
h - - - - - 147.143687 -
i - - - - 丨 6.193939 - -
j 丨 0.897635 - - - - - -
k - - 9.0507185 - 9.5986157 14.9429943 -
I - - - 丨垂 • -
m 8.6281115 ‘ - - - 24.9328907 -
n - - ： - 37.720686 - -
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
a - - 115.065218 - - 28.6105042 -
b - - 9.211333063 - - 43.9412875 -
d - - - - - 42.3776159 -
e - - 11.81264319 -
f - 52.03701 - - -
h - 35.3905206 - - - 29.3860671 44.22333785 
I - - - - - • 
J - - - — - • — 
k * " - - — - • • 
I 38.58097 丨6.5230735 - - « - - 23.丨5420482 
m - - 144". 7252488 77.6331574 - - -
n - - n .36505071 - - ^ 8.059778503 
Normalization of hybridization signal of PGE2-treated JCS-14 cells with 
housekeeping gene, Hypoxanthine phosphoribosyl transferase (HPRT). The 
normalized value was calculated by multiplying the raw data to the ratio of 
hybridization signal of HPRT at untreated to that of PGE2-treated (56.172/37.163). 
Those genes, which showed less than 2.5-fold of the background signal, were 
represented by “-，，. They were neglected in further analysis. 
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Table 2.6 Relative gene expression level in PGErtreated JCS-14 cells 
Block A 
1 2 3 4 5 6 7 
a ND 0.616830679 ND/10.05 0.219514368 ND/5.393 0.333297975 0.774491847 
b ND ND 0.528971405 ND/6.04 丨 ND/6.986 ND/9.90 丨 ND 
c 0.422297596 ND/4.12 ND ND/8.615 0.660375869 0.607069798 ND/7.88 
d ND ND 0.705100206 ND/4.405 ND/7.835 ND/9.456 ND 
e 0.831027057 2.047606951 ND/4.494 ND 0.747744674 ND ND 
f 1.451628254 0.460119659 ND ND 0.72570468 ND ND 
g ND ND/8.952 ND/7.621 0.44 丨 3750 丨丨 ND 0.426070767 ND 
h ND 0.704650565 ND ND/9.322 ND ND/5.585 1.071592592 
i 0.603526277 1.133280715 0.799824748 ND ND ND/23.549 ND 
j 0.6丨9316687 2.0548685丨丨 1.030463653 0.509058343 1.269099803 0.704406403 ND/10.03 
k 0.704779472 1.482194015 0.711116917 0.412507381 ND 0.789361507 ND/12.871 
I ND/11.534 丨.065699452 0.498194043 丨.478387383 0.974370463 0.736830055 0.918774407 
m ND/5.238 ND/9.460 Nb/14.754 ND ND 0.810076867 1.039273468 
— n _ _ 10.777100343 ND/6 009 0.529362063 ND ND/9.77 ND/5.79 1.067042413 
Block B 
I 2 3 4 5 6 7 
a ND/6.929 0.715330342 ND/13.603 ND/6.751 ND 0.715028329 ND/4.234 
b 0.35 丨64863 丨 ND ND ND ND 0.788089403 0.8丨460丨906 
c 0.734954856 ND ND/4.584 ND/11.221 ND ND/6.829 ND 
d 0.991659005 ND/5.857 ND 0.820554738 ND/7.774 ND ND 
e ND/13.922 ND ND 0.51689186 ND/5.57 ND ND 
f 0.475628126 ND ND/8.66 ND/4.363 ND ND/3.982 0.603695068 
g ND ND/4.104 ND/4.563 0.5丨2302878 ND 0.9丨 856298丨 0.799450254 
h 0.47718905 丨 0.845989223 ND/22.823 1.182435153 ND ND ND 
i ND/24.9 ND ND ND/10.857 1.142953604 ND ND/7.442 
j ND ND ND 0.924450702 ND Nl)/5.997 ND/13.118 
k 0.76873 丨 851 ND/7.808 ND/5.44 ND ND/6.398 1.133398359 ND/7.237 
I 0.62091664 ND ND/7.731 ND ND/6.275 ND ND 
m 丨.253760405 ND ND ND/5.458 0.889937055 ND 0.569259844 
n ND/4.609 ND ND/4.384 ND/5.927 ND/11.453 ND ND/4.165 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
a ND 0.745053725 ND/6.263 ND/8.189 ND 0.710969275 ND/6.659 
b ND/8.513 1.202715496 ND 0.502933629 ND/5.981 0.46673386 丨 ND/10.074 
c ND/18.996 1.074282775 ND/7.491 1.197961997 ND/11.841 ND ND 
d ND ND/7.566 ND 0.397332847 0.508306079 ND ND/6.529 
e 0.403002045 ND 0.378141391 0.211576473 ND/5.103 ND ND 
f 0.493119821 ND 0.61606611 8.007690225 0.439685393 ND ND/4.938 
g 0.62900 丨 831 ND/5.659 ND/5.344 ND ND/6.533 ND ND/10.729 
h 0.56316652 ND 0.493309378 ND/9.551 ND/15.251 ND/24.302 ND 
i ND ND ND ND/10.232 ND 0.36615344 ND/13.677 
j ND ND ND/8.222 0.58583045 ND/5.736 0.629769343 0.504112143 
k 0.51404099 0.349388428 0.33027513 ND ND/10.146 ND 2.106113628 
I ND ND/4.842 ND ND ND/5.111 0.700606788 ND 
m 1.011501754 ND ND ND/5.016 ND ND ND 
n ND/11.666 ND ^ ND 0.602453579 ND/8.242 ND/4.377 
Block D 
1 2 3 4 5 6 7 
a ND 0.520335823 ND 3.582424651 ND ND/6.085 ND 
b ND/5.313 ND/8.687 0.896747583 1.109162927 ND ND 0.629029355 
c ND ND 1.801225788 ND ND ND ND 
d ND/9.422 0.429228264 ND/14.995 ND/6.349 ND/8.883 ND/4.628 ND/6.162 
e ND ND ND ND/22.968 ND/7.612 ND 0.863719109 
f ND/5.996 ND/5.814 ND/4.26 ND ND ND ND 
g ND/11.287 0.411035427 ND ND ND 1.953476994 ND/4.102 
h ND/14.993 ND/5.638 0.330341613 ND/10.478 1.963712358 ND/21.568 ND/7.46 
i ND/15.986 ND ND ND/17.234 ND ND 3.463838394 
j ND/8.851 ND 0.506786546 0.889126522 ND ND/6.086 1.331141853 
k ND ND ND ND/10.414 ND 0.758581576 0.694340594 
I 0.282685059 ND/4.435 0.521327574 1.380475052 1.039518226 0.51085948 ND 
m 0.432806002 ND/4.257 1.946662067 ND/5.083 1.415204308 ND ND/4.485 
n ND/22.489 ND ^ ND ND/4.Q37 ND ND/10.469 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
a ND ND/4.304 ND ND ND/4.097 ND/4.691 ND 
b ND/6.33 ND 13.594/ND ND ND ND ND/7.227 
c ND 12.697/ND 0.887703305 12.07/ND ND ND/4.637 ND/5.181 
d ND/7.357 4.111479037 ND/8.495 ND/18.065 ND/4.095 ND/7.647 ND 
e ND ND/114.218 ND/4.725 ND ND ND/12.091 ND/11.595 
f ND ND/5.193 ND ND/5.326 ND ND ND 
g ND 20.145/ND 8.995/ND 11.527/ND ND 0.217342001 0.98173482 
h ND ND/27.261 ND ND/6.325 ND 147.143/ND ND/4.075 
i ND ND ND ND 16‘194/ND ND ND 
j 丨 0.898/ND ND ND ND ND/24.726 ND/24.476 ND/10.644 
k ND/16.581 ND 9.051/ND ND 9.599/ND 14.942/ND ND/7.22 
I ND/11.396 ND ND/12.947 ND ND/13.61 ND/39.158 ND 
m 8.628/ND ND ND/4.661 ND ND 2.900714762 ND 
n ND/23.932 ND/3.996 ND ND 4.618258198 ND ND 
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Continue table 2.3 
Block G 
1 2 3 4 5 6 7 
a ND ND/6.096 0.924407955 ND/6.909 ND 0.575748055 ND 
b ND/8.284 ND 1.055452273 ND ND 0.68272681 ND 
c ND/13.203 ND ND ND ND ND ND 
d ND/4.397 ND ND/8.706 ND ND 0.549465944 ND/4.055 
e ND ND 0.725908916 ND/9.725 ND ND ND 
f ND ND ND 0.64947826 ND/12.989 ND ND/13.835 
g ND ND/7.018 ND ND ND ND/9.782 ND/5.979 
h ND 0.629607495 ND/7.665 ND/24.146 ND/11.921 0.413798224 0.775223094 
i ND ND ND ND ND ND ND 
j ND ND ND ND ND ND/6.748 ND 
k ND/5.397 ND ND ND ND ND ND/5.002 
I 0.721269723 0.433844427 ND/21.142 ND/7.869 ND/10.762 ND/14.034 0.559880761 
m ND/4.62 ND/6.077 0.980297552 1.023034234 ND ND/6.238 ND 
n ND/7.298 ND ——0.511518716 ND m ND 丨.911163661 
Relative expression of each gene dot were calculated by dividing the normalized 
value of PGE2-treated JCS-14 cells with untreated control. The neglected data were 
represented by "ND" in table. 
63 
Table 2.7 Differentially expressed genes in JCS-14 cells after 5 hours 
PGE2-induction 
Category Gene Gene description Fold of 
number change 
A. Genes with more than C4f PD-1 possible cell death inducer; Ig gene 8.01 
four-fold increase superfamily member 
E2d G-protein-coupled receptor (GPCR21) 4.11 
E5n CD 18 antigen beta subunit (leukocyte adhesion 4.62 
LFA-1)(CD3, P150, 95) 
B. Genes with more than A2e A-myb proto-oncogene; myb-related protein A 2.05 
two-fold increase A2j RNA polymerase I termination factor TTF-1 2.05 
C7k Ubiquitin-conjugating enzyme, yeast Rad6 2.11 
homologue; murine HR6B 
D4a Homeo Box protein 2.1 (Hox-2.1) 3.58 
D7i Transcriptional enhancer factor 1 (TEF-1) 3.46 
E6m Dystroglycan 1 2.90 
C. Expressed genes after Elj Granulocyte colony-stimulating factor receptor 
PGE2-induction Elm ERBB-2 receptor (c-neu, HER2 protein tyrosine 
kinase) 
E2c Fibroblast growth factor receptor Basic (b 
FGF-R) 
E2g Limphotoxin receptor (TNFR family) 
E3b Somatostatin receptor 2 
E3g Interleukin-? receptor 
E3k Calcitonin receptor lb 
E4c Prolactin receptor PRLR2 
E4g 5-Hydroxytryptamine (serotonin) receptor Ic 
E5i Glutamate receptor, ionotropic NMDA2A 
(epsilon 1) 
E5k Nicotinic acetylcholine receptor 
E6h CD 14 antigen 
E6k CTLA-4 (immunoglobin superfamily member) 
D. Genes with more than A4a Pim-1 proto-oncogene 0.22 
four-fold decrease C4e p55cdc; cell division control protein 20 0.21 
E6g CD7 antigen 0.22 
E. Genes with more than Ale BRCA2; Breast cancer susceptibility locus 2 0.42 
two-fold decrease product 
A2f B-myb proto-oncogene; myb-related protein B 0.46 
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A31 B-Raf proto-oncogene 0.49 
A4g Ski proto-oncogene 0.44 
A4k c-Abl proto-oncogene 0.41 
� 6 a Cyclin A (G2/M-specific) 0.33 
A6g Cyclin D2 (Gl/S-specific) 0.43 
B1 b HSP60; heat shock 60 kDa protein 1 0.35 
(chaperonin, GroEL homologue); mitochondrial 
matrix protein P1 
B1 f Osp94 osmotic stress protein; APG-1; 0.48 
hsp70-related 
B1 h HMG1 -related VDJ recombination signal 0.48 
binding protein 
C1 e BAG-1 ； bcl-2 binding protein with anti-cell 0.40 
death activity 
C l f Bak apoptosis regulator; BcI-2 family member 0.49 
C2k c-Akt proto-oncogene; Rac-alpha; proteine 0.35 
kinase B (PKB) 
C3e FAFl; Fas-associated protein factor, apoptosis 0.38 
activator 
C3h FLIP-L; apoptosis inhibitor; FLICE-like 0.49 
inhibitory protein 
C3k IGFR II; insulin-like growth factor receptor II, 0.33 
cation-independent mannose-6-P receptor; 
elevated in Wilms's tumor cells 
C4d Nur77 early response protein; thyroid hormone 0.4 
(TR3) receptor 
C5f AP endonuclease; apurinic/apyrimidinic 0.44 
endonuclease (Apex) 
C6b DNA-polymerase delta catalytic subunit 0.47 
C6i MHR23A; Rad23 UV excision repair protein 
homologue; xeroderma pigmentosum group C 
(XPC) repair complementing protein 
Dll Caudal type Homeobox 1 (Cdxl) 0.28 
D im Caudal type Homeobox 2 (Cdx2) 0.43 
D2d Erythroid transcription factor NF-E2 0.43 
D2g DP-1 (DRTF-polipeptide 1) cell cycle regulatory 0.41 
transcription factor 
D3h Glial cells missing gene homolog (mGCM 1) 0.33 
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F21 Insulin-like growth factor binding protein-4 0.43 
(IGFBP-4) 
F6h Cathepsin D 0.41 
F. Repressed genes after Al l p53; tumor suppressor; DNA-binding protein 
PGE2-induction A im Rb; ppl05; Retinoblastoma 
susceptibility-associated protein (tumor 
suppressor gene; cell cycle regulator) 
A2c WTl ； Wilms tumor protein; tumor suppressor 
A2g c-ErbA oncogene; thyroid hormone receptor 
A2m c-rel proto-oncogene 
A2n Ear-2; v-erbA related proto-oncogene 
A3a Elk-1 ets-related proto-oncogene 
A3e Gli oncogene; zinc finger transcription factor 
A3g Jun-D; c-jun-related transcription factor 
A3m Cot proto-oncogene 
A4b c-Fms proto-oncogene (macrophage colony 
stimulating factor 1 (CSF-1) receptor) 
A4c c-Kit proto-oncogene (mast/stem cell growth 
factor receptor tyrosine kinase) 
A4d Met protooncogene 
A4h Sky proto-oncogene (Tyro3; Rse; Dtk) 
A5a Lymphocyte-specific tyrosine-protein kinase 
LCK 
A5b c-Cbl proto-oncogene (Adaptor protein) 
A5d Lfc proto-oncogene 
A5n Tiam-1 invasion inducing protein; GDP-GTP 
exchanger-related 
A6b Cyclin Al (G2/M-specific) 
A6d Cyclin B2 (G2/M-specific) 
A6h Cyclin D3 (G1 /S-specific) 
A6i Cyclin E(G1/S-specific) 
A6n Cdk5; cyclin-dependent kinase 5 
A7c pl8ink4; cdk4 and cclk6 inhibitor 
A7j Cdc25a; cdc25Ml; MPIl (M-phase inducer 
phosphatase 1) 
A7k Cdc25b; cdc25M2; MPI2 (M-phase inducer 
phosphatase 2) 
B1 a HSP27; heat shock 27kD protein 1 
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Ble MTJl; DnaJ-like heat-shock protein from 
mouse tumor 
B1 i MmMre 11 a putative endo/exonuclease 
Bin Oxidative stress-induced protein mRNA 
B2d Golgi 4-transmembrane spanning transporter; 
MTP 
B2g B7-2; 丁 lymphocyte activation antigen CD86; 
CD28 antigen ligand 2, B7-2 antigen; 
alternative CTLA4 counter-receptor 
B2k Eph3 (Nuk) tyrosine-protein kinase receptor 
B3a Htk; Mdk2 mouse developmental kinase; Eph 
-related tyrosine-protein kinase receptor 
B3c Interleukin-6 receptor beta chain; membrane 
glycoprotein gpl30 
B3f Prostaglandin E2 receptor EP4 subtype 
B3g Tie-1 tyrosine-protein kinase receptor 
B3h Transferrin receptor protein (p90, CD71) 
B3k Beta2-RAR ; retinoic acid receptor beta-2 
B31 CRE-BPl, cAMP response element binding 
protein 1 
B3n I-kappa B beta 
B4a NF-kappa-B transcription factor p65 subunit; 
rel-related polypeptide 
B4c RXR-beta cis-11 -retinoic acid receptor 
B4f StatSa; mammary gland factor 
B4i Transcription factor A10 
B4m Crk adaptor protein 
B4n Csk; c-Src-kinase and negative regulator 
B5d Syk tyrosine-protein kinase (activated 
p21cdc42Hs kinase [ack]) 
B5e Syp; SH-PTP2; adaptor protein tyrosine 
phosphatase 
B5k Jnk stress-activated protein kinase (SAPK) 
B51 LIMK; LIM serine/threonine kinase 
B5n MAPKAPK-2; MAP kinase-activated protein 
kinase; MAPKAP kinase 2 
B6c MAPKK4; MAP kinase kinase 4; Jnk activating 
kinase 1; (JNKKl; SEKl; MKK4) 
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B6f PKC-beta; protein kinase C beta-II type 
B6j PI3-K pi 10; phosphatidylinositol 3-kinase 
catalytic subunit 
B7a Gem; induced, immediate early protein; Ras 
family member 
B7i Dvl2; dishevelled-2 tissue polarity protein 
B7j GapIII; GTPase-activating protein 
B7k IRFl; interferon regulatory factor 1 
B7n Zyxin; LIM domain protein; alpha-actinin 
binding protein 
C lb Caspase-3; Nedd2 cysteine protease (positive 
regulator of programmed cell death ICH-1 
homologue) 
C lc Caspase-7; Lice2; ICE-LAP3 cysteine protease 
C1 n Glutathione S-transferase A 
C2d GST Pi 1; glutathione S-transferase Pi 1; 
preadipocyte growth factor 
C2g Adenosine A2M2 receptor 
C21 CD27; lymphocyte-specific NGF receptor 
family member 
C3a Chop 10; murine homologue of Gaddl53 
(growth arrest and DNA-damage-inducible 
protein) 
C3c CRAFl; TNF receptor (CD40 receptor) 
associated factor; TRAF-related 
C3g Fasl; Fas antigen ligand; generalized 
lymphoproliferation disease gene (gld) in mice 
C3j Gadd45; growth arrest and 
DNA-damage-inducible protein 
C4a NADPH-cytochrome P450 reductase 
C4h PS-2; homologue of the Alzheimer's disease 
gene 
C4i Relaxin , 
C4m STAM; signal transducing adaptor molecule 
C5b TNF 55; tumor necrosis factor 1 (55kd) 
C5c TRAIL; TNF-related apoptosis inducing ligand; 
Apo-2 ligand 
C5e Activator -1 140 KD subunit (replication factor 
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C 140KD) 
C5g Atm; ataxia telangiectasia murine homologue 
C5h ATP-dependent DNA helicase 丨 I 70 kDa 
subunit; thyroid Ku (p70/p80) autoantigen p70 
subunit; p70 Ku) 
C5j DNA ligase I 
C5k DNA ligase III 
C51 DNA polymerase alpha catalytic subunit (p 180) 
C6h HR21spA; protein involved in DNA 
double-strand break repair; PW29; 
calcium-binding protein 
C6n MmRad52; yeast DNA repair protein Rad52 
homologue 
C7a MSH2 DNA mismatch repair protein; MutS 
homologue 2 
C7b PCNA; proliferating cell nuclear antigen; 
processivity factor 
C7d PMS2 DNA mismatch repair protein; yeast 
PMSl homolog2 
C7f RadSO; DNA repair protein 
C7g RAG-1; V(D)J recombination activating protein 
C7i ShcC adaptor; She-related; brain-specific 
C7n XRCCl DNA-repair protein, affecting ligation 
D1 b Activating transcription factor 4 (mATF4) 
Did AT motif-binding factor ATBF1 
Dlf Brain factor 1 (Hfhbfl) 
D1 g Brain specific transcription factor NURR-1 
D1 h Bm-3.2 POU transcription factor 
D1 i Butyrate response factor 1 
D l j CACCC Box- binding protein BKLF 
Din Sim transcription factor 
D2b Engrailed protein (En-1) homolog 
D2f DNA-binding protein SMBP2 
D2h E2F-5 transcription factor 
D21 ERA-1 Protein (ERA-1 -993) 
D2m Erf (Ets-related transcription factor) 
D3d GA binding protein beta-2 chain 
D3f GATA-3 transcription factor 
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D4d Homeo Box protein 3.1 (Hox-3.1) 
D4e Homeo Box protein 4.2 (Hox-4.2) 
D4h Homeobox protein HOXD-3 
D4i Ikaros DNA binding protein 
D4k Interferon inducible protein 1 
D4m Kruppel-like factor LKLF 
D5d Myogenic factor 5 
D5e Neuronal helix-loop-helix protein NEX-1 
D5n SRY-box containing gene 3 (Sox3) 
D6a PAX-5 (B cell specific transcription factor) 
D6d PSD-95/SAP90A 
D6h T-lymphocyte activated protein 
D6j Transcription factor BARXl (homeodian 
transcription factor) 
D7d Transcription factor S-II (transcription 
elongation factor) 
D7g Transcription factor SP2 
D7h Transcription factor IJBF 
D7m Zinc finger transcription factor RU49 
D7n Zinc finger X-chromosomal protein (ZFX) 
E1 b Orphan receptor 
Eld C-C chemokine receptor (Monocyte 
chemoattractant protein 1 receptor (MCP-1RA) 
E1 k Monotype chemoattractant protein 3 
E11 D-Factor/LIF receptor 
E ln ERBB-3 receptor 
E2a Erythropoietin receptor 
E2e Granulocyte-macrophage colony-stimulating 
factor receptor 
E2f Growth factor receptor 
E2h Macrophage mannose receptor 
E2n Interleukin-1 receptor type II 
E3d Interleukin-3 receptor 
E3e Interleukin-4 receptor (membrane-bound form) 
E31 Estrogen receptor 
E3m Glucocorticoid receptor form A 
E4d Low density lipoprotein receptor 
E4f 5-Hydroxytryptamine (serotonin) receptor lb 
70 
E4h 5-Hydroxytryptamine (serotonin) receptor le 
beta 
E5a Cannabinoid receptor 2 (macrophage, CB2) 
E5d GABA-A receptor alpha-1 submit 
E5j Glutamate receptor, ionotropic NMDA2B 
(epsilon 2) 
E51 P-selectin (glycoprotein ligand-1) 
E6a CD2 antigen 
E6c CD3 antigen, delta polypeptide 
E6d CD31 (Platelet endothelial cell adhesion 
molecule 1) 
E6e CD44 antigen 
E6j Cell surface glycoprotein MAC-1 alpha subunit 
E61 Desmocollin 2 
E7b Integrin alpha 4 
E7c Integrin alpha 5 (CDS 1) 
E7e Integrin alpha 7 
E7h Integrin beta 7 subunit 
E7j Lamimin receptor 1 
E7k Neuronal-cadherin (N-cadherin) 
F ib Bone morphogenetic protein 1 
Flc Bone morphogenetic protein 2 (BMP-2) 
(TGF-beta family) 
Fid Bone morphogenetic protein 4 (BMP-4) 
(TGF-beta family) 
F1 k Fibroblast growth factor 9 
F1 m Gamma interferon induced monokine (MIG) 
Fin Glial cell line-derived neurotrophic factor 
F2a Granulocyte colony-stimulating factor (G-CSF) 
F2g Inhibin alpha subunit 
F2m Insulin-like growth factor binding protein-5 
(IGFBP-5) 
F3d Leukemia inhibitory factor (LIF) (cholinergic 
differentiation factor) 
F3h Mad related protein 2 (MADR2) 
F31 Nerve growth factor beta (beta-NGF) 
F4a Placental ribonuclease inhibitor (Angiogenin) 
F4e Thrombopoietin 
71 
F4h Tumor necrosis factor beta TNF-beta 
(Lymphotoxin-alpha) 
F41 Interleukin 10 
F5f CamK II; Ca2+/calmodulin-dependent protein 
kinase II (beta subunit) 
F5h Cytoskeletal epidermal keratin (14 human) 
F5l Fetal myosin alkali light chain 
F6g Cathepsin B 
F6j Cathepsin L 
F61 Cytotoxic cell protease 2 (BIO) 
F6m Cytotoxic T lymphocyte-specific serine protease 
CCP I gene (CTLA-1) 
F7d Protease nexin 1 (PN-1) 
F7f Urokinase type plasminogen activator 
F7g Alpha-1 protease inhibitor 2 
F7k I Serine protease inhibitor 2.4 
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2.5 Discussion 
2.5.1 Morphological study of JCS-14 cell differentiation 
There are various approaches for differentiation assay. Among them, cell 
morphological study is an easy and inexpensive method. It relies on the knowledge 
of morphological characteristics of distinct cell stages. Moreover, more the cell we 
examine or count, more accurate of the assay. 
Generally, cell differentiation is characterized by the cessation of 
proliferation and expression of surface markers typical for maturing cells. Moreover, 
the heterogeneity in functions and morphology are also identified as markers of cell 
differentiation. Since JCS-14 cells is a bipotent granulocyte-monocyte cell line with 
observable phenotypes, morphological change of cells treated by PGE2 was 
examined. Cells were cytospined and fixed followed by histochemical staining in 
experiment. Differentiation was evidenced by the marked morphological change of 
cells from blast cells to either monocytic (macrophage-like cells) or granulocytic 
lineage (lobed-nucleus neutrophils). At least 500 cells were studied in each 
population among three individual experiments. 
2.5.2 Differentiation commitment of JCS-14 cell under P G E 2 induction 
WEHI-3B JCS-14 cells is a recently isolated and characterized subclone of 
JCS cells (Mak et al, 2000, author's unpublished data). These two cell lines have 
their unique characteristics and responses to differentiation-inducing agent. P G E 2 has 
distinguishing biological effect on them as discussed in section 1.4.2. Moreover, it 
affects the growth and differentiation of hematopoietic cells. JCS cells differentiated 
towards the monocytic lineage when incubated with non-cytotoxic concentration of 
P G E 2 (25 nM) (Chiu, 2001). Based on our preliminary result, JCS-14 cells was likely 
to have the lineage preference to granulocytic differentiation after triggered by P G E 2 
(Figure 2.1). 
JCS-14 cells showed their differentiation characteristics obviously after 
they were incubated with 4 |iM P G E 2 for 3 days (Table 2.1). The percentage of blast 
cells dropped markedly from 97.7 士 0.3% to 23.8 ± 0.2%. In contrast, the percentage 
of cells at intermediate stage rose from 1.7 土 0.10/0 to 41.1 土 1.5o/o. Meanwhile, the 
proportion of metamyelocyte and PMN were strongly increased to 22.0 士 l.Oo/o and 
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12.5 士 O.70/0 respectively. 
The uniqueness of JCS-14 cells upon P G E 2 treatment may rely on specific 
signal pathway and/or genetic mechanism of differentiation commitment. To 
investigate the critical genes exerting maximum influence over granulocytic 
differentiation, early responder/master genes which at the top of the regulatory 
cascade are worth noting. These master genes may be the central to differentiation 
commitment, hence directing the transcriptional activities of downstream genes 
along the cell differentiation and maturation. Therefore, overall early transcriptional 
activity (5 hours) of PGE2-induced JCS-14 cells was proposed to study as one cell 
cycle of JCS-14 is 18 hours. 
2.5.3 Gene expression profile by microarray 
In this project, microarray was applied to study the gene expression profile 
of PGE2-induced JCS-14 cells. The array membranes were purchased from Clontech. 
This ready-to-use array, along with the optimized reagents needed to synthesize 
cDNA probes provided us a quick, simple and convenient analysis. However, the 
cDNA array only covered 588 known genes. Novel genes would not be identified in 
our work. Furthermore, only two membranes were included in each purchase. Thus, 
only two mRNA samples (untreated and 5 hours PGE2-treated JCS-14 cells) were 
analyzed at once. Although the array was suggested to reuse after stripping, the 
sensitivity of the array would decrease. In our study, the membranes failed to reprobe 
after stripping. Certainly, we could order more arrays for the investigation of more 
RNA samples. However, it would be costly. 
In radioactive labeling reaction, the isotope, ^^P was employed. Because of 
its high sensitivity by nature, non-abundant mRNAs could be detected. On the other 
hand, signal produced by a hot spot on the array became less closely confined to the 
spot's center, causing signal bleed to neighboring spots. This would complicate the 
interpretation of results for nearby genes in analysis. 
2.5.4 Gene expression profile of 5 hours PGE2-induced JCS-14 cells 
To study the genetic mechanism of differentiation commitment, one of the 
possible approaches is to investigate the overall transcriptional activities in 
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PGE2-induced JCS-14 cells. Hybridization to cDNA array was performed on RNA 
samples from JCS-14 cells induced with 4 |iM PGE2 as well as uninduced control 
cells. Table 2.7 presents those genes whose expression changed by more than 2-fold 
after 5 hours induction with P G E 2 . The majority of these genes (214) were 
down-regulated, whereas only 22 genes were up-regulated. Among them, some were 
shown to play a role in hematopoietic cell differentiation, proliferation, survival, 
apoptosis as well as functional activation. 
Genes with increased expression 
The three most strongly up-regulated genes were PD-1 possible cell death 
inducer, G-protein-coupled receptor (GPCRs) and CD 18 antigen beta subunit. The 
Programed Death-1 {PD-1) gene is a member of the immunoglobulin superfamily of 
genes (Ishida et al, 1992). The PD-1 receptor is a 55 kDa type I transmembrane 
protein of the Ig superfamily, with an extracellular region having one V-like domain 
(Agata et ai, 1996). Murine PD-1 {mPD-1) was originally isolated from 
activation-induced apoptosis in 2B4.11 murine T cell hybridoma cells (Ishida et al, 
1992). mPD-1 was highly expressed on activated T cells, B cells (Agata et al, 1996) 
as well as activated myeloid cells such as macrophages (Nishimura, H., and Honjo, 
T.，1998, unpublished). Recently, human Programmed Death-1 (hPD-1) was shown a 
time dependent up-regulation during activation and differentiation of several T cell 
leukemia including the Jurkat and Sup-T-1 cell lines (Vibhaker et al, 1997). Thus, 
up-regulation of mPD-1 in JCS-14 may temporally correlate with activation and 
functional development of the cells. 
G-protein-coupled receptors (GPCRs) comprise the largest family of 
transmembrane receptors that respond to a lot of signals including neutrotransmitters 
and peptide homones. These receptors couple to second messenger signaling cascade 
mechanisms via heterotrimeric G-proteins (reviewed in Rios et al, 2001). PGE 
receptors are also members of GPCRs (reviewed in Noriyuki et al, 2002). 
Furthermore, distinct kinds of GPCRs such as CCRl, CCR4, CXCRl, CXCR2, 
CXCR4, HM63 and FPRl, were selectively expressed on activated granulocytes 
(Yousefi et al, 2001). The differential expression of these receptors may correlate to 
the function and activation of cells. For example, IL-8 receptor, which is also a 
GPCR, contributed to the granule release and adherence of neutrophils (Knall et al, 
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1996). Moreover, CCR2 and CCR5 of GPCRs exerted a direct effects on T cell 
differentiation (Luther et al, 2001). In present study, augmented expression of GPCR 
gene may refer to the enhanced expression of PGE receptor of JCS-14 cells after 
PGE2-induction. Meanwhile, other types of GPCRs may be up-regulated during the 
differentiation and maturation of JCS-14 cells. 
Besides, CD 18 p2 leukocyte antigen was strongly up-regulated during 
PGEi-induced JCS-14 cells. CD 18 is expressed exclusively by lymphocytes and 
myeloid cells. It forms heterodimers with either CD 11 a, C D l l b or C D l l c to 
generate antigens commonly known as LFA-1, Mac-1 and pi50/95 respectively. 
LFA-1 is expressed on all leukocytes (Kurzinger et al” 1981), while Mac-1 and 
pi50/95 are found primarily on granulocytes and monocyte respectively (Springer et 
al, 1986). During myeloid differentiation, CD18 mRNA expression increased 
markedly due to an increased in CD 18 transcription (Rosemarin et al, 1992). The 
increased steady-state level of CD 18 mRNA was revealed in granulocytic 
differentiation of HL-60 cells (Hickstein et al, 1989). The expression of CD 18 was 
found to mediate the leukocyte adhesion during cell differentiation and maturation 
(Fischer et al, 1988). Additionally, the CD18 promoter was shown to require binding 
by PU.l transcription factor for myeloid expression (Rosmarin et al, 1995). 
Genes with decreased expression 
From the result, the three most strongly down-regulated genes were pim-1 
proto-oncogene, p55Cdc/Cdc20 and CD7 antigen. Pim-1 belongs to the family of 
serine/threonine protein kinase. It acts as hematopoietic cell survival factor. Enforced 
expression of Pim-1 protein in murine factor-dependent FDCPl cells prolonged 
survival after withdrawal of IL-3, while expression of a dominant negative Pim-1 
shortened survival. Importantly, expression of pim-1 highly enhanced expression of 
anti-apoptotic members of bcl-2 family (Lilly et al, 1999). Down-regulation of 
pim-1 and bcl-2 were detected in apoptosis of IL-6-depleted mouse B cell hybridoma 
7TD1 cells (Rahman et al, 2001). On the other hand, pim-1 acted as one of the target 
genes of STATS during GM-CSF induced monocyte differentiation (Lehtonen et al, 
2002). Hence, the down-regulation of pim-1 was reasonable as JCS-14 cell 
proliferation was arrested followed by differentiation. The half-life of granulocyte is 
shorter than that of macrophage. Cell undergoing granulocytic lineage may proceed 
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to cell death relatively faster. Therefore, the down-regulation o f p i m - \ may imply the 
proceeding of cell death during JCS-14 differentiation. 
p55Cdc/Cdc20 is a cell cycle protein expressing in cycling mammalian 
cells and appears to be required for normal cell division (Weinstein et al, 1994). 
Expression of p55Cdc/Cdc20 is regulated during cell cycle, peaking in late G1 and S 
phases. On the other hand, overexpression of p55Cdc/Cdc20 accelerated apoptosis in 
murine myeloid 32Dcl3 myeloid cells. The granulocytic differentiation of cells was 
inhibited (Kao et al, 1996). From our result, down-regulation of p55Cdc/Cdc20 may 
reveal the exit of cell cycle during JCS-14 cell differentiation. 
CD7 antigen is a type I transmembrane glycoprotein member of the Ig 
superfamily. It acts as a specific marker of mature T cells and NK cells and is 
expressed early in their development (reviewed in Bonilla et al, 1997). Besides, 
CD7 was also found to be expressed by leukemia cells from some acute myeloid 
leukemia (CD7+ AML). Interestingly, these myeloid cells tended to lose their CD7 
expression after in vitro culture with differentiation-inducing agent, phorbol ester 
(Tien et al, 1998). These suggested that the down-regulation of CD7 expression 
probably correlate to the terminal differentiation of myeloid cell. 
2.5.5 Further analysis of regulatory genes in PGE2-induced JCS-14 cell 
differentiation 
In this study, a number of regulatory genes during induced JCS-14 cell 
differentiation were identified. Further studies to elaborate on the novel function of 
these genes in cell lineage commitment and differentiation were inevitable. There are 
many approaches to address this question. For example, micro-injection of antibody 
against gene product, induced expression or antisense blocking of genes can be 
adopted. In addition, investigating the expression profile of these genes at additional 
time points under PGE2-treated JCS-14 cells would broaden the scope of study. 
However, because of the constraint of time and labour, a small subset of genes would 
be focused on the further investigation. Those regulatory genes that belong to 
proto-oncogenes as well as transcription factor-related oncogenes were considered as 
genes of interest. 
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Proto-oncogenes are involved in the basic essential functions of the cell 
related to control of cell growth and differentiation. Certain of these genes encode 
nuclear transcription factors controlling further gene expression. For example, est, 
fosjun and myc. Neutralization of the activity of these proto-oncogenes could result 
in a cell cycle blockage, preventing the mitogenic and differentiation response to 
growth factors (Hesketh, 1997). For instance, antisense of c-fos has been shown to 
block in vitro terminal differentiation of normal myeloblasts significantly (Lord et al, 
1993). Enforced expression of c-jun was found to initiate differentiation of WEHI-3B 
(D+) cells (Li et ai, 1994) and induction of partial differentiation of U937 cells 
(Szabo et al, 1994) in the absence of differentiating inducer. 
Among the identified genes in transcriptional profiling, some of them • 
refer to proto-oncogenes and transcription-related. B-myb proto-oncogene, c-erbA 
oncogene and transcription termination factor 1 (TTF-l) are the examples. The 
functions of these three genes related to the differentiation of hematopoietic cells and 
leukemia cells will be discussed in Chapter Three. The novel function of these three 
genes in both JCS-14 cell and JCS cell differentiation would be characterized in the 
following study. 
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Chapter Three Expression profile of identified genes in 
WEHI-3B JCS-14 and JCS cell 
differentiation 
3.1 Introduction 
Differentially expressed genes during PGE2-induced WEHI-3B JCS-14 cell 
differentiation were identified in previous chapter. Among them, three novel 
functional genes were chosen for further study. Their mRNA expression levels would 
be further confirmed. In present, a variety of methods are used to approach this work, 
such as Northern blotting, RT-PCR and in situ hybridization. In this report, real-time 
reverse transcriptase-polymerase chain reaction (RT-PCR) was used to study the 
expression level of mRNA genes. It is a fluorescence-based RT-PCR enabling 
semi-quantification of the PCR product in real time. In other word, the PCR 
amplification reaction is monitored as it happens. The strength and quantification 
principle of real-time RT-PCR will be introduced in section 3.1.1 and 3.1.2 
respectively. 
To study a more complete expression profiles, induction time points of 0, 1, 
5，18 and 48 hours were revealed. Selection of these time points was based on the 
colony stimulating factors (CSF) gene expression profiles in myeloid cells. CSF, as 
mentioned in Chapter One, are the main regulator of hematopoiesis. Some of them are 
particularly important in myeloid cell differentiation. Most of these genes, e.g. IL-2, 
IL-5, IL-6 and TNF, represent early response genes peaked at 1 to 6 hours at least in 
activated blood mononuclear cells and T cells. These genes have half-life ranging 
from 15 minutes to over 5 hours (reviewed in Szeto, 1996). Thus, time courses at 1 
hour and 5 hours were counted as early gene responses during cell differentiation. On 
the other hand, one cell cycle of JCS-14 and JCS cells are about 18 hours. Moreover, 
cells exhibited differentiation phenotypes after 48 hours induction (personal 
communication with Dr. N.K. Mak). 
In addition, expression pattern of the genes during both PGEi-induced 
JCS-14 and JCS cell differentiation were also examined. By comparing the expression 
patterns in these two cell models, may allow us to correlate the change of mRNA 
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levels of these three genes with the differentiation program of monocytic/granulocytic 
differentiation as well as lineage commitment. 
3.1.1 Quantitation of mRNA by Real-time RT-PCR 
Real-time RT-PCR is a sensitive technique measuring PCR product 
accumulation during the exponential phase of the reaction before critical reactants 
become limiting. Furthermore, it provides information as rapidly as the amplification 
process itself without post-PCR manipulations. Conventional techniques like RT-PCR, 
laborious post-PCR processing, such as agarose gel electrophoresis are required. In 
addition, the end-point detection of PCR is less sensitive than real-time PCR. Because 
agarose gel resolution is very poor as it is unable to detect little fold of change, e.g. 
two-fold change. In contrast, real-time PCR can detect as little as a two-fold of change. 
Northern blot is a more labour intensive approach. Moreover, it is insensitive in 
detection and large amount of mRNA is often required. On the other hand, in situ 
hybridization do not need RNA or DNA preparation from the cells and the spatial 
distribution of the mRNA can be determined. Nevertheless, it is technically 
demanding. 
The starting material for real-time RT-PCR is total RNA which is converted 
into cDNA. The cDNA in turn are used as templates for PCR using specific primers. 
Since it is RT-PCR method, only little amount of RNA sample is needed ( � 0 . 0 1 - 1 pg 
of transcript) (Kohler et al, 1995). During real-time RT-PCR, double-stranded 
DNA-binding dye, SYBR Green, continuously incorporate into synthesized double 
stranded PCR products. It has an undetectable fluorescence when it is in its free form. 
However, once bound to dsDNA, it starts to emit fluorescence (Figure 3.1). The 
increase in fluorescence emission can be measured by the ABI PRISM 7700 Sequence 
Detection System (Perkin-Elmer Applied Biosystems) after each completed PCR 
cycle, providing real-time detection of amplified PCR products. 
A computer software program calculates a ARn using the equation ARn = 
Rn+ - Rn", where Rn+ is the fluorescence emission of the product at each time point and 
Rn" is the fluorescence emission of the baseline. Amplification plots (Figure 3.2) using 
real-time data are constructed. The ARn values are plotted versus the cycle number. 
During the early cycles of the PCR amplification, the ARn values do not exceed the 
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baseline. Threshold cycle (Cj) values are calculated by determining the point at which 
the fluorescence exceeds the threshold limit. Since C r is reported as the cycle number 
at this point, Ct values decrease linearly with increasing input target quantity. The 
change in gene transcript among different samples can be determined from the 
difference in their Ct values. 
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Figure 3.1 DNA binding dyes (SYBR Green). (A) The dyes free in the reaction 
solution do not emit fluorescence light when the DNA is denatured. (B) As soon as the 
SYBR Green binds to the dsDNA, target fluorescence occurs, (adapted from Giulietti 
et al, 2001). 
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Figure 3.2 Amplification curve of real-time PCR. The Threshold line' is the level 
of detection or the point at which a reaction reaches a fluorescent intensity above 
background. The threshold line is set in the exponential phase of the amplification for 
most accurate reading. The cycle at which the sample reaches this level is called the 
'Cycle Threshold' (CT). The quantitative measurement of DNA among different 
samples can be calculated from the value of CT. (Reproduced from reference of 
Real-time PCR vs. Traditional PCR, Applied Biosystems). 
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3.1.2 Relative quantitation of gene expression 
To quantify the results obtained by real-time RT-PCR, two different 
methods are commonly used: the standard curve method and the comparative 
threshold (CT) method. In our study, the comparative CT method was applied. In this 
method, arithmetic formulas are used to calculate relative expression levels, compared 
with a calibrator, which usually is a control (untreated) sample. The amount of target 
(treated sample), normalized to an endogenous housekeeping gene and relative to the 
calibrator, is then given by where AACj = ACiCsample) - ACiCcalibrator), and 
ACT is the C j of the target gene subtracted from the CT of the housekeeping gene. The 
equation thus represents the normalized expression of the target gene in the unknown 
sample, relative to the normalized expression of the calibrator sample (Livak et al, 
2001). 
Validation experiment 
Before using the comparative Ct method for quantitation, a validation 
experiment should be performed to ensure the efficiencies of target and reference 
amplification are approximately equal. The same efficiencies can be tested at how ACT 
varies with template dilution. Figure 3.3 demonstrates a plot of log input amount 
versus ACT. If the efficiencies of the two amplicons are approximately equal, the plot 
should have a slope of about zero or less than 0.1 in absolute value. The slope in figure 
is 0.0492, which passes the test. Once it is proven, comparative Cj method for the 
relative quantitation of target can be used. If the efficiencies of the two systems are not 
equal, new primers should be designed (User Bulletin #2’ ABI Prism 7700 sequence 
detection system, PE Applied Biosystem). 
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Figure 3.3 Plot of log input amount versus ACT in validation experiment. 
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3.2 Materials 
3.2.1 Cell lines 
The murine myeloid leukemia cell lines WEHI-3B JCS-14 and JCS (Mak et 
al, 1993; 2000) were kindly contributed by Dr. N. K. Mak in the Department of 
Biology, the Hong Kong Baptist University. JCS and JCS-14 cells were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS, GibcoBRL), 2 
mM glutamine, 50 U/ml penicillin, 50 |il/ml streptomycin and 10 jig/ml neomycin. 
Cultures were incubated under a humidified atmosphere of 95% air/5% CO2 at 37°C. 
3.2.2 SYBR® Green PGR core kit Perkin Elmer 4304886 
1. AmpErase UNG 
2. AmpliTaq Gold DNA polymerase 
3. dNTP Blend (2.5 mM each dATP, dCTP, dGTP and 5mM dUTP) 
4. 25 mM MgCb 
5. lOX SYBR PGR buffer 
3.2.3 Chemicals 
1. Agarose Sigma A6013 
2. Cesium chloride (CsCl) GibcoBRL 15507-015 
3. Diethyl pyrocarbonate (DEPC) Sigma D5758 
4. Dulbecco's phosphate buffered saline (DPBS) GibcoBRL 21600-051 
5. Ethanol Riedel-deHaen 32221 
6. Ethidium bromide Sigma E8751 
7. Fetal bovine serum (FBS) GibcoBRL 16000-044 
8. Guanidinium thiocyanate Sigma G9277 
9. Penicillin-streptomycin-neomycin (PSN) GibcoBRL 15640-055 
10. Prostaglandin E2 (PGE2) Sigma P5640 
11. p-mercaptoethanl Sigma M7154 
12. RPMI-1640 medium GibcoBRL 23400-021 
13. Sodium acetate (NaOAc) Sigma S2889 
14. Sodium bicarbonate Sigma S5761 
15. Sodium hydroxide (NaOH) Sigma S8045 
16. Synergel Diversified Biotech SYN-100 
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17. 1 o x Tris-acetate-EDTA (TAE) Sigma T9650 
3.2.4 Solutions and buffers 
1. Cesium chloride solution 5.7 M CsCl, O.OIM EDTA (pH 7.5) 
2. DPBS 1 package of RPMI powder dissolved in 
1L milli-Q H2O and autoclaved 
3. 1.5 % Synergel 1.5% (w/v) Synergel with 0.7% (w/v) 
agarose in IX TAE buffer 
4. Guanidinium thiocyanate solution 4M guanidinium thiocyanate, 0.1 M 
TrisHCl (pH 7.5)，1% p-mercaptoethanl 
5. NaOH 1 M NaOH in distilled water 
6. 10 mM Prostaglandin E2 1 mg PGE2 dissolved in 284 |il 
absolute ethanol 
7. 1X RPMI-1640 medium 1 package of RPMI powder dissolved in 
1L milli-Q H2O, 2g sodium bicarbonate 
per liter medium, pH 7.2-7.4 adjusted by 
NaOH and filter-sterilized by 0.22nm 
membrane 
8. RPMI complete medium 1X RPMI 1640 medium supplemented 
with 10% FBS and 1% PSN 
3.2.5 Enzymes and nucleic acids 
1. 25 bp DNA ladder GiboBRL 10597-011 
2. 100 mM Dithiothreitol (DTT) Promega P1171 
3. Moloney murine leukemia virus (M-MLV) 
reverse transcriptase (200 U/|al) GiboBRL 28025-013 
4. 1 kb plus DNA ladder GiboBRL 10787-026 
5. Real-time PGR primers see Table 3.1 
6. Oligo d(T)i2-i8 Pharmacia 27-7858-01 
7. RnaseOUT™ ribonuclease inhibitor (40 U/|al) Invitrogen 10777-019 
8. Ultrapure dNTP set Pharmacia 27-2035 
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Table 3.1 List of specific primers for real-time PCR 
Gene Sequence (5'to 3') Tm (°C) Product size 
(bp) 
GAPDH Upper CCCCAATGTGTCCGTCGT 59 91 
Lower ~~CTCAGATGCCTGCTTCACCAC 59 
B-myb^ Upper ~CTCTGGCTCTCGACATTATGGA 5 8 ^ 
Lower CTGGGTGTGACACTGGTTGG 58 — 
c-erbA^ Upper ~GGCGTTTGAGCACTACGTCA 59 ^ 
Lower CGATCATGCGGAGGTCAGT 58 
TTF-lUpper ~AAAAAGACGGCCAGATCCAA 58 ^ 
Lower CCTTCATCACTGTCATCATCGC 5 9 ~ ~ 
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3.3 Methods 
3.3.1 Preparation of total RNA from PGEz-induced JCS-14 and JCS cells 
3.3.1.1 Preparation of cell lysates 
WEHI-3B JCS-14 and JCS cells were induced by 4 ^M and 25 ^M PGE2 
respectively for 1, 5, 18 and 48 hours. Approximately 1x10^ induced cells, including 
the uninduced control, were harvested by centrifugation at 2,000 rpm for 5 minutes at 
room temperature. The supernatant was decanted and the cells were washed once in 
cold DPBS. The cells were resuspended in 200 fil cold DPBS and the cell suspension 
was added drop by drop to 5 ml 4 M GT solution under vortex. The resulting cell 
lysates were stored at -70°C until use. 
3.3.1.2 Isolation of total RNA 
The total RNA from PGE2-induced JCS-14 and JCS cells at 0, 1, 5, 18 and 
48 hours were isolated from the prepared cell lysates by guanidium thiocyanate and 
cesium chloride method as described in section 2.3.2.2. 
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3.3.2 Reverse transcription (RT) 
The total RNAs from various cell types were firstly reverse transcribed to 
first strand cDNA. 1 |ig of total RNA isolated from each treatment of cells was heated 
to 65°C for 5 minutes and reverse transcribed at 37°C for 1 hour by addition of master 
mix of a total volume of 10 having 40 U RNase inhibitor, 0.1 oligo dT^-ig, 0.2 
mM dNTP mixture, IX first strand buffer, lOmM dithiothreitol (DTT) and 200 U 
Moloney murine leukemia virus (M-MLV) reverse transcriptase. This reaction could 
be scaled up for 5 }ig total RNA per reaction by increasing the amount of each 
component in proportion. 
3.3.3 Design of real-time PCR primers 
The specific primers used in real-time PCR reaction for analysis of gene 
expression are crucial to the success of the analysis. The specific primers were 
designed using Primer Express software (Perkin-Elmer Applied Biosystems). There 
are some essential parameters that needed to be considered. First, the size of amplicon 
ranges from 50-150 bp. Second, the GC content of the primers should be in 20-80%. 
Third, identical nucleotide, especially G-rich (four or more G) should be avoided in 
each primer. Moreover, the five nucleotides at the 3'-termini of the primers should not 
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have more than two G and/or C bases. The Tm should be 58-60°C. All above 
parameters were suggested by user bulletin of Applied Biosystems. Besides above 
consideration of primer design, some other parameters also have to be taken into 
account. For instance, the primer selected should form stable duplex formation with 
the specific site on the target DNA. The primer should not prime on any site on other 
site (false priming). Furthermore, primers should be free from complementarity 
especially at the 3'termini. Otherwise, primer-dimer artifacts may yield. 
Computer-aided PCR primer design programme, OLIGO™ could help the checking of 
the primers. 
3.3.4 Determination of relative efficiency of target and reference amplification 
by validation experiment 
The resulting first strand cDNA was synthesized by reverse transcription. A 
total volume of 5 containing first strand cDNA derived from 0.1 |ag total RNA of 
untreated JCS-14 cell was made a serial dilution for testing the efficiency of 
amplification. The diluted templates were boiled for 5 minutes to denature the cDNA 
and chill on ice immediately. The real-time PCR was performed using SYBR Green 
PCR kit. 5 |Lil boiled cDNA template was added in a 50 |il real-time PCR reaction 
containing 5 |il lOX SYBR PCR buffer, 6 |al 25mM MgCb, 4 dNTP Blend (2.5 mM 
dATP, 2.5 mM dCTP, 2.5 mM dGTP, 5 mM dUTP), 0.25 AmpliTaq Gold (5 U/^1), 
0.5 |al AmpErase UNG (1 U/|LI1), 0.5 |j,l of each 5 |LIM specific primers including the 
three genes and GAPDH primers. No-template-control (NTC) for each specific 
primers were prepared using ddHaO instead of cDNA template. 
No-amplification-control (NAC) of each type of template were prepared as the 
component of sample except for no AmpliTaq Gold and AmpErase UNG. The 
real-time PCR reaction was performed in ABI PRISM 7700 Sequence Detection 
System (Perkin-Elmer). The reaction mixture was incubated at 50°C for 2 minutes to 
activate AmpErase UNG and followed by 95°C for 10 minutes to activate AmpliTaq 
Gold. Then the PCR amplification was carried out 40 cycles at 95°C melting 
temperature for 15 seconds and 60°C annealing/extending temperature for 1 minute. 
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3.3.5 Confirmation of expression profile of identified genes in JCS-14 and JCS 
cells by comparative C t method in real-time PCR 
The real-time PCR was performed using SYBR Green PCR kit. Volume of 5 
[i\ containing cDNA derived from 0.1 |ig RNA of each sample was used as template in 
PCR. They were boiled for 5 minutes to denature cDNA and chill on ice immediately. 
Boiled cDNA templates was added in a 50 |il real-time PCR reaction containing 5 jj.1 
lOX SYBR PCR buffer, 6 jil 25mM MgCb, 4 |_il dNTP Blend (2.5 mM dATP, 2.5 mM 
dCTP, 2.5 mM dGTP, 5 mM dUTP), 0.25 |il AmpliTaq Gold (5 U/^il), 0.5 
AmpErase UNG (1 U/|al), 0.5 |j,l of each 5 ^M specific primers including the three 
genes and GAPDH primers. No-template-control (NTC) for each specific primers 
were prepared using ddHiO instead of cDNA template. No-amplification-control 
(NAC) of each type of template were prepared as the component of sample except for 
no AmpliTaq Gold and AmpErase UNG. The real-time PCR reaction was performed 
in ABI PRISM 7700 Sequence Detection System (Perkin-Elmer). The reaction 
mixture was incubated at 50°C for 2 minutes to activate AmpErase UNG and followed 
by 95°C for 10 minutes to activate AmpliTaq Gold. Then the PCR amplification was 
carried out 40 cycles at 95°C melting temperature for 15 seconds and 60°C 
annealing/extending temperature for 1 minute. The amplification of a single size 
product was further verified by gel electrophoresis. After real-time PCR, 15 fil of PCR 
products were electrophoresed on an ethidium bromided-containing 1.5 % Synergel. 
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3.4 Results 
3.4.1 Analysis of total RNA from PGE2-induced JCS-14 and JCS cells 
WEHI-3B JCS-14 and JCS cells were treated with 4 |iM and 25 fiM PGE2 
respectively for 1, 5,18 and 48 hours. Total RNA of induced cells as well as uninduced 
control cells was extracted by guanidinium thiocyanate/cesium chloride 
ultracentrifugation (Chirgwin et al, 1979). The quality and quantity of RNA were 
determined by spectrophotometric measurment (OD260nm and OD280nm) 
(Biophotometer, Eppendorf). The purity of each sample was estimated by ratio of 
O D 2 6 0 n m to OD280nm (Table 3.2). 
The integrity of RNA samples was also analyzed by gel electrophoresis. 1 
|ig of total RNA of each sample was resolved in 1% agarose gel (Figure 3.4). Clear 
28S and 18S ribosomal RNA (rRNA) bands were observed. The intensities of 28S 
bands were roughly double of the intensities of 18S bands, which implies the 
intactness of RNA samples without major degradation. No significant genomic DNA 
contamination was found in the samples. 
Table 3.2 Spectrophotometric analysis of total RNA prepared from P G E 2 -
induced JCS-14 and JCS cells. 
Sample OD260nm/OD280nm Concentration 
Uninduced JCS-14 cells 2.06 2.63 jLig/pl 
JCS-14 cells of 1 hours PGE2-induction 2.09 1.86 
JCS-14 cells of 5 hours PGE2-induction 2.09 2.98 
JCS-14 cells of 18 hours PGE2-induction 2.07 4.42 
JCS-14 cells of 48 hours PGEi-induction 2.08 4.03 
Uninduced JCS cells 2.04 6.68 \ig/\i\ 
JCS cells of 1 hours PGE2-induction 2.03 6.75 |ag/|il 
JCS cells of 5 hours PGEz-induction 1.98 7.40 
JCS cells of 18 hours PGE2-induction 2.03 6.44 
JCS cells of 48 hours PGE2-induction 2.07 4.93 |ag/fil 
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Figure 3.4 Total RNA of PGEz-induced (A) JCS-14 cell and (B) JCS cell. Total 
RNA extracted from cells under different PGE2 induction times (0，1,5, 18 and 48 
hours) were resolved in 1% agarose gel. Distinct 28S and 18S rRNA bands were 
observed. Lane M was the 1 kb plus DNA ladder marker. 
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3.4.2 Validation experiment of real-time PCR primers 
The relative amplification efficiency of specific real-time PCR for B-myb, 
C-erbA and TTF-l were evaluated in this test. Table 3.3 shows the average Cj value for 
three specific primers, B-myb, c-erhA and TTF-l, and also the control gene, GAPDHdX 
different input amounts. The log input amount versus ACj of B-myb, c-erbA and 
TTF-l are showed in figure 3.5，3.6 and 3.7 respectively. The absolute values of slope 
in these three graphs are also less than 0.1. Finally, the amplification curves of these 
three specific primers are demonstrated in figure 3.8, 3.9 and 3.10. 
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Table 3.3 Average C j values for three specific primers and GAPDH at different 
input amounts 
Input amount ng B-myb GAPDH ACy 
total RNA - Average C t Average C t B-myb - GAPDH 
0 . 1 2 3 . 6 1 ± 0 . 4 5 1 5 . 7 3 ± 0 . 1 2 7 . 8 8 土 0 . 4 6 
0.05 24.78 ±0.31 16.98 ±0.11 7.80 ±0.32 
0.025 25.23 ±0 .27 17.60 ±0.36 7.62 ±0.45 
0 . 0 1 2 5 2 6 . 4 7 ± 0 . 1 7 1 8 . 5 1 ± 0 . 1 1 7 . 9 6 土 0 . 2 0 
Input amount ng c-erbA GAPDH ACj 
total RNA Average Cj Average C t c-erbA - GAPDH 
28.27 ±0.61 15.64 ±0.25 12.63 ±0.65 
0.025 29.32 土 0.49 1 6 . 5 0 ± 0 . 1 9 12.81 ± 0 . 5 2 
0 . 0 1 2 5 3 0 . 1 9 ± 0 . 5 8 1 7 . 2 4 ± 0 . 1 4 1 2 . 9 5 土 0 . 6 0 
0 . 0 0 6 2 5 3 0 . 8 6 土 0 . 3 2 1 8 . 3 0 士 0 . 2 9 1 2 . 5 6 ± 0 . 4 3 
Input amount ng TTF-1 GAPDH AC^ 
total RNA Average C t Average C t TTF-1 - GAPDH 
2 6 . 8 9 土 0 . 2 5 1 6 . 1 0 土 0 . 0 8 1 0 . 7 9 ± 0 . 2 6 
0 . 0 2 5 2 7 . 9 1 ± 0 . 2 3 1 6 . 9 8 土 0 . 0 1 1 0 . 9 3 ± 0 . 2 3 
0.0125 28.89 ±0.01 18.01 ±0 .0 10.88 ±0.01 
0 . 0 0 6 2 5 2 9 . 7 3 土 0 . 2 5 1 9 . 0 3 ± 0 . 2 1 1 0 . 7 0 ± 0 . 3 2 
The average values and standard deviation {sd) were calculated from the two 
duplicated samples of each specific sample. The ACT value is determined by 
subtracting the average GAPDH Ct value from the average specific gene C j value. 
The standard deviation {sd) of the difference is calculated from the standard deviations 
of the specific gene and GAPDH values using the formula, sd = •^Jsd�! +sd2^ . All 
ACt of No-template-control (NTC) were 40 in value. 
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Figure 3.5 Relative efficiency plot B-myb & GAPDH. The equation of the plot is 
•y = 0.0073x + 7.7983. The absolute value of the slope of log input amount vs. ACt is 
0.0073, which is less than 0.1. 
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Figure 3.6 Relative efficiency plot c-erbA & GAPDH. The equation of the plot is 
V = -O.OOSx + 12.758. The absolute value of the slope of log input amount vs. ACj is 
0.008, which is less than 0.1. 
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Figure 3.7 Relative efficiency plot TTF-l & GAPDH. The equation of the plot is 
y = -0.032x + 10.905. The absolute value of the slope of log input amount vs. ACT is 
0.032, which is less than 0.1. 
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Figure 3.8 Amplification plots oi B-myb specific primers in validation experiment. 
Each reaction was duplicated in the test. In this figure, only one of the representative 
curves for each duplicated sample is shown. Samples with five different RNA input 
amounts for (A) B-myb specific primers and GAPDH (B) primers are shown by 
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Figure 3.9 Amplification plots of c-erbA specific primers in validation 
experiment. Each reaction was duplicated in the test. In this figure, only one of the 
representative curves for each duplicated sample is shown. Samples with five different 
RNA input amounts for (A) c-erhA specific primers and (B) GAPDH primers are 
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Figure 3.10 Amplification plots of TTF-l specific primers in validation 
experiment. Each reaction was duplicated in the test. In this figure, only one of the 
representative curves for each duplicated sample is shown. Samples with five different 
RNA input amounts for (A) TTF-1 specific primers and (B) GAPDH primers are 
shown by specific color lines. 
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3.4.3 Expression profile of specific genes in JCS-14 and JCS cells by comparative 
C t method 
After the confirmation of relative amplification efficiency of specific 
real-time PGR primer by validation test, the expression profile of three specific genes, 
B-myb, c-erbA and TTF-1, in PGE2-induced JCS-14 and JCS cells were performed. 
Table 3.4, 3.5 and 3.6 show the average Cy value for genes, B-myb, c-erbA and TTF-1 
respectively. Also these C j were used to determine ACt , AACj and relative amount of 
gene in mRNA expression. The amplification curves of these three genes are 
demonstrated in figure 3.11-3.16. Finally, the resulting products in real-time PCR were 
loaded in 1.5% Synergel to confirm the amplification of specific PCR product. 
Specific gene product is showed in each sample, except the one of 
No-template-control (NTC) in figure 3.17. 
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Table 3.4 Average C t values oi B-myb in PGE2-induced JCS-14 and JCS cells 
J C S - 1 4 cell B-myb GAPDH A ^ AACT 2 霍 T 
treated with Average C t Average C t B-myb - GAPDH 
PGE； for 
o S 23.68 ± 0 . 0 4 1 5 . 7 9 ±0.25 7.89 ±0.26 0.00 ± 0.26 L O ^ 
Ihr 23.67 ±0.04 15.68 ±0 .12 8.00 ±0.13 0.11 ±0 .13 0.93 
5hr 24.85 ±0.02 15.49 ±0.23 9.36 ± 0.23 1.48 ±0 .23 0.36 
18hr ‘ 25.69 ±0.08 15.85 ±0 .29 9.85 ± 0.30 1.96 ±0 .30 0.26 
48hr 28.28 ±0.02 16.34 土 0.03 11.94 ±0 .04 4.05 士 0.04 0.06 
JCS cell treated B-myb GAPDH A ^ AACj 
with PGE2 for Average Or Average C j B-myb - GAPDH 
Ohif 23.57 ± 0 . 0 8 1 5 . 2 2 ±0 .27 8.35 ±0 .28 0.00 土 0.28 KO 
Ihr 23.01 土 0.05 14.92 土 0.09 8.09 ±0.11 -0.26 ±0.11 1.2 
5hr 24.63 ±0.06 15.05 ±0.13 9.58 ±0 .14 1.23 ±0 .14 0.4 
18hr 25.94 ±0.39 15.43 ±0 .16 10.52 土 0.43 2.17 ±0 .43 0.2 
48hr 28.17 ±0 .36 16.08 ±0.00 12.09 ±0 .36 3.74 ±0 .36 0.1 
The average values and standard deviation (^ sd) were calculated from three individual 
samples. The ACT value is determined by subtracting the average GAPDH Cj value 
from the average B-myb Ct value. The standard deviation {sd) of the difference is 
calculated from the standard deviations of the specific gene and GAPDH values using 
the formula, sd = ^ d � ) + sdj^ . The AACj calculation involves subtraction by the 
ACt calibrator value (0 hr sample). The values represent the relative expression 
ratio of B-myb in treated samples comparing to the untreated one. All ACT of 
No-template-control (NTC) were 40 in value. 
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Table 3.5 Average C j values oic-erbA in PGE2-induced JCS-14 and JCS cells 
JCS-14 cell C-erbA GAPDH A ^ A A C j 2援丁 
treated with Average Cj Average Cj c-erbA - GAPDH 
PGEz for 
Ohr 27.65 ± 0 . 2 4 1 5 . 6 3 ± 0 . 0 4 1 2 . 0 2 ±0.25 0.00 ± 0.25 Ho 
Ihr 28.65 土 0.56 15.92 ±0.22 12.73 ±0 .60 0.71 ±0.60 0.61 
5hr 29.49 ±0 .04 15.58 ±0.23 13.91 ±0 .24 1.89 ±0.24 0.27 
18hr 28.56 ±0 .06 15.77 ±0.33 12.80 ±0 .34 0.77 ±0 .34 0.59 
48hr 28.27 ±0 .37 16.09 ±0.06 12.18 ±0 .37 0.16 ±0 .37 0.90 
JCS cell treated c-erbA GAPDH AC^ AACj 2复丁 
with PGEz for Average Ct Average Ct c-erbA - GAPDH 
Ohr 28.20 ± 0 . 0 2 1 4 . 7 4 ±0.21 13.46 ±0.21 0.00 ±0.21 iTo 
Ihr 28.34 ±0 .06 14.72 ±0.09 13.63 ±0.11 0.17 ±0.11 0.89 
5hr 28.61 ±0.21 14.44 ±0.30 14.17 ±0 .37 0.71 ±0 .37 0.61 
18hr 29.16 ±0.13 14.72 ±0 .14 14.44 ±0 .20 0.98 ±0 .20 0.51 
48hr 29.24 ±0 .28 15.43 ±0.13 13.81 ±0 .30 0.35 ±0 .30 0.79 
The average values and standard deviation {sd) were calculated from three individual 
samples. The ACy value is determined by subtracting the average GAPDH Ct value 
from the average c-erhA Cj value. The standard deviation (sd) of the difference is 
calculated from the standard deviations of the specific gene and GAPDH values using 
the formula, sd = . The AACT calculation involves subtraction by the 
ACt calibrator value (0 hr sample). The values represent the relative expression 
ratio of c-erbA in treated samples comparing to the untreated one. All ACj of 
No-template-control (NTC) were 40 in value. 
c 
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Table 3.6 Average C t values of TTF-l in PGEz-induced JCS-14 and JCS cells 
^ J C S - 1 4 cell TTF-l GAPDH AC^ AACj 2碰丁 
treated with Average C t Average C j TTF-l - GAPDH 
PGE2 for 
Ohi^  26.89 ± 0 . 1 7 1 6 . 1 2 ± 0 . 0 2 1 0 . 7 8 ± 0 . 1 7 0 . 0 0 土 0.17 LO 
Ihr 27.51 ±0 .32 16.29 ±0.11 11.22 ±0.33 0.45 ± 0.33 0.73 
5hr 26.52 ±0 .04 15.86 ±0.35 10.66 ±0.36 -0.12 ±0 .36 1.09 
18hr 26.81 士 0.15 15.29 ±0.03 11.52 ±0 .16 0.74 ±0 .16 0.60 
48hr 30.12 ±0 .06 18.61 ±0.01 11.51 ±0 .07 0.73 ±0 .07 0.60 
JCS cell treated TTF-l GAPDH A Q AACT ！一‘丁 
with PGE2 for Average C t Average C j TTF-l - GAPDH 
Ohr 24.36 ± 0 . 2 4 1 4 . 6 7 ±0 .16 9.69 ± 0.28 0.00 ± 0.28 K O ^ 
Ihr 24.45 土 0.05 14.72 ±0 .42 9.74 ± 0.42 0.05 ± 0.42 0.97 
5hr 23.73 ±0 .19 14.47 土 0.38 9.26 土 0.43 -0.44 ±0 .43 1.35 
18hr 24.31 ±0 .27 14.76 ±0.32 9.56 土 0.42 -0.13 ±0 .42 1.10 
48hr 25.11 ±0 .03 15.52 ±0.02 9.59 ± 0.04 -0.11 土 0.04 1.08 
The average values and standard deviation (sd) were calculated from the three 
individual samples. The ACT value is determined by subtracting the average GAPDH 
Ct value from the average TTF-l Ct value. The standard deviation {sd) of the 
difference is calculated from the standard deviations of the specific gene and GAPDH 
values using the formula, sd = -^sd^ + sd^ . The AACT calculation involves 
subtraction by the ACT calibrator value (0 hr sample). The l'欣飞 values represent the 
relative expression ratio of TTF-l in treated samples comparing to the untreated one. 
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Figure 3.11 Amplification plots of B-myb expression in PGEi-induced JCS-14 cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 
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Figure 3.12 Amplification plots of B-myb expression in PGEi-induced JCS cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 
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Figure 3.13 Amplification plots of c-erbA expression in PGEz-induced JCS-14 cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 
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Figure 3.14 Amplification plots of c-erbA expression in PGEi-induced JCS cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 
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Figure 3.15 Amplification plots of TTF-l expression in PGEz-induced JCS-14 cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 





1 � 1 Amplification - Pa11^ 18D*c02 
• “ I I 丨 I [ I I 十.. •+-1— 
^ y ^ ^ V Y Y Y Y T'i'T T 
_____ 
0 2 4 6 9 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4 2 6 2 8 5 0 3 2 3 4 5 6 3 8 4 0 
C|e1« 
B 
，�1 Ainplifkatiffn - Pullyl^ DBcOZ 
_ •— — t 
： [ i J J . i | i | " | 胖 11111111 
丰：年 _ _ _ _ _ 
獲f 
IMI 11 111 丨 j I I I I i i I 丨 11 i I 丨丨 111 丨丨丨 111 H 11 丨 11 
0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4 2 6 2 8 ^ 3 2 3 4 3 « 4 0 
cacit 
A B 
0 hr 0 hr 
1 hr 1 hr 
- « — 5 hr 5 hr 
- « — 18 hr 18 hr 
48 hr 48 hr 
Figure 3.16 Amplification plots of TTF-1 expression in PGEi-induced JCS cell. 
Each reaction was duplicated in the experiment. In this figure, only one of the 
representative curves for each sample is shown. Samples of cells treated with PGE2 for 
different incubation times for (A) TTF-1 and (B) GAPDH are shown by specific color 
lines. 
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Figure 3.17 (opposite page) Gel electrophoresis of real-time PCR product (A) 
B-myb, (B) c-erbA and (C) TTF-l in 1.5% Synergel. The fragments were amplified 
in the cDNA derived from 0.1 jig of total RNA of JCS-14 and JCS cells for 40 cycles 
by real-time PCR. M: 25 bp DNA ladder. NT: no-template-control (NTC); +ve: 
GAPDH. The number shown on top of each of the photo indicates the time point of 
the sample. 
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3.5.1 Study of gene expression profiles in JCS-14 and JCS cell differentiation 
The exogenously added PGE2 was shown to be a potent inducer of JCS-14 
and JCS cells differentiating into granulocytes and monocytes respectively. In Chapter 
Two, differential gene expression of PGE2-induced JCS-14 cell was investigated by 
microarray hybridization. Three novel functional genes, B-myb, thyroid hormone 
receptor {c-erbA) and transcription termination factor 1 {TTF-1) among the candidates 
genes were selected for further study. Following previous study, we continued to 
examine the expression pattern of these three genes in term of mRNA levels in both 
JCS-14 and JCS cells. Hence, their possible involvements in induced myeloid cell 
differentiation as well as differentiation commitment triggered by PGE2 may be 
evaluated. Furthermore, the range of our time course study was extended. This would 
provide us a more complete view of the overall effects of the transcriptional activation 
rate and transcript degradation of the specific genes in cell differentiation. 
3.5.2 Transcription analysis by real-time PCR 
Real-time PCR 
In this study, real-time PCR was adopted to study the differentiation 
processes of JCS-14 and JCS cells. This is a fast and sensitive method for detecting 
dramatic changes of mRNA expression even a small or marginal change among 
samples. In the real-time PCR system, the quantity of the bound SYBR Green in 
double strand PCR products represent the quantity of PCR product as well as amount 
of m R N A transcript. However, specificity is diminished due to the risk of amplifying 
non-specific PCR products (Simpson et al., 2000). Indeed, SYBR Green binds to any 
double strand DNA, detecting not only the specific target, but also non-specific PCR 
products and primer dimmers. This is a major disadvantage of using SYBR Green dye. 
There are a few ways of handling this problem (Ririe et al, 1997). For instance, a 
careful design of the primers and optimization of the reaction conditions. Moreover, 
the setting of "No-template-control" (NTC) and "Non-amplification-control" (NAC) 
in PCR reaction can help us to detect the non-specific fluorescent signal of SYBR 
Green dye. Furthermore, gel electrophoresis of final PCR products could confirm the 
synthesis of only single specific PCR product. According to our result, all ACT values 
of NTC and NAC were 40 cycles (Table 3.4-3.6). That meant no amplified product 
114 
was detected by the sequence detection system along the 40 PGR cycles. It indicated 
that no non-specific signal or primer-dimer was produced in these control reactions. 
Furthermore, only desirable PGR products were synthesized, except the one of NTC, 
in each amplification (Figure 3.17). Therefore, the over-estimation of PCR signal was 
eliminated in our analysis. 
Normalization of real-time PCR 
In order to ensure the equivalent conversion of RNAs to cDNA and PCR 
amplification among samples, house keeping gene, GAPDH was used as internal 
control for quantitation. However, the expression of house keeping genes may be 
affected by experimental or physiological conditions. There is plenty of evidence that 
the expression of GAPDH is influenced by experimental treatment or condition 
(Bustin et al., 2000). Luckily, such problem did not occur in our cell system. Refer to 
the result of RT-PCR (data not showed), the expression levels of GAPDH were more 
or less the same in distinct JCS-14 and JCS cell samples. 
Validation experiment 
For the relative quantitation of gene expression (comparative Ct method) to 
be valid in analysis, the efficiency of the target amplification and the efficiency of the 
reference amplification must be approximately equal. A sensitive method, validation 
experiment, for assessing if two amplicons have the same efficiency is to look at how 
ACT varies with template dilution. From the result, the plot of log input amount versus 
ACT has a slope of about zero or less than 0.1 in absolute value for each real-time PCR 
primer (Figure 3.5-3.7). Therefore, same efficiencies were obtained with cDNA 
template dilution in the PCR reactions. Once it was confirmed, comparative Cj assay 
for relative quantitation of target genes was applied in the following. 
3.5.3 Gene expression profiles during PGEz-induced JCS-14 and JCS cell 
differentiation 
In this study, both microarray hybridization and real-time RT-PCR were 
adopted to study the three differentially expressed genes in myeloid cell differentiation. 
Comparing the results of these two analysis (Table 3.7), expression patterns of B-myb 
and C-erbA genes were quite consistent in PGE2-induced JCS-14 cells. Among the 
JCS-14 and JCS cell systems, all of the three genes showed certain degree of 
C 
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differential expression. Their changes in expression level will be discussed in detail in 
the following. 
B-myb 
B-myb belongs to myb oncogene family, which encode nuclear proteins that 
function as transcriptional transactivators. In sharp contrast to A-myb and c-myb, the 
C-terminal domain of B-myb protein exert a positive regulation of its transcriptional 
transactivation activity (Oh and Reddy, 1998). Furthermore, B-myb is expressed 
virtually in all proliferating cells (reviewed in Sala and Waston, 1999). Its expression 
is cell cycle-regulated with the induction of B-myb specific message late in the Gi 
phase and maintained throughout S phase reaching peak level in the G2/M phase. 
Repression of B-myb expression during Go and Gi phases of the cell cycle is mediated 
through binding a protein complex containing the E2F transcription factor (Lam and 
Waston, 1993). In addition, B-myb appears to be phosphorylated during the S phase of 
the cell cycle by cyclin A or cyclin E (Robinson et al, 1996). Besides, co-expression 
of cyclin A or cyclin E leads to significant increase in B-myb transactivation potential 
(Sala et al, 1997). This implicates the correlation between cyclin-dependent 
phosphorylation and increase of B-myb transactivation potential. Other than cell cycle 
progression, B-myb may also play an important role in differentiation. B-myb is 
expressed in neuroblastoma cell lines and is down-regulated during retinoic 
acid-induced differentiation. When it is constitutively expressed in these cells, the 
retinoic acid-induced differentiation was blocked. (Raschella et ai, 1995). One 
hypothesize that the increasing B-myb levels in tumor cell lines may render cells 
refractory to cell transformation. On the other hand, the role of B-myb in 
hematopoietic cell growth and differentiation appears to be very dependent on the 
nature of stimuli that induce differentiation. For instance, overexpression of B-myb 
prevented growth arrest and followed terminal differentiation in murine Ml cells that 
was induced to differentiate by IL-6. Nevertheless, the differentiation markers still 
appeared in the cells (Bies et al, 1996). On the contrary, overexpression of B-myb in 
murine 32Dcl3 cells accelerated terminal differentiation of cells to a granulocytic 
lineage with concomitant growth arrest (Oh and Reddy, 1998). In these cells, 
overexpression of c-myb led to continuous growth and blockage to terminal 
differentiation (Oh and Reddy, 1998). In domain swapping experiment, the various 
domains of C-myb were exchanged with those B-Myb revealed that the C-terminal 
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domain of B-myb was responsible for the acceleration of terminal differentiation (Oh 
and Reddy, 1998). During TPA or DMSO-induced differentiation of HL-60 cells, the 
expression level of B-myb decreased in both monocytic and granulocytic lineages 
(Arsura et al, 1994). 
In the present study, the expression level of B-myb was steadily 
down-regulated during PGE2-induced JCS-14 cell differentiation. The 
down-regulation in expression was notable at 48 hours. Similarly, it also showed 
down-regulated pattern at late hours in a gradual manner in PGE2-induced JCS cells. 
In contrast to the expression profile in PGE2-induced JCS-14 cells, it was likely to 
have a transient up-regulation at 1 hour in JCS. However, the up-regulated level was 
very marginal in ratio. We may conclude that the expression level of B-myb at 1 hour 
was more or the less the same as 0 hour during JCS differentiation. Further analysis 
must be done to confirm the early expression of B-myb in PGE2-induced JCS. 
Taken together, B-myb has a similar expression in both JCS-14 and JCS cells, 
which was highly expressed in proliferating JCS-14 and JCS cells. However during 
PGE2-induction, it decreased gradually along the cell terminal differentiation. It 
suggested that the down-regulation of B-myb expression may be both required for 
PGE2-induced JCS-14 and JCS cell differentiation. The down-regulation of the gene 
may arrest the cell growth while the cells exit the cell cycle. Then the differentiation 
program may switch on. 
Thyroid hormone receptor {c-erbA) 
Thyroid hormone receptor {c-erhA) is a typical member of nuclear hormone 
receptors that effectively induce gene transcription when activated by cognate ligand 
(reviewed in Mangelsdorf et al, 1995). c-erbA remains bound to DNA but exists in 
two distinct conformations. In the absence of hormone, binding of the co-repressor 
complex leads to chromatin inactivation and gene repression, while binding of the 
ligand thyroid hormone (T3) causes dissociation of co-repressors, co-activator binding 
and transcriptional activation accompanied by local opening of chromatin structure. 
The working action of c-erbaA is closely correlated to its structural domains. Its 
N-terminal domain contains a potential transactivation function (AF-1) as well as 
phosphorylation sites important for receptor localization and activity (Hadzic et al, 
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1995; Andersson and Vennstrom, 1997). Moreover, this domain is also responsible for 
specific binding to thyroid hormone response elements in c-erbA target genes. 
Meanwhile, it is involved in receptor dimerization (Perlmann et al, 1996). In the 
absence of ligand, the receptor recruits transcriptional repressor complexes, consisting 
of receptor-bound nuclear co-repressors such as NcoR, SMRT and SUN-CoR (Chen 
and Evans, 1995; Zamir et al., 1996) which activate histone deacetylase eventually. 
These activated co-repressor complexes may locally convert chromatin into an 
inactive state, which restrict access of the basal transcriptional activity. The C-terminal 
of C-erbA is a ligand-binding domain which contain the major ligand-inducible 
transactivation function 2 (AP-2) (Wagner et al., 1995). It heterodimerize with retinoid 
X receptor (RXR) for high-affinity binding to cognate ligand (Leblanc et al., 1995). In 
addition, it binds numerous proteins as well as multiple co-activators, such as TIFl 
(LeDouarin et ai, 1995) and CBP/p300 (Kamei et al, 1996). These co-activators 
interact with histone acetylase or display intrinsic histone acetylase activity, inducing 
chromatin to an active conformation for transcriptional activation (Wong et al, 1997). 
It is well established that c-erbA is involved in erythroid cell growth and 
differentiation. The v-erbA oncogene, a retrovims-transduced version of c-erbA 
contained in the avian erythroblastosis virus AEV, represents an oncogenic version of 
C-erbA. The v-erbA lacks hormone binding activity and ligand-dependent 
transcriptional activator function AF-2，but still contain the binding potential to 
co-repressors (reviewed in Damm, 1993). In erthyroid cells, v-erbA effectively 
suppresses expression of erythroid specific genes, such as band 3 and carbnic ahydrase 
II and inhibits terminal differentiation (reviewed in Batunek and Zenke, 1998). In 
marked contrast, ligand-activated c-erbA was found to effectively induce red cell 
specific gene transcription and to accelerate erythroid cell differentiation in vitro 
(Schroeder et al, 1992; Gandrillon et al, 1994). Conversely, additionally unliganded 
C-erbA repressed ethyroid cell differentiation and supported sustained growth of 
SCF-dependent erythroid progenitor cells in vitro (Bartunek and Zenke, 1998). But 
once they were activated by thyroid hormone (T3) or T3 plus retinoid acid, the 
progenitor cells progressed in terminal differentiation with morphological change and 
accumulation of hemoglobin (Bartunek and Zenke, 1998). Thus, c-erhA appears to act 
as a binary switch affecting erthyroid cell fate. 
c 
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In our study, c-erbA showed overall down-regulated expression in JCS-14 
and JCS cells after PGE2 induction. It expressed in untreated JCS-14 cells. After 1 and 
5 hours incubation with PGE2, the expression of the genes was constitutively 
decreased. But this declined level did not sustain, as the gene expression was slightly 
up-regulated at 18 and 48 hours when compared to the early time points. Similarly, 
C-erbA showed down-regulated expression in gradual manner after induction in JCS 
cells. In contrast to JCS-14 cells, that low level remained at 18 hours. The decreased 
expression became less remarkable at 48 hours. Despite c-erbA could be served as a 
ligand-operated switch between the proliferation and differentiation of erthyroid 
progenitors, it showed differentiation-associated decrease in expression during 
monocytic/granulocytic differentiation. Hence, c-erbA may play distinct functions in 
erythroid and monocytic/granulocytic cell differentiation. The down-regulation of the 
gene may be specific for JCS-14 and JCS cell terminal differentiation. 
Transcription termination factor {TTF-1) 
Transcription termination factor {TTF-1) is a characterized RNA 
polymerase I (Poll) terminator. It binds specifically to a repeated DNA element, 
termed 'Sal box' located downstream of the rRNA coding region for mediating 
termination of Poll transcription (reviewed in Reeder and Lang, 1994). The DNA 
binding domain of TTF-1, which resides within the C-terminal of the protein, shows 
striking homology to that of the proto-oncoprotein c-Myb (Kanei-Ishii et al, 1990). 
Mutation of these residues prevented TTF-1 binding to the 'Sal box’ motif (Evers et al, 
1995). In contrast, N-terminal of TTF-1 may be important for termination activity as 
deletion of this part impaired this function (Evers et al, 1995). In addition, the further 
function of the N-terminal domain was examined. The DNA binding activity of 
recombinant full-length TTF-1 was lower than that of N-terminally truncated versions 
in vitro (Sander et al, 1996). This suggested that the N-terminal domain repress its 
own DNA binding function. In fact, masking of DNA binding domain of transcription 
factor is common for regulating their activity. For instance, NF-KB1 and 2 are both 
synthesized as precursor protein and require proteolytic processing for maturation 
(reviewed in Bauerle and Henkel, 1994). Furthermore, p53 and members of ets family 
of transcriptional regulators also require partial proteolysis to release their internal 
inhibitory region (Bardwell et al, 1994). Currently, TTF-1 was suggested as 
transcription activator favouring slippage of Poll complex and remodeling of the 
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chromatin at the site of initiation (Langst et al, 1998). In addition, the 
chromatin-binding affinity of TTF-l revealed as cell-cycle regulated. It showed that its 
DNA-binding affinity was lower during mitosis than during interphase in cell cycle 
(Sirri et al, 1999). Moreover, TTF-l was found to be phosphorylated during mitosis 
under the control of the cdc2-cyclin B kinase (Sirri et al, 1999). Thus, the mitotically 
phosphorylated form of TTF-l may involve in the repression of rDNA transcription. 
Furthermore, it may have some roles in cell cycle progression. 
In our study, TTF-l expression was 2-fold up-regulated in 5 hours PGE2 
induced JCS-14 cells in microarray assay. However, its expression was only slightly 
up-regulated in real-time PCR study. Besides, the increased level was quite marginal. 
Thus, we could not make any conclusion on the role of TTF-l in JCS-14 cell 
differentiation. During JCS cell differentiation, TTF-l showed a relatively high 
expression level at 5 hours PGE2 induction. The level was slightly declined thereafter. 
Up-regulation of the gene may be essential for the differentiation and functions of 
JCS-cells even its expression was less than 1 -fold. Further study would be done to 
examine its novel role in this field. 
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Chapter Four Inhibition of specific gene expression in 
WEHI-3B JCS-14 and JCS cells using 
"antisense blocking technique 
4.1 Introduction 
Apart from the investigation of the expression profiles of the three 
identified genes, B-myb, c-erbA and TTF-1, in WEHI-3B JCS-14 and JCS cell 
differentiation, it is meaningful to prove whether these three genes are essential for 
differentiation events. In this chapter, gene function study was performed to achieve 
this purpose. Useful strategies like inducible system (e.g. tet on/off expression 
system) or antisense technique may be a good choice for assay. Besides, 
micro-injection of antibody against the target gene may also be one of the 
approaches. 
In our study, the putative roles of the three genes in JCS-14 and JCS cell 
differentiation were determined by antisense technique. The ability of antisense 
technique to efficiently disrupt gene expression has been an important experimental 
tool for studying the biological function of a gene at the single-cell level and in intact 
organisms (Stein et al, 1993). This approach using antisense oligonucleotides relies 
on specific nucleotides base pairing for targeting and down-regulating the gene of 
interest. Hence, it can achieve a highly specific manipulation of gene expression. 
There are many potential applications of antisense technique, but more recently, 
efforts have concentrated predominantly on cancer biology (Curcio et al, 1997). For 
instance, proto-oncogene c-myb is implication in the proliferation and differentiation 
of hematopoietic cells. Several studies have shown the in vitro inhibition of leukemic 
cells and human bone marrow mononuclear cells using an antisense oligonucleotide 
against c-myb (Citro et al, 1992; Gewirtz and Calabretta, 1988). The inhibition was 
shown to demonstrate a dose-response, with increasing amounts of the antisense 
increasing the degree of inhibition of the colonies. Similar studies using melanoma 
cells have shown that injection of antisense oligonucleotide against c-myb can 
produce a 50% reduction in overall tumor size (Hijiya et al, 1994). Thus, the roles of 
c-myb in the proliferation and differentiation of hematopoietic cells are further 
confirmed. In this study, we wish antisense blocking technique would help us to 
c 
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approach some ideas of the molecular regulation in JCS-14 and JCS cell 
differentiation. The principle and related information of antisense blocking technique 
will be introduced in section 4.1.1 - 4.1.3. 
In the present study, the differentiation pattern of cells upon antisense 
blocking was determined using morphological examination as described in section 
2.1.2. Accordingly, down-regulation of B-myb and c-erbA were observed in 
PGE2-induced JCS-14 and JCS cell differentiation. Some important information of 
these two genes may be revealed if we suppress the expression of these genes in 
uninduced JCS-14 and JCS cells. That is, if the untreated cells differentiate or alter 
their lineage commitments upon inhibition of the genes by antisense blocking, the 
genes may probably be very important negative regulators for cell differentiation and 
lineage development. The possible role of TTF-1 in differentiation may also be 
elucidated by comparing the development of both PGEi-treated and untreated cells 
upon the antisense testing. 
4.1.1 Action mechanism of antisense oligonucleotides 
Antisense oligonucleotides refer to any single-stranded DNA or RNA that 
contain complementary sequences to a target mRNA. Through the complementary 
base pairing, the expression of mRNA and the translation into protein are disrupted. 
There are several proposed mechanisms concerning the translation impairment of 
antisense oligonucleotides (Figure 4.1). The first theory involves direct binding of 
the antisense oligonucleotides to sense mRNA, thereby physically inhibiting the 
translation by ribosomes. The antisense oligonucleotides are complementary to the 
translation initiation codon (AUG) and surrounding sequences that cause the 
blockade of large ribosome unit (60s) binding on the mRNA. Hence, the initiation of 
translation would be arrested (Scalzitti and Hensler, 1999). Other theories implicate 
the 5,-capping site attachment to mRNA that inhibits the binding of translation 
factors (Curcio et al, 1997). However, inhibition of target gene expression appears to 
be dependent on RNase H activity in many cases. The formation of RNA/DNA 
duplex through the binding of oligonucleotides to the coding region of target RNA 
may lead to activation of RNase H enzyme. This enzyme is a ribonuclease that is 
widely available and cleaves mRNA in hybrid RNA/DNA duplex, thus making it 
inactive. Consequently, the mRNA is eliminated and the corresponding protein level 
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Figure 4.1 Potential mechanisms of action of antisense oligonucleotides. (A) 
Antisense oligonucleotides complementary to the translation initiation codon and 
flanking sequences are believed to inhibit the synthesis of a target protein through 
steric blockade of translation initiation. (B) The activation of RNase H, an enzyme 
that cleaves the RNA strand of an RNA-DNA hybrid, also mediates the inhibitory 




4.1.2 Design of antisense oligonucleotides 
Modification of oligonucleotides 
Naturally occurring antisense oligonucleotides are composed of 
phosphodiester-backbone oligomer. Oligonucleotides based on this structure would 
be sensitive to 5' or 3' exonucleases in serum, and possibly to endonuclease activity 
inside the cells (Kregenow et al, 1995). Accordingly, the half-life of unmodified 
phosphodiester oligonucleotides in fetal calf serum is about 1 5 - 6 0 minutes (Curcio 
et al, 1997). There are multiple strategies to modify oligonucleotides in order to 
increase their resistance to degradation by nucleases. The most commonly used 
oligonucleotides are the phosphothioates and methylphosphonates (Figure 4.2). 
Phosphothioates involve a substitution of non-bridging oxygen with sulfur atom in 
phosphodiester bond. They can retain charge of these oligonucleotides. Importantly, 
phosphothioates still allow the binding of RNase H to breakdown the RNA-DNA 
duplex (Kregenow et al, 1995). On the contrary, methylphosphonates involve the 
substitution of a methyl group rather than a sulfur atom at the non-bridging oxygen. 
This modification changes the oligonucleotides without carrying any charge, 
enabling them to enter the cells via passive diffusion. However, methylphosphonates 
are not recognized by RNase H. Thus, they must rely on ribosomal inhibition through 
steric hindrance (Curcio et al, 1997). 
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Figure 4.2 Modifications of the phosphodiester backbone of oligonucleotides. 
The modification promotes the stability of the molecule without sacrificing the 
ability to enter cells and hybridize with nucleic acids. The methylphosphonates 
(CH3PO4) are quite adapted at crossing cell membranes because they are 
hydrophobic. Nevertheless, they are poorly soluble and are not permissive of RNase 
H binding. Phosphorothioates do not cross membrane easily, but are soluble and do 
allow the binding of RNase H (reproduced from Kregenow et al, 1995). 
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Sequence selection of the antisense oligonucleotides 
It is evident that most antisense-mediated effects rely on the successful 
binding of the oligonucleotides to its target mRNA region. However, there is no firm 
conclusion can be drawn as to the optimal site to target within the gene. The reported 
efficiencies of different oligonucleotides are widely varying (Zhao and Lemke, 1998). 
For instance, antisense directed the regions flanking the initiation codon AUG or the 
5' cap site may inhibit the binding and message-reading of ribosome. On the other 
hand, oligonucleotides against to other coding regions or the 3' site of the mRNA can 
trigger the enzymatic activity of RNase H. In some reports, other successful targets 
included the splicing sites of introns or polyadenylation signal (Cotter and Pocock, 
1996). 
In addition, the affinity of oligonucleotides for its target sequence should 
also be considered. The affinity results from hybridization interactions that depends 
on hydrogen bonding between the bases of the two oligonucleotides. Theoretically, 
higher G-C base pairs proportion will lead to higher affinity towards the target. 
However, long G-C repeats would decrease specificity. Furthermore, four contiguous 
guanosine residues may result in the formation of intra- or intermolecular helix 
within the oligonucleotides (Scalzitti and Hensler, 1999). The ratio of G-C: A-T in 
oligonucleotides was suggested to keep below 70%, thereby avoiding the decrease of 
specificity. Moreover, sequences with terminal G-C pairs that resulted in "clamps" on 
the ends of the oligonucleotides can be selected (Wahlstedt, 1994). 
Lastly, uniqueness of the selected sequence of oligonucleotides is also 
significant. The sequence recognized must fall within the region showing no 
homology between other non-specific genes and the various members of the same 
family. The homology or the mismatching of the oligonucleotides can be checked in 
the GeneBank database through the BLAST program. 
Length of the oligonucleotides 
The length of the oligonucleotides is a major determinant of specificity and 
affinity. Shorter sequences are of course easier to be taken up by cells and less costly 
to synthesize, but lack sequence specificity. While longer sequences would increase 
the uniqueness, but also result in non-specific binding in cells. Furthermore, it is 
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more expensive to produce and may not be taken up by cells. In general, 
oligonucleotides of 15 nucleotides to a maximum of 25 nucleotides in length are 
desirable (Kregenow et al, 1995). 
4.1.3 Transfer of oligonucleotides to cells 
Oligonucleotides, with the exception of methylphosphonate derivatives, 
are polyanionic. Thus, they are hydrophilic and incapable of passively diffusing 
across cell membranes. On the other hand, oligonucleotides can be uptaken by cells 
through two active processes: fluid phase endocytosis and receptor-mediated 
endocytosis (Cotter and Pocock, 1995). An 80 kDa cell surface protein is one of the 
examples of surface receptor that facilitates the entry of oligonucleotides into cells 
(Yakubor et al, 1989). Since the efficiency of these oligonucleotides internalization 
is quite poor, different artificial methods bypassing the natural mechanism are 
developed. For example, microinjection or electroporation of oligonucleotides into 
the target cells (Kregenow et al, 1995). Besides, liposome delivery is one of the 
common choices. Liposomes are closed structures comprised of phospholipidic 
membrane bilayers surrounding an internal aqueous space (Thierry and Takle, 1997). 
They range in diameter from about 10 nm to 10 |im. They encapsulate both lipophilic 
and aqueous drugs because lipophilic drugs can be intercalated within the membrane 
while the aqueous one can be encapsulated in the internal aqueous space. 
Furthermore, liposomes are non-toxic and biodegradable. Various types of liposomes 
were developed. In our study, cationic liposomes were used. Cationic liposomes are 
composed of the positively charged synthetic lipid 
N-[l-(2,3-clioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and 
dioleoyl phosphatidylethanolamine (DOPE). These liposomes actually do not entrap 
nucleic acids, but neutralize negatively charged nucleic acids and provide a complex 
with a net positive charge. These positively charged and colloidally stable complexes 
can associate with the negatively charged surface of the cells for gene delivery 




4.2.1 Cell lines 
The murine myeloid leukemia cell lines WEHI-3B JCS-14 and JCS cells 
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS, GibcoBRL), 2 mM glutamine, 50 U/ml penicillin, 50 |al/ml streptomycin and 
10 i^g/ml neomycin. Cultures were incubated under a humidified atmosphere of 95% 
air/50/0 CO2 at 3 7 � C . 
4.2.2 Chemicals 
1. Canada balsam Sigma C1795 
2. Dulbecco's phosphate buffered saline (DPBS) GibcoBRL 21600-051 
3. Ethanol Riedel-deHaen 32221 
4. Fetal bovine serum (FBS) GibcoBRL 16000-044 
5. Hemacolor solution 1 Merck 1.11955 
6. Hemacolor solution 2 Merck 1.11956 
7. Hemacolor solution 3 Merck 1.11957 
8. Penicillin-streptomycin-neomycin (PSN) GibcoBRL 15640-055 
9. Prostaglandin E2 (PGE2) Sigma P5640 
10. RPMI-1640 medium GibcoBRL 23400-021 
11. Sodium bicarbonate Sigma S5761 
12. Sodium hydroxide (NaOH) Sigma S8045 
4.2.3 Reagents 
1. Lipofectin® Invitrogen 18292-011 
2. Opti-MEM I reduced serum medium Invitrogen 31985-062 
4.2.4 Solutions 
1. DPBS 1 package of DPBS powder dissolved 
in IL milli-Q H2O and autoclaved 
2. NaOH 1 M NaOH in distilled water 
3. 10 mM Prostaglandin E2 1 mg PGE2 dissolved in 284 fil absolute 
ethanol 
4. IX RPMI-1640 medium 1 package of RPMI powder dissolved in 
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1L milli-Q H2O, 2 g sodium bicarbonate 
per liter medium, pH 7.2 - 7.4 adjusted 
by NaOH and filter-sterilized by 0.22 
[im membrane 
5. RPMI complete medium IX RPMI 1640 medium supplemented 




4.3.1 Design of antisense oligonucleotides 
In our study, the AUG start codon and nearby bases of AUG in the coding 
region were selected for antisense inhibition. Figure 4.3 shows the mRNA sequences 
of the three studied genes, B-myb, c-erhA and TTF-l, and the selected sequences as 
well. The specificity of oligonucleotides against the target genes were checked with 
Genebank to avoid any significant homology with other mRNAs. Other than 
antisense oligonucleotides, sense sequences were also synthesized for use as control. 
All the oligonucleotides were in length of 15 - 18 base pairs. In addition, 
oligonucleotides were modified to enhance their stability in vitro. The nucleotides on 
the terminal ends of oligo were changed to phosphorothioates. The information of the 




1 CAGACCTGCA GACACGCTGA CGCCTGAGAG CACCGCCTGG GGCCCGGAGC 
51 GGCTCGAGCA GCCTGAGTCC TGACCCCGGC CCGGCTCCCG CTCCGGGCTC 
lOlGGCCGGCGGG CGTAAGGGTG CGGCGGGGTC CGGGCCGGGG GGATGTCTCG 
151 GCGGACGCGC TGCGAGGATC TGGATGAGTT ACACTACCAG GACGTGGACT 
201 CAGACCTCCT GGAGCAGAGA GACAACAGAT GTAAGGTTAA ATGGACCCAC 
251GAGGAGGACGAGCAGTTGAG GGCCCTGGTG AGGCAGTTTG GACAGCAAGA 
301CTGGAAGTTC TTGGCCAGTC ACTTTCCTAA CCGCACAGAC CAGCAATGCC 
351 AGTACCGGTG GCTGAGGGTT TTGAATCCCG ACCTTGTTAA GGGACCATGG 
(B) C-erbA 
1 GTGAATGGAA CAGAAGCCAA GCAAGGTGGA GTGTGGGTCA GACCCAGAGG 
51AGAACAGTGC CAGGTCACCA GATGGAAAGC GAAAAAGAAA GAACGGCCAA 
lOlTGTCCCCTGA AAAGCAGCAT GTCAGGGTAT ATCCCTAGTT ACCTGGACAA 
151AGACGAGCAG TGTGTCGTGT GTGGGGACAA GGCCACCGGT TATCACTACC 
201GCTGTATCAC TTGTGAGGGC TGCAAGGGCT TCTTTCGCCG CACAATCCAG 
251 AAGAATCTCC ATCCCACCTA TTCCTGCAAG TATGACAGCT GCTGTGTCAT 
301CGACAAGATC ACCCGGAATC ACTGCCAGCT GTGCCGCTTC AAGAAGTGCA 
351 TTGCTGTGGG CATGGCCATG GACTTGGTTC TAGATGATTC GAAGCGGGTG 
(C) TTF-1 
IGGAAGACGAG CGCTACATTG TCGCTGGGGA CAGGATGAAA GGGGGCACAA 
51GCAAATTTAA GACCCACACT GAAACTTTGT ACAAGAAAAA GAAATGGTCT 
lOlTCTGTGTCTG AAAAAAGACC TCAGAAATGT CCCTCTCAGT GCTTGGAGAG 
151CAAGCAGCCT CAGGTATCTG TGTTGGGGAA GAGGAGGAGG GCGTCCCAGA 
201CACCAGCCCA GGAGACCTTA GAGAGTGAGT GGCCTCAAAA GGCCAAGAAG 
251AAGAAGAGAA GGGGGGAACCCCAGACACCAACCCAAGAGA GTTTGGAGAG 
301TGAGCAGCCT CCAGTGTCCT TGCTGGGGAA GAGAAGGAGG GAATCCCAGA 
3 51C ACC AGCCC AGG AG A ACTCG GAGAGTGAGC AGCCTCGGAA AGCCAAGAGA 
Figure 4.3 Partial mRNA sequences of (A) B-myb, (B) c-erbA and (C) TTF-1. 
The ATG translation initiation codon is highlighted in boldface fonts. The targeted 
regions of antisense oligonucleotides are underlined 
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Table 4.1 List of oligonucleotides for antisense blocking 
Gene Oligo # Sequence (5 ' to3 ' )** Length (bp) 
B-mybMF 925 sense GGGGGGATGTCTCGG 15 
MF 926 antisense CCGAGACATCCCCCC 15 
C-erbAMF 927 sense GTGAATGGAACAGAAGCC 18 
MF 9 2 8 a n t i s e n s e G G C T T C T G T T C C A T T C A C 18 
TTF-1MF 929 sense GGGGACAGGATGAAAGGG 18 
MF 9 3 0 a n t i s e n s e C C C T T T C A T C C T G T C C C C 18 
* *Phosphorothioate-modified base are highlighted and underlined in boldface fonts 
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4.3.2 Transfection of oligonucleotides into cells 
The JCS-14 and JCS cells were firstly washed with serum-free RPMI 
medium. Cells were seeded at a density of 5 x 10^ cell/ml in serum free medium. 
Cationic liposome, Lipofectin®,was used as a delivery tool to enhance the uptake of 
oligonucleotides into cells. Lipofectin® reagent (Invitrogen) was added to 
Opti-MEM® I reduced serum medium (Invitrogen) for 45 minutes at room 
temperature. Then, sense and antisense oligonucleotides were added to the mixture 
and incubated at room temperature for further 15 minutes. The lipofectin-DNA 
complex was then mixed gently with the oligonucleotide(10}iM) containing cell 
suspension. After 5 hours of transfection (5% CO2, 37°C), 1 volume of freshly 
prepared medium with 20% FBS was added to the cells. The transfected cells were 
further incubated at humidified atmosphere of 95% air/5% CO2 at 37°C until 
differentiation assay was carried out. 
4.3.3 Morphological study of PGEi-induced JCS-14 and JCS cells 
Transfected JCS-14 and JCS cells were treated with 4 ^iM and 25 |iM 
PGE2 respectively and their ethanol solvent for 3 days. Approximately 5x10"^ cells 
of each treated and untreated sample were centrifuged at 500 rpm for 5 minutes onto 
clean slides by using the Shandon Cytospin 3 Centrifuge (Shahdon Scientific). Cells 
were fixed and stained as described in 2.3.1. Finally, cells were categorized as blast 
cells, intermediate, metamyelocyte, macrophage and polymorphonuclear cell (PMN) 
according to the cytological features of the cells under light microscopic examination. 
At least 500 cells were counted in each sample. 
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4.4 Results 
There were several groups of samples to be studied in this assay. First, both 
JCS-14 and JCS cells were transfected with only sense or antisense oligonucleotides 
of B-myb, c-erbA and TTF-l. Second, antisense and sense transfected JCS-14 and 
JCS cells were incubated with 4 ^iM and 25 jiM PGE2 respectively. Finally, PGE2-
and solvent-treated cells were used as controls in study. After cytospin preparation 
and staining, cells were categorized and scored as different cell types under 
microscopic observation (Table 4.2 and 4.3). The results were expressed as mean 士 
standard deviation. Since the mean values in particular samples were different upon 
antisense blocking, we wanted to know whether difference was due to an effect of 
antisense oligonucleotides or only by chance. Thus, probability values (P values), 
that the difference we observed between samples means occurred only by chance, 
were required to be calculated in order to answer this question. One-way ANOVA 
analysis, which is one of the statistical analysis programs, was applied to do this 
calculation. The results of P value calculation were presented in table 4.4 and 4.5. 
4.4.1 Effect of antisense oligonucleotides on JCS-14 cell differentiation 
Table 4.2 shows the differentiation response of JCS-14 cells under 
antisense inhibition. The cells with only sense or antisense oligonucleotides B-myb, 
C-erbA and TTF-1 demonstrated a similar result as the ethanol control cells (Figure 
4.4 A). More than 92% of cells retained at the blast stage. No terminally 
differentiated cells were observed in cultures. In case of transfected cells with sense 
oligonucleotides B-myb, c-erhA and TTF-1 and followed PGE2-induction, they 
proceeded along the differentiation pathway with sharp increase in the proportion of 
cells in the intermediate stage. Furthermore, most of the differentiated cells 
undergoing granulocytic lineage have a larger proportion of metamyelocyte and 
PMN. Their differentiation preferences were same as the PGE2-treated control cells 
(Table 4.2). However, sense oligonucleotides c-erbA and TTF-1 exerted interruption 
of cell differentiation during PGE2 induction. The percentage of metamyelocyte was 
increased and that of PMN was decreased unexpectedly when compared with the 
PGE2-treated control cells. Furthermore, the P values among different upon c-erbA 
and TTF-1 sense blocking were at least less than 0.01 (Table 4.4). Hence, the result 
of antisense blocking of both c-erbA and TTF-1 were inconclusible in our study. 
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On the other hand, transfected JCS-14 cells with B-myb antisense 
oligonucleotides showed distinct differentiation patterns in contrast to the 
PGE2-treated control and PGE2-treated sense oligonucleotides cells (Figure 4.4 C and 
D). Most of the differentiated cells blocked at metamyelocytic stage, not terminally 
differentiated to PMN. Based on the results of One-way ANOVA analysis (Table 4.4), 
the P values among different means upon B-myb antisense blocking were less than 
0.001. It indicated that the change of differentiation pattern of JCS-14 cells was due 
to B-myb antisense oligonucleotide, not by chance. Importantly, the P value upon the 
sense effect was larger than 0.05. Hence, the result of B-myb antisense blocking was 
conclusible in study. 
4.4.2 Effect of antisense oligonucleotides on JCS cell differentiation 
The effect of antisense oligonucleotides on JCS cell differentiation is 
shown in table 4.3. The cells with only sense or antisense oligonucleotides B-myb, 
C-erbA and TTF-l gave a similar result of cell proportion as the ethanol control. 
Majority of cells remained at the blast stage without spontaneous differentiation. For 
the cell transfected with sense oligonucleotides B-myb, c-erbA and TTF-l and treated 
with PGE2, they were driven, as expected, to monocytic differentiation pathway 
which was matched to the PGE2-treated control cells. However, the percentage of 
macrophage was decreased upon sense c-erbA and TTF-l oligonucleotides when 
compared with PGE2-treated control cells. These two sense oligonucleotides may 
cause this defect. 
In antisense B-myb transfected JCS cells, lineage preference was still the 
monocytic pathway during PGE2 induction. However, the proportion of cells in 
macrophage was decreased significantly from 74.0 土 1.8 % to 57.0 土 5.1 % in 
contrast to the cell with sense oligonucleotides and PGE2 induction (Figure 4.5 C). 
Importantly, the P values among difference of macrophage population between 
B-myb antisense plus P G E 2 and P G E 2 control was less than 0.05 (Table 4.5). It 
suggested that the blockage of monocytic lineage was likely due to the B-myb 
antisense inhibition. Interestingly, the cell size of macrophage was relatively smaller 
in B-myb antisense treated differentiated cells (Figure 4.5 C). For the transfected JCS 
cells with antisense c-erbA and TTF-l oligonucleotides and followed PGE2 treatment, 
their corresponding sense control caused defect on JCS cell differentiation. Thus, we 
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cannot draw any conclusion of the antisense blocking of c-erbA and TTF-1 on JCS 
differentiation. 
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Figure 4.4 (following 2 pages) Morphological study of JCS-14 cells upon 
antisense blocking. (A) Morphology of solvent-treated cells; (B) Morphology of 4 
\iM PGE2-treated cells; (C) & (D) Morphology of B-myb antisense oligomer treated 
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Figure 4.5 (following 2 pages) Morphological study of JCS cells upon antisense 
blocking. (A) Morphology of solvent-treated cells; (B) Morphology of 25 \iM 
PGE2-treated cells; (C) & (D) Morphology of B-myb antisense oligomer treated cells 











4.5.1 Effects of antisense B-myb on JCS-14 and JCS cell differentiation 
In our study, we demonstrated that antisense B-myb partially inhibited the 
terminal differentiation of both JCS-14 and JCS cells in response to PGE2, as 
measured by morphological examination. According to our experiment, repression of 
B-myb expression did not induce differentiation of JCS-14 and JCS in the absence of 
differentiative inducer. Furthermore, it did not alter their lineage commitments in 
response to PGE2. Nevertheless, it seems to correlate to the cell terminal 
differentiation and cell maturation. PGE2-induced JCS-14 and JCS cells lost the 
capability to differentiate terminally along the granulocytic and monocytic pathways 
respectively upon antisense treatment. JCS-14 cell differentiation arrested in 
metamyelocytic stage and the number of macrophage decreased sharply in JCS cell 
differentiation. In addition, the development of macrophage was inhibited in JCS cell 
as the cells became smaller in size. Importantly, the effect of antisense B-myb on 
JCS-14 and JCS cell differentiation were statistically significant (P < 0.05). It 
suggested that basal expression of B-myb at early stage may be associated to JCS-14 
and JCS cell differentiation. 
B-myb is ubiquitous and its expression is cell-cycle-related. Expression of 
B-myb is able to promote cells into S and M phases of cell cycle by overcoming the 
checkpoints (Lane et al, 1997). A number of studies indeed implicate B-myb in 
regulation of cell growth. Antisense studies have shown that it is required for cell 
proliferation of several different human hematopoietic cell lines of myeloid, 
erythromyeloid, T-, and B-lymphoid origins (Arsura et ai, 1992). Conversely, 
constitutive expression of B-myb prevented cell arrest of serum-deprived BALB/c 
3T3 fibroblasts (Sala et al, 1992) and IL-6-treated M l myeloid leukemia cells (Bies 
et al, 1996). On the other hand, B-myb is down-modulated during terminal 
differentiation of hematopoietic cells (Golay et al, 1991 and Reiss et al, 1991). 
Decreased expression of the gene during cell differentiation was also observed in our 
experiment (refer to chapter 3). 
Since differentiating cells usually have a retardant proliferation rate or 
even growth arrest, the down-regulation of B-myb may account for the proliferation 
arrest and the exit of cell-cycle of cells. Up to now, there are many evidence 
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suggesting the functional role of B-myb in cell differentiation. However, their 
observations and conclusions are not consistent. For instance, constitutively 
expressing B-myb inhibited the terminal differentiation of myeloid cell line GFD8 in 
response to PMA, as well as the expression of differentiation markers (Golay et ai, 
1997). On the contrary, constitutive expression of the gene accelerated the 
differentiation of myeloid precursor cell line 32Dcl3 (Oh and Reddy, 1998). In 
previous antisense studies, blocking of B-myb did not induce differentiation of 
myeloid cell line HL-60 and U937. Also, the blockage of B-myb apparently was not 
affected the differentiation process of cells in response to PMA and RA (Arsura et al, 
1992). 
In conclusion, blockage of JCS-14 and JCS cell differentiation was likely 
due to the antisense treatment of B-myb. In particular, whether the inhibition of cell 
differentiation is associated to the repression of B-myb in our main concern. Further 
work can be done to see if the B-myb expression is repressed upon antisense blocking 
during cell differentiation. 
4.5.2 Effects of antisense thyroid hormone receptor {c-erbA) and transcription 
termination factor {TTF-l) on JCS-14 and JCS cell differentiation 
In antisense c-erbA and TTF-l treated JCS-14 and JCS cells, no 
marked difference was found in contrast to the control cells. Antisense alone of these 
two specific genes did not cause spontaneous differentiation or proliferative 
inhibition in the absence of inducer in JCS-14 and JCS cells. Besides, PGE2-induced 
differentiation, as well as lineage preference, of these two cell lines were not 
interrupted upon blocking of c-erbA and TTF-L However, the sense oligonucleotides 
of C-erbA and TTF-l showed similar effect on cell differentiation as the antisense 
oligonucleotides. Thus, the results of antisense blocking of these two genes were 
unconvincing. Overall, the roles of c-erbA and TTF-l in JCS-14 and JCS cells 
processes were inconclusive in this experiment. New antisense oligonucleotides or 
vector-derived antisense transcript may probably be designed in order to investigate 
the functions of these two genes in JCS-14 and JCS cells again. 
c 
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Chapter Five General Discussion 
5.1 Introduction ^ 
Cell differentiation is an indispensable process in hematopoiesis. Likewise, 
lineage commitment also occurs at different stages during hematopoiesis for 
restricting the developmental capacity and function of cells. In bipotential 
granulocyte-macrophage progenitor cells, the commitment limits the cells to enter 
either granulocytic or monocytic lineages. Such commitment can be studied using a 
myeloid leukemia cell model, WEHI-3B JCS-14 and JCS cells, which upon 
induction differentiate towards the granulocytic or monocytic pathways with 
observable phenotypes. Precise regulation of hematopoiesis is important for normal 
maintenance and function of a variety of blood cells. Any abnormality in 
differentiation and/or proliferation in hematopoiesis may lead to leukemia. With the 
aid of a leukemia cell model, the control mechanism of cellular processes may be 
dissected. In the present study, the molecular mechanism underlying the 
Prostaglandin E2-induced myeloid leukemia cells JCS-14 and JCS differentiation was 
studied. Such investigation may give insight to the molecular biology of the 
regulation of both normal hematopoiesis and leukemic situation. 
5.2 Differentiation program triggered by Prostaglandin E2 
5.2.1 Lineage preference during differentiation 
WEHI-3B JCS cells have been demonstrated to differentiate into either 
monocytes or granulocytes. For instance, biochanin A drove the cells towards the 
monocytic pathway (Fung et al, 1997). Besides, midazolam was able to drive the 
cells to produce both granulocytes and monocytes (Mak et al, 1996). Recently, 
prostaglandin E2 was found to serve an inducers of JCS cells. When 25 |liM of PGE2 
was added to JCS cells, more than 70% of cells differentiated into macrophage while 
only a small portion of PMN was found (Chiu, unpublished data). In contrast, PGE2 
likely induced WEHI-3B JCS-14 cells to differentiate along the granulocytic pathway. 
JCS-14 cell is a subclone derived from the JCS cells. With the treatment of 4 }iM of 
PGE2, over 30% of JCS-14 cells were driven to stages of metamyelocyte and PMN 
(Table 2.1). These two cell lines may be an ideal system for us to investigate the 
lineage response genes or the differentiation markers along the bipotential 
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granulocyte-monocyte lineages. 
5.2.2 Differentially expressed genes during PGE2—induced JCS-14 cell 
differentiation 
To search for genes that are essential to the genetic program for JCS-14 cell 
differentiation, we initially search the genes that showed differential expression 
during the differentiation. We examined the gene expression profile of the 
differentiating cells at 0 and 5 hours after induction with PGE2. This time course 
study should encompass the expression of early response genes during differentiation. 
According to the results from microarray anaysis (Table 2.7), 22 out of 588 identified 
genes were up-regulated or induced by PGE2, in which 3 genes showed over 4-fold 
increase in expression. Among them, 13 induced genes were found in PGE2-induced 
cells. On the other hand, a total of 214 genes were shown to be down-regulated or 
repressed by PGE2 Among these genes, 30 genes were down-regulated including 3 
genes with more than 4-fold decrease and 27 genes with more than 2-fold decrease in 
expression. 
Most of the genes found differentially expressed in PGE2—induced JCS-14 
cells were essential for hematopoietic cell differentiation, proliferation, apoptosis as 
well as functional activation. Of course, we may further study all of these candidate 
genes during JCS-14 cell differentiation in order to obtain more complete picture of 
the molecular regulation. However, due to the constraint of time and labour, our 
further work only focused on several genes of interest. In particular, those regulatory 
genes belonged to proto-oncogenes as well as transcription factor-related oncogenes. 
B-myb proto-oncogene, thyroid hormone receptor (c-erbA) and transcription 
termination factor \{TTF-I) are the examples. These genes may be candidates of 
lineage response genes or differentiation-associated genes. Thus, the three mentioned 
oncogenes were chosen for further investigation. 
5.2.3 Expression patterns of the three differentially expressed genes in 
PGEz-induced JCS-14 and JCS cells 
The expression level of the three genes, B-myb, c-erhA and TTF-l，was then 
further quantified using real-time quantitative RT-PCR. In order to gather more 
information, we examined the gene expression at 0, 1, 5, 18 and 48 hours after 
c 
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incubation the cells with PGE2. In our studies, quantification by microarray analysis 
and real-time PGR of B-myb and c-erhA in PGE2-induced JCS-14 cells led to similar 
result (Table 3.7). 
A gradual decrease in expression of B-myb was observed in PGE2-induced 
JCS-14 cells. However, B-myb was increased in marginal level or at least maintained 
at early stage after induction before it was gradually decreased during PGE2-induced 
JCS cells. Since B-myb protein levels closely parallel to the proliferation state of the 
cells (Arsura et al, 1994), down-regulation of B-myb may indicate the growth arrest 
of differentiating cells. Besides, the relationship with proliferation process, 
down-regulation of B-myb may be specific to the monocytic/granulocytic cell 
differentiation events. Decrease of B-myb expression was also showed in 
differentiated cells, for example TPA- or DMSO-induced differentiation of HL-60 
cells and IL-6 induced differentiation of M l cells (Bies et al, 1996). 
Besides B-myb gene, the expression level of c-erbA also decreased during 
PGEi-mediated JCS-14 and JCS cell differentiation. However, the marked 
down-regulation of the gene only exhibited at 5 and 18 hours after PGE2 treatment. 
At 48 hours, the expression was slightly up-regulated as compared to the early 
induction time points. Thus, such expression of c-erbA may commonly required for 
the differentiation of JCS-14 and JCS cells. This observation was distinct with the 
C-erbA expression studied in erythroid cell. As stated before, c-erbA was found 
up-regulated during erythroid cell differentiation which showed reversed expression 
in our cell models. Therefore, c-erbA may play specific functions to erythroid and 
monocytic/granulocytic lineages. 
Among the three studied genes, TTF-1 showed an inconsistent result in 
cDNA arrays and real-time quantitative RT-PCR. In microarray analysis, it was 
up-regulated for more than 2-fold at 5 hours PGEr induced JCS-14 cell. However, its 
level was very marginally increased at 5 hours induction time in real-time PGR study. 
Hence, we may not draw any conclusion of the gene expression in JCS-14 cell 
differentiation. During PGE2-mediated JCS differentiation, TTF-1 was slightly 
up-regulated at 5 hours. This indicated that the gene may be specifically involved in 
the early stage of monocytic cell differentiation, having different pattern of 
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expression with B-myb and c-erbA. 
5.2.4 Antisense blocking during differentiation 
Apart from predicting differential expression profile, it was inevitable to do 
the functional study of the three identified genes in myeloid cell differentiation. To 
prove directly whether the genes are essential for JCS-14 or JCS cell differentiation, 
antisense technique was adopted in our study. Accordingly, B-myb and c-erbA had a 
down-regulated trend in PGE2-induced JCS-14 and JCS cell differentiation. Hence, 
we expected to use antisense blocking to suppress the expression of these two genes 
in untreated JCS-14 and JCS cells. If the lineage commitment was affected by the 
antisense treatment, the genes may be suggested to be negative regulator and 
sufficient factor for JCS-14 and JCS cell differentiation or lineage development. On 
the contrary, if the cells do not differentiate or change in lineage specificity upon 
antisense treatment, the role of gene in differentiation cannot be identified. For 
TTF-1, its possible role in myeloid cell differentiation, especially in JCS cell could 
be checked by comparing the development of both PGE^-treated and untreated cells 
upon the antisense blocking. Since TTF-1 is up-regulated at 5 hours in JCS cells after 
PGE2 induction, antisense oligonucleotides can be used to check if the differentiation 
may be blocked or lineage preference may be altered in the presence of PGE2. Also, 
suppressed expression of TTF-1 in untreated JCS cells may check if the gene is 
sufficient to initiate the differentiation program of JCS cells. 
In our study, results of antisense treatment of c-erhA and TTF-1 on cell 
differentiation were inconclusive. Because both sense and antisense oligonucleotides 
of C-erbA and TTF-1 also gave a similar effect upon P G E 2 induction of JCS-14 and 
JCS cells. Therefore, we could not draw any conclusion of the role of c-erbA and 
TTF-1 playing in the PGErinduced JCS-14 and JCS cell differentiation. Similarly, 
controlled expression of B-myb in untreated JCS-14 and JCS cells did not initiate the 
differentiation events of cells. But in case of antisense treatment, monocytic lineage 
differentiation of JCS cells was inhibited as the granulocytic differentiation of 
JCS-14 cells was promoted in the presence of PGE2. Interestingly, the PGE2-induced 
JCS-14 cells were arrested mainly in metamyelocytic stage. Furthermore, the 
development of macrophage in PGE2-treated JCS cells was inhibited as the size of 
macrophages became smaller. This may imply that repression of B-myb may 
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associate to the inhibition of JCS-14 and JCS cell differentiation and maturation. If 
this correlation is proved, it may suggest that an immediately early down-regulation 
of B-myb is specific to PGE2-induced JCS-14 cell differentiation. On the contrary, 
maintenance of B-myb expression at early may be required to monocytic 
differentiation of PGE2-induced JCS cells. Further speculation on function of B-myb 
should be done in order to confirm its function in myeloid differentiation and 
development. 
5.3 Further studies 
In the present study, candidate genes involved in PGE2-induced myeloid 
leukemia cell differentiation were identified. However because of the limited scope 
and time of this study, only three of these genes were chosen for further study in 
expression profile examination and antisense testing. Among these three chosen 
genes，B-myb was suggested to relate to terminal differentiation and maturation of 
JCS-14 and JCS. Further investigation must to be done in order to identify the role of 
B-myb in cell differentiation and development. For example, quantification of B-myb 
mRNA expression upon antisense blocking by real-time RT-PCR or Northern 
blotting. After the checking of the repression of efficiency of antisense blocking on 
B-myb expression, the effect of cells upon antisense treatment may be analyzed. 
Up to now, we have only used cell morphological study to examine the 
effect of antisense oligonucleotides on cells. In fact, there are many other methods 
may be used after the gene functional studies. For instance, flow cytometry may give 
a more precise record of number of differentiated cells and distinct cell types. 
Furthermore, functional test and in vivo tumorigenicity assay may provide us more 
information on the degree of cell maturation. Such study may give us a new insight 
of the regulation of myeloid cell differentiation. Lastly, whole set of our experiment 
can be done in other myeloid cell models, normal and/or leukemia types. 
Besides, we may further characterize the regulated genes, which being 
mentioned in Chapter Two, and determine their novel function in JCS-14 and JCS 
cell differentiation. Their expression profiles at different time points of 
differentiation can be examined using several methods. Firstly, we may repeat 
microarray analysis to study the whole set of genes at different time courses. 
c 
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Secondly, we may focus on some of genes by using real-time RT-PCR or Northern 
blotting. Study of the gene expression pattern among different induction time points 
of cell models, JCS-14 and JCS cells, may give us more information of their 
involvements during myeloid cell differentiation. 
Moreover, functional studies of differential expressed genes during cell 
differentiation are highly recommended. For the down-regulated genes after 
PGE2-induction, inducible expression system may be employed to extend the 
expression of these genes during differentiation. If down-regulation of these genes is 
essential for JCS-14 and/or JCS cell differentiation, the cells may continue to 
proliferate without differentiation even in the presence of PGE2. Alternatively, if the 
down-regulation are crucial for lineage commitment, the cells will differentiate but 
with a different lineage preference. Instead of using inducible expression system, 
antisense techniques can be adopted, especially for the up-regulated genes. It can be 
used to check if JCS-14 and/or JCS cells differentiation can be blocked or lineage 
choice can be altered under the induction of PGE2 after antisense blocking. 
With the use of some other myeloid cell models and experimental 
approaches, we may be able to dissect the control mechanism of cell differentiation 
and/or lineage commitment. Such investigation will be rewarding in understanding 
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